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Lung cancer is currently the highest cancer-related cause of death worldwide, accounting for 
1.7 million deaths in 2018. Non-small cell carcinoma (NSCLC) is the most frequent type, 
accounting for approximately 80% of all lung cancer cases. Chemotherapy is still the first-line 
therapy offered to NSCLC patients in most countries. While new therapies (targeted 
compounds, immunotherapy) are evolving, chemotherapy is considered to be used for at 
least two more decades. Resistance to chemotherapy is among the major factors contributing 
to lung cancer mortality and has been well established to date through multiple preclinical 
studies and clinical trials. Currently, there are very few biomarkers, mostly clinical, for 
predicting chemotherapy efficiency. In addition, sensitization of cancer cells to those 
compounds is largely ineffective clinically. This study explores new avenues of lung cancer 
cell sensitization to four common chemotherapeutics (cisplatin, carboplatin, gemcitabine, 
and vinorelbine), with a particular focus in epigenetics and the role of extracellular vesicles. 
Using a wide spectrum of molecular and cell biology methods (cloning, inducible transgene 
expression, shRNA-based silencing, proliferation and apoptosis assays, the neutral comet 
assay, RT-qPCR, pyrosequencing-based DNA methylation analysis, western blots, EV isolation 
and characterisation etc.), I analysed a large number of parameters in relation to drug 
resistance in NSCLC cell lines. Following establishment of the IC50 of each four drugs in eight 
NSCLC cell lines, resistant cell lines were chosen for sensitization with epigenetic drugs (VPA 
and DAC), Aminomethylphosphonic acid (AMPA) and fendiline.  
VPA demonstrated a significant sensitization potential for all the four chemotherapeutics and 
this is a novel finding for lung cancer cells. Both VPA and DAC triggered a significant increase 
in apoptosis activity in cells treated with cisplatin or carboplatin. Double strand DNA breaks 
were caused by gemcitabine in A549, CALU-6 and COR-L23 the NSCLC cell lines and pre-
treatment with VPA increased this effect, this also being a novel finding in this study.  
I also looked into the role of LANCL1-AS1; a long-noncoding RNA, which our research group 
found to be diminished in NSCLC tissues. After establishing an inducible expression model in 
the SK-MES-1 cell line, it was shown, contrary to the original hypothesis, that LANCL1-AS1 
triggered an increase in proliferation rate, migration invasion, sensitivity to gemcitabine and 
vinorelbine, increased resistance to platin compounds and, interestingly, expression of its 
coding counterpart gene, LANCL1. LANCL1 shRNA-based silencing led to a decrease in 
proliferation, migration and sensitivity to oxidative stress. However, sensitivity to all four 
drugs followed the same pattern as for overexpression of LANCL1-AS1, raising thus questions 
on whether these two functions are related or independent, without being able at this point 
to exclude the off-target effects of the shRNA approach. 
Relatively recently, the role of extracellular vesicles (EVs)' in cancer development and drug 
resistance has come under investigation. I thus decided to test whether the LANCL1-AS1 
dependent sensitivity to gemcitabine can be transferred through EVs. Increased LANCL1-AS1 
expression led to an increase in the EVs release in a dose-dependent manner. Unfortunately, 
a number of technical issues related to the toxicity of the EV isolation reagent did not allow 
establishing knowledge of how LANCL1-AS1 induced EVs affect gemcitabine resistance when 
transferred to a recipient cell line. In conclusion, this study has provided a number of novel 
insights into sensitizing NSCLC cells in a preclinical setting. Further research is required to 
establish whether these results have clinical value and how they might affect clinical 
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Chapter 1: Introduction 
 
1.1 Lung Cancer 
Lung cancer is one of the most common cancers in the world, occupying in fact the third 
position, with 1,825,000 new cases diagnosed in 2012 only (Naseer et al. 2018). The highest 
incidence rate was in North America while the lowest is in middle Africa, substantially 
depending on the different range of risk factors but also on available means of diagnosis  
(Alberg et al. 2013). 
In 2016, around 47,235 new cases were recorded in the UK, accounting for almost 13% of the 
entire cancer cases. Overall, it has been concluded that both genders generally have the same 
incidence rate, while the rate for females is higher in Northern Ireland (CancerResearchUK 
2019). 
Lung cancer is currently one of the most severe public health problems, caused by a mosaic 
of risk factors which contribute to contracting the disease in both genders. The most 
important factor is smoking tobacco, which demonstrates dose-dependence taking into 
account the length of time and the number of cigarettes per day, generally expressed as 
“pack-years”. Moreover, smoking has been noted to be a greater risk factor for squamous cell 
carcinomas (SCC) than for adenocarcinoma (ADC) (Molina et al. 2008). Furthermore, inhaling 
radon gas, which can be found in uranium rocks or ‘nuclear waste’, can also cause lung cancer, 
as recorded in the south-west region of the UK. Meanwhile, exposure to a specific type of 
chemical such as asbestos found in diesel or silica produced in glass making are also 
mentioned among potential risk factors (Molina et al. 2008). 
Moreover, air pollution is  considered to be a significant risk factor when it comes to lung 
cancer (Raaschou-Nielsen et al. 2013). A family history of lung cancer can also increase the 
risk (Matakidou, Eisen, and Houlston 2005). A past history of other cancers e.g. breast, head 
and neck or oesophageal cancer as well as pulmonary disease (TB, chlamydia, pneumonia, 
COPD etc) can also increase the risk (Biesalski et al. 1998). 
Other risk factors are immunocompromisation (e.g. HIV patients) and immunosuppression 
(e.g. for organ transplantation). These can increase the risk threefold, while this can be 
twofold in the case of lupus (Schulz 2009; Cadranel et al. 1999). As a result, having recognised 
some of the most important risk factors, many campaigns have attempted to raise awareness 
around the world (Molina et al. 2008; Biesalski et al. 1998). However, one of the most 
important problems in lung cancer is late detection. Several symptoms can lead the physician 
to suspect lung cancer, such as haemoptysis, prolonged chest pain, hoarseness, bone pain, a 
wheezing sound with short breathing, unsuspected weight loss, feeling tired most of the  time 
and losing energy, among others (Biesalski et al. 1998). 
 
1.1.1 Classification 
Most lung cancers have an epithelial origin, more particularly the World Health Organisation 
(WHO) has classified lung cancer into many different types (Figure 1.1). The primary two 
categories are small cell carcinoma and non-small cell carcinoma, with the majority of cases 
being classified under these categories. In fact, approximately 80% of cases are non-small cell 
lung cancer (NSCLC) (Heighway and Betticher 2004). 
 
 
Figure 1.1: Classification of Lung Cancer. 
 
There are three subtypes of NSCLC, namely squamous cell carcinoma (SCC), adenocarcinoma 
(ADC), and large lung cancer, each specified with unique characteristics. 
Squamous cell carcinoma is recognised through the keratinised and intercellular edge coming 
from the bronchial epithelium (Table 1.1), the most severe risk factor for this type of 
carcinoma being smoking, with around 90% of the squamous cases (Molina et al. 2008). 
Adenocarcinoma is characterised by a granular or mucin appearance as ‘acinar, papillary and 
bronchiolar alveolar’ with a mucin growth pattern, its diagnosis depending on a combination 
of cytomorphology and architectural features of the cluster. It is characterised by a ‘single-
ring cell’ shape. A large single cell filled with mucin and disabled cytoplasm leads to 
compressing the nucleolus to the margins (Heighway and Betticher 2004). 
Despite the fact that large cell lung cancer is rarely differentiated from non-small cell lung 
cancer, it can be recognised through the lack of the cytological and architectural shape of 
small cell cancer, while it is not glandular or squamous (Heighway and Betticher 2004). 
Small cell carcinoma, also known as epithelium malignant tumour, is recognised through a 
small cell scattered within the cytoplasm, with inexistent or ill-defined cell borders and a high 
mitotic rate, while necrosis is typical and can be found as a cluster arranged in a linear pattern. 
Sheet growth without a neuroendocrine morphology pattern is generally the cause (Heighway 






























Necrosis and cellular debris  
Large display cell in the central 
Hyper-chromatin, irregular, 
one or more nuclei, small, 
bundle 
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Oval, spindle, round 
Small, less than three cells 
lymphocyte 
Scattered cytoplasm 
A bundle of an inconspicuous 
nucleus  
Finely granulated neural 
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1.1.2 Lung Cancer Stages  
Appropriate lung cancer staging is key in deciding which treatment is suitable for the patient. 
However, the stage is often not definite until the surgery has been carried out. Many systems 
have been used to categorise the lung cancer stages, such as the UK official system called the 
TNM (tumour, node, and metastases) system. Here, ‘tumour’ is related to the size and 
position of the tumour, ‘while node’ to whether the cancer is related to the surrounding 
lymph nodes or not and ‘metastasis’ relates to whether the cancer has spread to another part 
of the body (Lardinois et al. 2003). 
There are four main stages of lung cancer which have been identified. While in the first stage, 
the cancer is small and is localised in one area of the lung, in the second and third stages, the 
size of the cancer increases, most likely having invaded the adjacent or surrounding tissues, 
most probably locally. Finally, in the fourth stage, advanced cancer is found in the lymph 
nodes and has begun to spread to other parts of the body through metastasis. The TNM 
system has sub-categories, which are illustrated in (Figure 1.2) (Molina et al. 2008). 
TNM has different stages, namely that in cases such as tumours (T): a, b, 2, 3, 4), most stages 
are in the main description (Table 1.2), while, nodes have three stages: N0, no lymph invasion; 
N1, cancer is in the lymph nodes near the mediastinum, but on the same side of the affected 
lung; N2, lymph in the branches, wind pipe; N3, lymph nodes in the opposite lung or the 
collarbone or the top of the lung are invaded; M0, cancer has not spread anywhere or to any 
part; M1, tumour spread in both lungs and the fluid surrounding the lungs involves malignant 
pleural effusion and pericardial effusion; M2, cancer invades distant organs or bones 
(Lardinois et al. 2003). 
 
 
Figure 1.2: TNM system adapt from. Adopted from (Nasser 2010). 




Table 1.2: Lung cancer tumour (T) stages (Lardinois et al. 2003). 
Stage   
1 1a At this stage the tumour is small up to 3cm 
1b The tumour size is between 3 to 5cm 
May invade the near tissue “main airway of the lung (bronchus) or the 
membrane covers the lung (pleura) or lung collapsed” 
2 2a Two states: 
• Cancer size between 5 to 7 cm and no lymph nodes infected  
• Size is 5cm or less and cancer in near lymph nodes  
In both states, cancer may spread to adjacent tissues (bronchus, pleura) 
collapse 
2b Different scenarios: 
• Size between 5 to 7cm and there is cancer in the lymph nodes near the 
affected lung 
• Larger than 7cm, there are no cancer cells in the lymph nodes  
• Not in the lymph nodes but it spread to the diaphragm, mediastinal pleura, 
and parietal pericardium 
• In branches near each lung  
• Any size but there is more than one tumour in the same lobe of the lung 
tumour  
3 3a Characters: 
• Size is larger than 7cm there are cancer cells in the near lymph nodes 
• Spread in near tissues (diaphragm, pleura and pericardium) or lymph 
nodes 
• Any size and it grows in the other adjacent tissues (trachea, oesophagus 
and larynx), bones 
• More than one lobe of the same lung and lymph nodes close. 
3b Cancer in the lymph nodes in the mediastinum and diaphragm, trachea major 
stream tune esophageal and main blood vessels 
4 It may be: 
• Both lungs  
• Other parts of the body, liver, and bones 








1.1.3 Molecular Biology of Lung Cancer 
In the last 20 years, an enormous amount of information has been produced with regard to 
gene alterations in lung cancer on multiple molecular levels (genetic, epigenetic and protein 
expression); in certain cases, such information has promoted the progress in diagnosis, 
prognosis, and treatment. Molecular alterations involved in aggravating cell proliferation or 
reducing cell death. In fact, many mutations have been recorded in a lung cancer cell, 
mutations such as duplication, point mutation, amplification and structure rearrangement in 
multiple oncogenes such as ALK, AKT, BRAF, EGFR, HER2, KRAS, c-MET, NRAS, PI3K, RET, and 
ROS1 causing uncontrolled signalling that leads to increased cell growth rates. Also, mutations 
as a deletion and point mutation in tumour suppressors’ genes such as PTEN, TP53 RB, STK11 
CDKN2A, FH1T, RASFIA, may cause reduction in cell death (Figure 1.3) (Larsen and Minna 
2011; Massion and Carbone 2003). The revolution brought by next generation sequencing has 
also increased the range of mutations detected. Indeed, one study detected 727 new 
mutations in NSCLC patients by using a complex genome approach (Larsen and Minna 2011). 
Gene alteration is noticed in the early and late stage of NSCLC, more particularly losses of 
chromosomal regions in 3p and 9p are recognised in early stage, while point mutations in p53 
and KRAS have been reported in the late stage of NSCLC. Molecular alteration that promotes 
cell growth such as the amplification or overexpression of growth factors, an oncogene or 
hormonal receptor, can lead to NSCLC (Brady et al. 2015; Takenaka et al. 2007). 
 





Figure 1.3: Oncology pathways: EGFR, c-MET, VEGF and ROS1 are signalling downstream 
pathways, such as RAS-RAF pathway, MEK-ERK pathway, PI3K-AKT-mTOR pathway and JAK-
STAT3 pathway, which play a role in cell survival, proliferation, invention, differentiation 
and anti-apoptotic that control cell growth. Any pathogenic molecular alteration leads to 




































Molecular alteration that occurs in EGFR VEGF, c-MET, ROS1 leads to uncontrolled signalling 
to PI3K-mTOR, RAS-RAF-MAPK pathways that increase cell proliferation, survival, invasion, 
angiogenesis, while metastasis also has an anti-apoptotic effect (Table 1.3) (Larsen and Minna 
2011; Massion and Carbone 2003). 
On the other hand, the molecular alterations in the tumour suppressor genes (TSG) is 
carcinogenic; in other words, TSGs such as p53, retinoblastoma RB and serine tyrosine kinase 
STK11, CDKN2A, FH1T, RASFIA, PTEN work as a negative regulator for cell proliferation 
(Cooper et al. 2013). The loss of TSGs occurs in many types of cancer, including lung cancer, 
in which case alleles are usually inactivated either epigenetically through methylation, 
deacetylation, and DNA adduct, or by another type of alteration (Massion and Carbone 2003). 
Meanwhile, the inactivation of the secondary allele occurs by losing the heterozygosity LOH 
region of the chromosome by deletion, non-reciprocal translocation or mitotic recombination 
(Cooper et al. 2013).  
   
 
   
 
Table 1.3: Genes involved in lung cancer 
Genes Gene Alteration 
Epidermal growth factor 
receptor EGFR 
EGFR mutations appear in intracellular tyrosine kinase domain in four exons (18, 19, 20 and 21), 45% of 
the EGFR mutation in NSCLC is deletion {del E746 – A750] in the exons19, 40%-point mutation L858R in 
exon 21, 14% mutation in exon 18 and 5-10% duplication in exon 20 (Raparia et al. 2013). 
Vascular endothelial growth 
factor VEGF 
Four polymorphisms in VEGF regulate the expression. Meanwhile, 2578 C/C, 634 G/G, 1154 A/A alleles 
lead to under-expressed VEGF, while 2578 C/A 634 G/C, 1154 C/A alleles lead to over-expressed VEGF in 
36 NSCLC patient pathway (Koukourakis et al. 2004). 
C-MET The amplification of c-MET causes over-expression that leads to increased cell survival through PI3K-
mTOR. 
ROS1 ROS1 rearrangement occurs in lung cancer with a F16 gene in 2% of NSCLC cases. In addition, some 
infusion is noted with KDEIR2, SDC4, LR1G3, EZR, SLC34AZ, CD74 (Cooper et al. 2013). 
KRAS 
Gene alteration of ATP leads to increasing the RAS signalling. 30% of NSCLC cases have RAS mutation. 
Approximately 25-40% of ADC cases are caused by KRAS point mutation in codon 12, while this rarely 
occurs in codon 13 and 16 (Cooper et al. 2013). 
BRAF The mutation occurs in NSCLC located in kinase domain-like V600E, D594G, and L596R or G-loop-like 
G465V and G468A. V600E accounts for 50% of BRAF mutation in NSCLC (Cooper et al. 2013). 
MEK Somatic mutation in MEK in exon 2 has been reported in two cases of ADC in NSCLC (Cooper et al. 
2013). 
Anaplastic lymphoma ALK Intron 19 of ALK is infused with intron 13 of EML4 [ALK(inv(p21;p23)] or exon 1-3 of EML4 joined exon 
20-29 of ALK (Raparia et al. 2013). 
   
 
   
 
P13K-AKT-mTOR pathway 
Around 50-70% of NSCLC cases involve molecular alterations in the P13K-AKT-mTOR pathway, while this 
more likely occurs in SCC (47%) (Cooper et al. 2013). Uncontrolled activation of the P13K pathway 
occurs through amplification of P13K or loss of PTEN, which usually occurs to stop P13K working. 
Around 5% of NSCLC cases involve amplification of P13K. AKT mutations occur in 0.5%-2% of NSCLC 
cases (Raparia et al. 2013). 
Fibroblast growth factor 
receptors FGFR FGFR amplification most likely occurs in 20% of SCC cases (Larsen and Minna 2011; Cooper et al. 2013). 
Discoidin Domain Receptor 
DDR2 c.2304T>A (S768R) mutation (Cooper et al. 2013). 
RET RET-KIF5B rearrangement occurs in 1-2% of ADC cases, the translocation is fused between exon 12-20 of 
the RET tyrosine kinase domain with the first 15 exons of the KIF5B (kinase family B gene). 
Phosphatidylinositol-4,5-
bisphosphate 3-kinase TP53 
Homozygous deletion of TP5 has occurred in 90% of small lung cancer cases, 65% of NSCLC cases and 
around 60-100% of lung cancer cases (84% SCC and 45% ADC) (Cooper et al. 2013). G/T transversion 
occurs more than G/A transversion in cancer patients who have never smoked. G/T transversion that 
has occurred in smoking patients causes the bulking of the DNA adduct, which involves ‘covenant 




c.697C>T (R233) mutation results in the introduction of a premature stop codon into the PTEN gene 
(Cooper et al. 2013). 
LKB1 (STK11) LKB1 mutation as deletion occurs in ADC cases, with a with 10-11%rate (Cooper et al. 2013). 
P16INK4-cyclinD1-CDK4-RB 
pathway 
80% of ADC NSCLC cases involve inactivated P16INK4 due to the methylation that prevents the G1 
passing through the checkpoint, while it occurs in 75% of SCC cases. 40% of NSCLC cases involve 
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1.2 Therapy 
The tumour type and location, the diagnosis clinical phase and the general health status are 
considered vital elements required to treat non-small cell lung cancer (NSCLC) (Table 1.4). 
Once the position of the tumour has been established and based on the patient’s good health 
status, the best treatment option is surgery, followed by additional chemotherapy and 
radiotherapy. Nevertheless, neither surgery nor radiotherapy are viable options in 
metastasized cancer cases; such cases can only be treated with various courses of 
chemotherapy if not showing resistance, otherwise target therapy would be suggested 
(Howington et al. 2013). 
Table 1.4: Therapies applicable depend on the cancer stage (Howington et al. 2013). 
 Surgery Radiotherapy Chemotherapy 
Stage 0 
Applicable 
depending on the 
health state 
Depending on the 
health state 






Stage IIIB Not Applicable 
Stage IV Not Applicable Not Applicable 
Applicable with 
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1.2.1 Surgery 
Commonly, the first treatment choice for NSCLC patients who are in stable health at stages 1 
or 2 is video-assisted thoracic surgery (VATS), which involves a tiny camera attached to a light 
injected inside the lung (scope) with a monitoring video that allows the surgeon to cut the 
malignant part without the need for a major operation. Two systematic reviews conducted 
by (Soldà et al. 2013; Vansteenkiste et al. 2013) reveal the outcomes of thoracoscopic surgery 
compared to those of VATS in NSCLC’s case, more particularly the wider benefits including 
short duration of the chest tube insertion, a shorter stay in hospital, a longer overall survival 
(OS) rate and lower mortality rates in early stage NSCLC  (Soldà et al. 2013; Vansteenkiste et 
al. 2013). 
Three types of lung cancer surgery can be performed to treat NSCLC, depending on the size 
and position of the tumour. While in the early stages of NSCLC, the tumour is generally located 
in a single small area of the lung and in this case, ‘wedge resection or segmentectomy surgery’ 
is the best choice`, if a tumour is located in one lung lobe, a ‘lobectomy’ surgery is usually 
performed. Moreover, in some cases, the tumour could have spread across the middle lobes 
of one lung or even the entire lung; as a result, in such a case a ‘pneumonectomy’ surgery 
involving the removal of the whole lung is recommended; moreover, generally, the surgeon 
will also remove the affected lymph nodes during the surgery (Vansteenkiste et al. 2013). A 
recent review also shows a significant result in terms of increasing the overall survival rate in 




34       
 
Meanwhile, additional support following lung surgery via further chemotherapy or 
radiotherapy is recommended to avoid any regrowth of the remaining tumour cells that were 
not removed during the surgery. A systemic review also reveals a notable increase in the 
survival rate for NSCLC patients when they receive post-surgical chemotherapy 
(Vansteenkiste et al. 2013). 
 
1.2.2 Radiotherapy 
Several types of radiotherapy can be used to treat NSCLC, depending on the evolution of the 
disease; more specifically, in the early stage. Radiotherapy is generally the preferred option 
in the first, second and the third stages of NSCLC, when the patient suffers from heart disease 
or the cancer reaches the edge of the heart or has spread out too much to be solved through 
surgery (Vansteenkiste et al. 2013; Soldà et al. 2013). 
First, external beam radiation therapy (EBRT) involves radiation focused on the exterior of the 
body from different angles and aimed at the cancer cells, the measurement and the direction 
of the beam being generally determined in the simulation stage. Meanwhile, 3D-CRT, IMRT, 
SBRT, SRS are different types of radiotherapy that are used for various purposes, depending 
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1.2.3 Chemotherapy  
The process of chemotherapy supposes the use of an anti-cancer agent to eliminate tumour 
cells and reduce cancer symptoms, most frequently after the surgery (adjuvant 
chemotherapy) (Vansteenkiste et al. 2013). However, when surgery is not applicable, due to 
either the patient’s poor health or the cancer having spread to essential organs, 
chemotherapy can also be administered in the late stage to reduce the symptoms. 
Chemotherapy is usually conducted in cycles, the number of which depending on the stage 
and the severity of the disease (Vansteenkiste et al. 2013). In neoadjuvant settings, 
chemotherapy is given before surgery to reduce the tumour size, a technique that, in turn, 
increases the chance of removing all tumour cells during the surgery. However, combined 
chemotherapy is generally recommended for NSCLC patients who cannot undergo surgery 
due to their poor health state. In such case, platinum is generally the primary drug that is 
combined with a form of chemo, while in the late stage, target therapy is generally used along 
with chemo (Scheff and Schneider 2013; Burdett, Stewart, and Rydzewska 2006); 
chemotherapy treatments include  platinum “cisplatin, carboplatin”, vinorelbine, 
gemcitabine, paclitaxel (taxol), docetaxel (taxotere), pemetrexed, albumin-bound paclitaxel 
(reb-paclitaxel, abraxane), irinotecan (camptosar), vinblastine, etoposide (VP-16), 
pemetrexed (alimta) (see Table 1.5) (Scheff and Schneider 2013; Bunn and Kelly 1998). 
Different antineoplastic categories have been used to treat NSCLC. For example, alkylating 
agents such as platinum (cisplatin-carboplatin) are generally a non-specific cell cycle, usually 
active in the resting phase of the cell. In fact, this is the first non-hormonal drug to have been 
approved (Baxevanos and Mountzios 2018). Platinum stops cancer cell proliferation through 
the process of adding an alkyl group to the guanine base of the DNA molecule, at the number 
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7 nitrogen atom of the purine ring, preventing the strands of the double helix from joining 
and causing DNA damage that interferes with the cell replication (Scheff and Schneider 2013; 
Bunn and Kelly 1998). 
Plant alkaloids originate from plants, including the Vinca alkaloid, which comes from the 
periwinkle plant (vinorelbine and vinblastine), while other drugs, such as podophyllotoxin 
(etoposide), are generated from the mayapple plant.  
Antimetabolites, which normally are small molecules that replace the natural substance 
without performing its function, interfere with the cancer cell's metabolism, which leads to 
stopping the cell cycle in a specific phase. For example, antifolate pemetrexed can inhibit 
thymidylate synthase that stops the methylation of C5 of deoxyuridine monophosphate 
(dUMP), thereby preventing the synthesis of deoxythymidine monophosphate (dTMP). 
Another example is a pyrimidine antagonist such as gemcitabine, where fluorine atoms 
replace the hydrogen atoms on the 2' carbon of deoxycytidine incorporated into DNA strands, 
therefore leading to stopping further DNA synthesis and to cell death (Scheff and Schneider 
2013; Cullen 2003). 
Antitumour antibiotics work in nonspecific cell cycle phases. Antibiotics are extracted from 
microorganisms and affect DNA synthesis, while antihormones such as oestrogens generate 
an unsuitable environment for cancer cell growth.  
In order to increase the efficiency of the drug, combined chemotherapies are used, including 
platinum therapy, which has been combined in four regimens (Baxevanos and Mountzios 
2018), namely cisplatin plus paclitaxel or docetaxel and Cisplatin plus gemcitabine. Patients 
who received carboplatin plus paclitaxel show less toxicity compared to patients receiving a 
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cisplatin-based treatment. Other types of non-platinum combined therapy including 
gemcitabine plus taxanes or vinorelbine have been used to treat IV NSCLC.  
Histology can help make decisions regarding the combined chemotherapies that can be used. 
For example, cisplatin plus pemetrexed shows higher overall survival (OS) in adenocarcinoma, 
while cisplatin plus gemcitabine showed a better response in OS in squamous cell carcinoma 
(Scheff and Schneider 2013). The most common combined chemotherapies with cisplatin are 
etoposide and vinorelbine, which are widely recommended among the clinics (Vansteenkiste 
et al. 2013). 
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It stabilizes microtubules, preventing their depolymerization so inhibiting cellular motility, mitosis, and replication. 
Results in cell- cycle arrest at the G2/M phase and cell death hereby resulting in the inhibition of cell division with 
antineoplastic activity. Taxol: blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukaemia 2. 






Aminopyridine-based an ATP-competitive manner. It inhibits ALK kinase and ALK fusion proteins with antineoplastic 
activity. Alunbrig: inhibits the epidermal growth factor receptor (EGFR). Xalkori: inhibitsthe c-Met/hepatocyte 
growth factor receptor (HGFR). Alecensa: inhibits the gatekeeper mutation ALKL1196M. Lorbrena: ROS oncogene 1 
(Ros1). 
Everolimus (Afinitor) 
A derivative of the natural macrocyclic lactone sirolimus. It binds to the immunophilin FK Binding Protein-12 (FKBP-
12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target 
of Rapamycin (mTOR), a key regulatory kinase with immunosuppressant and anti-angiogenic properties. 
Trexall (Methotrexate) 
The disodium salt of a synthetic pyrimidine-based an antimetabolite and antifolate agent with antineoplastic and 
immunosuppressant activities. It inhibits the enzyme dihydrofolate reductase. Result in inhibition of purine 





Monoclonal immunoglobulin (Ig) G4 antibody directed against programmed cell death-1 ligand 1 (PD-L1; B7 
homolog 1; B7H1), with potential immune checkpoint inhibitory and antineoplastic activities. Opdivo: works against 
the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1,) 
Avastin (Bevacizumab), 
Cyramza (Ramucirumab) 
Monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. 
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Paraplat (Carboplatin) 
This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as 
GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-





The hydrochloride salt of mechlorethamine, a nitrogen mustard and an analogue of sulphur mustard, with 
antineoplastic and immunosuppressive activities. Mechlorethamine is metabolized to an unstable, highly reactive 
ethyleniminium intermediate that alkylates DNA, particularly the 7 nitrogen of guanine residues, resulting in DNA 
base pair mismatching, DNA interstrand crosslinking, the inhibition of DNA repair and synthesis, cell-cycle arrest, 
and apoptosis. 
Tafinlar (Dabrafenib) 
It is inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Activity of B-raf, which may inhibit the 
proliferation of tumour cells which contain a mutated BRAF gene. 
Portrazza (Necitumumab) A fully human IgG1 monoclonal antibody directed against the (EGFR) with potential antineoplastic activity. 
Gilotrif (Afatinib Dimaleate),  
Vizimpro (Dacomitinib), 
Tagrisso (Osimertinib) 
The dimaleate salt anilinoquinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal 
growth factor receptor (ErbB; EGFR) family, with antineoplastic activity. Gilotrif: EGFR mutants, Vizimpro: exon 19 
deletion, Tagrisso: exon 21 (L858R) the EGFR T790M gatekeeper mutation 
Mekinist (Trametinib) 
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1.2.4 Targeted therapy 
Thus far, chemotherapy has provided moderate to poor efficiency for treatment of lung 
cancer, as demonstrated by the very high mortality, but also the usually high toxicity of 
classical chemotherapy, which creates morbidity problems. In the last two decades, targeted 
therapy has started being implemented to eliminate cancer cells carrying specific aberrations. 
More specifically, Targeted therapy is a drug aimed to attack a certain molecular agent or 
pathway involved in the development of cancer such as erlotinib and gefitinib which work as 
inhibitors for cancer cell growth and are administered in NSCLC cases when surgery and 
radiotherapy are no longer applicable. On the other hand, target therapy is usually used 
instead of chemotherapy in the late stage (Ulivi et al. 2013), due to the fact that, in the 
advanced stage of NSCLC, cancer cells spread out and cannot be reached through surgery, 
while chemotherapy with radiotherapy involve some resistance. The first target for the doctor 
is stopping the spreading of tumour cells (Baxevanos and Mountzios 2018), which need new 
blood vessels to continue growing, therefore, inhibiting angiogenesis is required. A mono-
antibody such as ‘bevacizumab (avastin) and ramucirumab (cyramza)’ is the first target, while 
the other therapy goal involves the receptor of the vascular endothelial growth factor VEGF 
stopping the growth of new blood vessels. This targeted therapy is usually used in 
combination with chemotherapy (Baxevanos and Mountzios 2018; Rolfo et al. 2017). 
Moreover, most common tumours have a mutation in EGFR, ALK, ROS1 and BRAF genes (Rolfo 
et al. 2017; Vansteenkiste et al. 2013; Ulivi et al. 2013).  
Furthermore, EGFR plays a critical role in dividing and proliferation. Therefore, targeted 
therapy such as [erlotinib (tarceva), afatinib (gilotrif) gefitinib (iressa) osimertinib (tagrisso) 
dacomitinib (vizimpro) responsible for blocking EGFR signalling in NSCLC patients who have 
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an EGFR mutation is recommended. In some cases, NSCLC patients developed secondary 
mutations such as T790M showing resistance against specific targeted therapy; as a result, in 
this case osimertinib is recommended because it works against the T790M mutation (Ulivi et 
al. 2013; Rolfo et al. 2017). 
Furthermore, ALK rearrangement most commonly appears in adenocarcinoma in NSCLC, at a 
rate of approximately 50%. ALK rearrangement leads to an increase in cell growth and 
spreading. Target therapy such as crizotinib (xalkori), ceritinib (zykadia), alectinib (alecensa), 
brigatinib (alunbrig) and iorlatinib (iorbrena) is used for both ALK rearrangement and also for 
ROS1 mutation. BRAF gene alteration also leads to the spreading of cancer cells, therefore, 
target therapy such as dabrafenib (tafinlar) has been used to inhibit BRAF, with trametinib 
(mekinist) used to block MET (Golding et al. 2018; Hallberg and Palmer 2011; Ulivi et al. 2013). 
Crizotinib, ceritinib, and alectinib are ATP competitive molecules which function as ALK 
inhibitors. Two studies compared crizotinib with platinum target therapy and chemotherapy, 
the first showing an increase in progression-free survival PFS of 7.7 months for 347 NSCLC 
patients who had ALK rearmament and who were treated through chemotherapy, followed 
by crizotinib. This was compared with other NSCLC patients who still take chemotherapy with 
PFS (3 months) (Golding et al. 2018). Meanwhile, the other study involved 343 NSCLC patients 
who had ALK rearrangement and who received systemic treatment for advanced cancer, 
receiving either crizotinib orally or platinum through intervenors. The study shows better PFS 
results with crizotinib compared with platinum (10.9 vs. 7.0 months) (Golding et al. 2018). 
Resistance appears following treatment with crizotinib after two years because secondary 
mutations most likely develop in the ALK gene (Hallberg and Palmer 2011). Many mutations 
have been recorded in the ALK tyrosine kinase domain, such as 1151 Tins, which leads to 
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promoting ATP binding stability, while with active ALK, C1156Y does the same. Meanwhile, 
L1196M leads to inactivating sites that prevent crizotinib from binding, while G1269A impairs 
the affinity of crizotinib for the ATP binding site. In addition, D1203N located in ATP binding 
in ALK also plays a role in the resistance (Golding et al. 2018; Hallberg and Palmer 2011). 
 
1.2.5 Immunotherapy 
The main problem with classical chemotherapy is its low efficiency and high toxicity. However, 
targeted therapies used to overcome this obstacle are not problem free either, as in the case 
of lung cancers which are heterogeneous, exhibiting a mosaic of the targeted aberrations. For 
example, abnormalities have been shown in 10%-15% of EGFR and 2-7% of ALK 
rearrangement. Therefore, a new modality has been devised to treat human cancer, including 
lung, by targeting cancer cells through the patient's own immune cells (Davies 2014). 
Immunotherapy, aimed at using the immune cells to recognise and target cancer cells, has 
begun to be used to treat NSCLC by using immune checkpoint inhibitors, while usually the 
immune system uses these checkpoints to protect the normal cells attacked by the immune 
cells. These checkpoint inhibitors are aimed at turning off the checkpoints, which leads to 
recognising the cancer cells (Rolfo et al. 2017). 
Blood tests used to detect specific protein (PD-1) are usually requested because increasing 
the level of PD-1 leads to a better response with immune and target therapy cells (Rolfo et al. 
2017). Immunotherapy such as nivolumab (opdivo) and pembrolizumab (keytruda) targets 
programmed cell death PD-1.  
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NSCLC cases commonly involve the PD-1/PD-L1. More specifically, using anti-PD-1/PD-L1 
antibodies shows a significant increase in overall survival rate. NSCLC patients who have 
increased expression of PD-1 show a better survival rate when treated with one of the 
checkpoint inhibitors as well as less toxicity.  
Many studies have shown that the use of a combination of chemotherapy and 
immunotherapy as a first line treatment for NSCLC patients is highly beneficial (Baxevanos 
and Mountzios 2018; Iwai et al. 2002) as immunotherapy assists the immune system finding 
and destroying tumor cells (Lazzari et al. 2018). 
 
1.3 Drug Resistance  
It is now well established that drug resistance in cancer cells is caused by different levels of 
molecular alterations leading to increased drug efflux, drug inactivation, and sequestration 
by enzymes, DNA repair, target modification, and evasion of apoptosis (Wangari-Talbot and 
Hopper-Borge 2013). The usual late detection of lung cancer presents with a complication 
regarding drug sensitivity: the long natural history of tumour is normally associated with high 
molecular heterogeneity; therefore, an increased chance of acquired mutations that may 
cause drug resistance. 
When treated with chemotherapy agents, NSCLC patients may develop a second mutation 
(Wangari-Talbot and Hopper-Borge 2013) with diverse phenotypic outcome affecting drug 
response: increased DNA repair, high expression of oncogenes, or reduced expression/activity 
of tumour suppressor genes, reduced apoptotic potential the apoptosis pathway etc. 
(d‘Amato et al. 2007). 
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1.4 Selected chemotherapeutics in this study 
In this study, I selected to put the spotlight on four chemotherapeutic agents, i.e. 
gemcitabine, vinorelbine, cisplatin, and carboplatin. 
 
1.4.1 Platinum  
Platinum is a chemotherapeutic agent approved to treat cancers such as NSCLC, lipomas, and 
germ cell tumours. It is one of the oldest drugs still widely used and prescribed until present, 
especially in the third world where targeted therapy has not reached yet. Therefore, Cisplatin 
and Carboplatin have been chosen for this research. Both Cisplatin (Cis) and Carboplatin 
(Carb) lead to miscoding by adding alkyl agents where they do not belong, stopping the 
correct bases from combining. Platinum forms cross-linked bonds with DNA, both interstrand 
and intrastrand, therefore stopping cell proliferation. 
 
1.4.1.1 Platinum action 
Platinum is an antineoplastic which works through three different mechanisms. First, by 
adding an alkyl group to the DNA base, it stops both DNA synthesis and RNA transcription due 
to the fact that repairing enzymes start fragmenting the DNA to replace the alkyl group. 
Second, platinum leads to DNA damage by forming cross-like bonds between atoms and DNA, 
which also prevents DNA synthesis and transcription. Third, mutation occurs through the 
mispairing of nucleotides (Drugbanck 2019a) (Figure 1.4). 
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Figure 1.4: Cisplatin DNA adducts: Cisplatin is an alkylating agent that can add an alkyl 
group to the electronegative group under specific conditions inside the cell. Cisplatin 
directly targets the DNA by forming a cross-link. A: Cisplatin forms intrastrand (within 
the same strand) cross-links with DNA. B: interstrand cisplatin cross-links that occur 
between the two opposite strands of double-stranded DNA. C: Monoadducts form with 
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1.4.1.2 Platinum resistance 
Resistance to platinum develops through multiple factors and on either the external or 
internal pathways. Platinum adds an alkyl group to the DNA to form DNA adducts, resulting 
in cross-linking interstrands or intrastrands. Resistance can aggravate by recognising the 
defect and fixing it with one of these five DNA repair pathways: nucleotide excision repair 
NER, mismatch repair MMR, double-strand break repair, base excision repair BER, and direct 
repair (Martin, Hamilton, and Schilder 2008). 
 
1.4.2 Gemcitabine 
Gemcitabine is an antineoplastic antimetabolite, is a nucleoside analog used to treat NSCLC 
and many other cancers. Gemcitabine masks purine or pyrimidine in order to replace one of 
the nucleic acid building blocks, as well as replacing cytidine in nucleic acid during DNA 
replication, which stops cell division as new nucleosides cannot add to the affected 
nucleoside, arresting the cell in S phase and causing cell death. It can both inhibit the enzyme 
responsible for altering the cytosine nucleotide into the deoxy derivative (Conroy et al. 2011). 
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Figure 1.5: Gemcitabine mechanism of action: gemcitabine dFdC is carried into the cell by 
nucleoside transporters. First, deoxycytidine kinase (DCK) phosphorylates dFdC to 
gemcitabine monophosphate dFdCMP. Subsequently, dFdCMP phosphorylates to 
gemcitabine diphosphate dFdCDP by nucleoside monophosphate kinase. Gemcitabine 
diphosphate can effectively inhibit ribonucleotide reductase. Then, it phosphorylates to 
gemcitabine triphosphate dFdCTP by nucleoside diphosphate kinase. dFdCTP inhibits 
deoxycytidine monophosphate deaminase DCTD, which suppresses inactivation of 
dFdCMP. In contrast, most of the gemcitabine is inactivated by converting into2ʹ-deoxy-
2ʹ,2ʹ-difluorouridine (dFdU) by CDA. dFdCMP can also be inactivated by converting into 
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1.4.2.1 Gemcitabine Action 
Gemcitabine causes cell death by inhibiting thymidylate synthesis, resulting in the arrest of 
cell synthesis. It is a pro-drug activated after intracellular conversion by deoxycytidine kinase 
DCK into two active metabolites: gemcitabine-diphosphate and gemcitabine triphosphate. 
Gemcitabine-diphosphate inhibits ribonucleotide reductase, which is the enzyme responsible 
for catalysing the synthesis of deoxy nucleoside, triphosphates required for DNA synthesis. 
Gemcitabine triphosphate competes with endogenous deoxy nucleoside triphosphates for 
incorporation into DNA. Phosphorylated metabolites of gemcitabine can reduce cellular 5ʹ-
nucleotidase (5ʹ-NT), and dFdCMP is also converted and deactivated, by deoxycytidine 
monophosphate deaminase DCTD into (dFdUMP) (Figure 1.5) (Plunkett et al. 1996). 
 
1.4.2.2 Gemcitabine Resistance  
Resistance against Gemtcitabine (GM) has been a setback, being mainly caused through 
defects in the activation enzyme involved in the metabolism of GM or the proteins involved 
in programmed cell death (Baxevanos and Mountzios 2018). GM resistance is caused by either 
d-cyc deaminase (dCDA) or decreased d-cyc kinase (dCK), which plays a role in activation of 
GM through transfer dFdC to dFdCMP by RRM 1/2 which inhibit dCK (Figure 1.5) (Ueno, 
Kiyosawa, and Kaniwa 2007). Ribonucleotide reductase contains RRM 1/2 and is involved in 
DNA synthesis by working a critical role in converting ribonucleotides to deoxy-
ribonucleotides through DNA polymerisation and repair (Davidson et al. 2004). NSCLC 
patients were treated with GM advanced: the patients with RRM 1 +ve had worse OS and 
disease control than the patients with RRM 1 -ve tumours. Many studies have recognised 
RRM 2 is the reason behind GM resistance. One of the studies has indicated that RRM 2 
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expression was high in resistance cells. Also, it was found that the resistance was reversed 
through used GM8510 as an inhibitor for RRM 2 (Chen et al. 2018). GW8510 plus GM leads to 
autophagy induction parallel with the impairment of DNA DSB repair, increasing apoptosis 
and autophagy (Chen et al. 2018). 
 
1.4.3 Vinorelbine  
Vinorelbine (VRL) is an antitumour chemotherapy used to treat NSCLC and other cancers 
counting as the third generation of Vinca alkaloids. It combines with platinum or gemcitabine 
to treat NSCLC, the toxicity of a combined treatment was studied, and the combination 
increased the survival rate in lung cancer patients. Vinca alkaloids act as a poison for spindles 
and work through the depolymerisation of tubulin, which is necessary to make the 
microtubules that play a critical role in cell division (Wangari-Talbot and Hopper-Borge 2013) 
(Figure 1.6). 
 
1.4.3.1 Vinorelbine Action 
Vinorelbine is antimitotic and interacts with tubulin, leading to stop mitosis in metaphase. In 
cell division, VRL poisons the spindle (which plays a role in chromosome segregation), ending 
the cell in the G2/M phase. It has been hypothesised that just as VRL targets microtubulin, it 
can also target chromatin components. VRL can target chromatin, DNA, and histones (Figure 
1.7) (Drugbanck 2019b). 
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Figure 1.6: Vinca alkaloid mechanism: In normal metaphase, the micro-tubulin 
complex polymerase consists of tubulin dimers stacked to form the spindle. However, 
in the presence of Vinca alkaloids, microtubules depolymerise and cannot stack 
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Figure 1.7: Histone octamer: inside the cell, DNA combines with specific 
proteins, and histones make nucleosomes. Usually, a histone includes an ‘H1 
family and four core histone nucleosomes H2A, H2B, H3, H4’, set in an octamer 
shape. DNA is infolded within nucleosomes, which are chromatin units adding 
methyl and acetyl groups to regulate gene expression by controlling the 
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1.4.3.2 Vinorelbine Resistance 
Resistance against VRL has been identified in NSCLC patients, the mechanism behind the 
resistance possibly coming from micro-tubulin components. Micro-tubulin complex 
polymerase consists of tubulin dimers (one a-tubulin and one b-tubulin). Tubulin 
polymerisation and function can be regulated by micro-tubulin polypeptide proteins, such as 
t protein, micro-tubulin associate protein 4, and stable tubule only polypeptide protein (Sève 
et al. 2005). 
It has been noted that a high level of class III b-tubulin is associated with poor progression 
and short OS in NSCLC patients exposed to VRL, as it causes resistance (Sève et al. 2005). 
Moreover, it has been determined that the expression of the tubulin isotype is associated 
with resistance against anti-tubulin agents. Ninety-three NSCLC patients in stages III and IV 
treated with VRL-based chemotherapy showed the high levels of class III b tubulin expression 
associated with resistance against VRL. The increase of class III-tubulin isotype correlates with 
shortening progression-free survival and overall survival P=0.002. High p2-a tubulin was 
associated with short OS P=0.018 (Sève et al. 2005). Additionally, immunohistochemistry 
assays performed for 2665 patients in the NCIC JBR.10 trial demonstrated that high 
expression of III b-tubulin levels is related to promotion of the response to adjuvant 
chemotherapy Vinorelbine/Cisplatin (Sève et al. 2007). 
The ABC family, which binds to ATP, is one of the drug transporter proteins that plays a role 
in drug resistance. It has been recorded that increased expression of ABC leads to an increase 
in drug efflux and a decrease in the drug accumulation that causes resistance to Cisplatin and 
Vinca alkaloids. P-glycoprotein (P-gp) from the ABC family of proteins works as a drug efflux 
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pump and is found to be overexpressed in drug resistance to NSCLC. One study conducted by 
(Wangari-Talbot and Hopper-Borge 2013) found that increased expression of ABC transporter 
proteins (ABCC10/MRP7) in 12 lung cancer cell lines was related to VRL resistance.  
Moreover, RLIP76 non-ATP binding cassette transport proteins, has having a role in mediating 
VRL transport and resistance. The ATP catalysis depends on the efflux of unconjugated VRL, 
(Stuckler et al. 2005) finding that the augmented expression of RL1P76 increases efflux, which 
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1.5 Selected sensitising agents  
In this study, I selected two epigenetic drugs (sodium valproate and decitabine) and two other 
approved drugs (aminomethylphosphonic acid and fendiline) to increase chemosensitivity. 
The basis of selection was literature based. Epigenetic sensitisation has been previously 
shown (Lin et al. 2008) while AMPA and fendiline have also been shown to sensitise cells to 
certain chemotherapy agents (Woods et al. 2015), therefore I wanted to validate previous 
observations. 
 
1.5.1 Sodium valproate (VPA) 
Due to its anticonvulsant properties, sodium valproate (VPA) is used to treat epilepsy and 
functions as a histone deacetylase inhibitor (HDACi). HDACis are small molecules or 
compounds that can inhibit the activity of HDACs, activate the expression of a large number 
of genes and subsequently alter various phenotypic characteristics such as cell proliferation 
or apoptosis (Figure 1.8) (Eggert et al. 2001). 
Valproic acid, in addition to selectively inhibiting the catalytic activity of class I HDACs, 
stimulates proteasomal degradation of HDAC2. Valproic acid induced HDAC2 turnover 
critically depend on the E2 ubiquitin conjugase Ubc8 and the E3 ubiquitin ligase RLIM. Ubc8 
gene expression is induced by VP. Thus, poly-ubiquitination and proteasomal degradation 









Figure 1.8: Mechanism of histone deacetylation inhibitor. Normally, cells control the coiling 
and uncoiling of DNA around histones. a- In the transcription gene, opening of the 
chromatin by histone acetyl transferases (HAT) can acetylate the lysine residues in core 
histones. In contrast, silenced genes to control the transcriptional amount by histone 
deacetylases (HDAC) can remove the acetyl groups from the lysine residues formation of a 
condensed chromatin. b- Histone deacetylation inhibitor (HDACi) can reverse the closing 
of the chromatin by blocking the HDAC that leads to the hyperacetylation of histones which 
opens the chromatin and increases the transcription. In cancer, most of TSGs are silenced, 
therefore, HDACi is targeted to re-express the silenced genes. Adapted from (Kazantsev 
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It has been reported that VPA induces differentiation of tumour cells through acetylation of 
histone H3 as well as to induce acetylation of α-tubulin (Khan et al. 2008; Gurvich et al. 2004). 
Moreover, sodium valproate stimulates alterations in the expression of other cell cycle-
related proteins, for example (p27 and cyclin D1) (Johnson and Walker 1999). 
Corresponding to the results of pre-clinical studies and early clinical trials, HDACi in 
combination therapy with chemotherapeutics may be very useful (Nolan et al. 2008) both for 
small cell lung cancer (Hubaux et al. 2010) and NSCLC (Schiffmann et al. 2016). More 
particularly, in pre-clinical studies, HDACi has been revealed to be synergistic with various 
chemotherapeutics agents, therefore it is expected to be most effective therapeutically when 
used in combination with other anti-cancer agents (Nolan et al. 2008). 
 
1.5.2 aza-2’-deoxycytidine (Decitabine) 
Decitabine DAC was used to treat the myelodysplastic syndrome (MDS). More particularly, 
DAC can incorporate into DNA and RNA during replication and transcription. 5-aza-20 -
deoxycytidine (decitabine) contains nucleoside analogues, which are phosphorylated by 
cellular kinases. When incorporated into DNA, they form a covalent bond with the DNMT 
trapping the enzyme and making it unavailable for additional methylation, thus subsequent 
in demethylation of replicating nascent DNA (Szyf 2009).  
The incorporation of decitabine in the nascent DNA leads to the formation of an irreversible 
covalent bond between the nitrogen in the fifth position of the modified pyrimidine and the 
catalytic site of the DNMT1 (Raynal and Issa 2016). DAC works as an inhibitor of 
methyltransferase, which results in demethylation in the endogenous sequence. 
Demethylation of DNA leads to an increase in the hypomethylation of the DNA responsible 
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for differentiation or apoptosis, leading to renovate the gene functions that may be 
responsible for cell proliferation and differentiation (Figure 1.9). 
 
 
Figure 1.9: Methyltransferase DNMTs: DNA methylation controls gene expression by 
working as an epigenetic switch to open and close the chromatin by altering the 
interactions between DNA and proteins. Unmethylated cytosines open the 
chromatin and increase the transcription. DNA methylation performed by transfer 
of methyl groups from S-adenosylmethionine (SAM) to the C-5 position of cytosine 
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Moreover, DAC does not cause a major suppression of DNA synthesis. Furthermore, DAC can 
create a covalent adduct between DNA and DNA methyltransferase that increases the 
cytotoxicity in rapidly dividing cancer cells. DAC works in S phase of the cell cycle, so the non-
proliferating cells are not sensitive (Goffin and Eisenhauer 2002). Decitabine has been tested 
in several trials (Šorm et al. 1964; Goffin and Eisenhauer 2002) in head and neck squamous 
cell carcinoma (Viet et al. 2014) and NSCLC (Momparler and Ayoub 2001). 
 
1.5.3 Aminomethylphosphonic acid (AMPA) 
Aminomethylphosphonic acid (AMPA) is an approved drug, which functions as a Serine 
hydroxymethyltransferase1 (SHMT1) inhibitor (Anderson and Stover 2009). SHMT is the 
major source of one-carbon units required for nucleotide synthesis. Humans have cytosolic 
(SHMT1) and mitochondrial (SHMT2) isoforms, which are up-regulated in lung cancers (Wang 
et al. 2007), making the enzyme an attractive drug target (Scaletti et al. 2019).  
Serine hydroxymethyltransferase plays an important role in cellular one-carbon pathways by 
catalysing the reversible, simultaneous conversions of L-serine to glycine and 
tetrahydrofolate (THF) to 5,10-Methylenetetrahydrofolate. In addition to folate, changes in 
amino acid metabolism can also affect cofactor levels. For instance, glycine and serine provide 
methyl groups to SAM via the activities of serine hydroxymethyltransferase (SHMT) and the 
glycine cleavage system. SHMT plays a role in epigenetic changes (Meier 2013).  
In addition, AMPA has been determined to be a proliferation inhibitor and increases the 
apoptosis activity in pancreatic cancer (Parajuli et al. 2016). 
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One of the PhD students as a previous study in the lung group studied examined the effect of 
SHMT1 expression when PE/CA-PJIS cell line is treated with AMPA combined with a 5-Fu 
chemotherapy agent.  The study demonstrated that AMPA increased the sensitivity of the 5-
Fu (Li et al. 2013). 
 
1.5.4 Fendiline  
Fendiline acts as a calcium channel blocker. A study has reported that targeting calcium 
signalling can reverse epigenetic silencing of tumour suppressor genes (Raynal et al. 2016).  
Another study has demonstrated that calcium-mediated splicing monitoring mechanism 
depends on the changes of histone modifications. Especially, the regulation that appears 
across changes in calcium-responsive kinase activities results in alterations of that histone 
modifications and subsequent changes in the transcriptional elongation rate and exon 
skipping. Also, the study determined that increased intracellular calcium levels result in 
histone hyperacetylation along the body of the genes containing calcium-responsive 
alternative exons by disrupting the histone deacetylase-to-histone acetyltransferase balance 
in the nucleus. Accordingly, the RNA polymerase II elongation level increases remarkably in 
those genes, leading to in the skipping of the alternative exons (Sharma et al. 2014). 
Changes in sarcoplasmic reticulum Ca2+ release caused changes in the expression of the 
developmental phase specific genes, which may be the result of changes in class IIa HDAC-
localisation (Karppinen et al. 2018). 
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Finally, Fendiline was chosen in this research to re-sensitize chemotherapies due to the fact 
that a paper published in 2015 on evidence in pancreatic cancer which showed that Fendiline 
inhibits proliferation and invasion by interfering with b-catenin signalling in the Wnt pathway, 
which is often deregulated in pancreatic cancer (Woods et al. 2015).  
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1.6 LANCL1 and LANCL1-AS1 role in chemosensitivity  
Despite the fact that the long noncoding RNA (LncRNA) revolution has impacted on all levels 
of gene transcription, the functions of LncRNA still remain unclear, with many studies having 
been conducted to investigate the basic attributes. As a result, a part of the current work 
identifies LncRNA markers in cancer management. 
The lung group at the University of Liverpool has recently evaluated LncRNA deregulation in 
non-small-cell lung cancer (NSCLC) to support the existing data. More specifically, they 
achieved a major discovery with 44 tissue pairs (normal and tumour), besides employing both 
29 technical pairs (normal and tumour) and 38 independent biological pairs (normal and 
tumour) to validate the target. This research determined that the 14 LncRNA profile 
remarkably discriminated NSCLC tissue from normal lung tissue, one of them being LANCL1-











Figure 1.10: LANCL1-AS1 is absent in NSCLC tissue in comparison with normal lung tissue. 
The ideal threshold was a 2> fold change and they chose a p < 0.01 value as a validation 
goal. The p-value and fold change values were used to gain a descriptive estimation of the 
microarray analysis validity. Adapted from (Acha-Sagredo et al. 2020). 
 
1.6.1 LANCL1-AS1  
1.6.1.1 LncRNA 
Recent improvements in sequencing technology have led to the understanding of a 
transcriptional profile of the entire human genome. This work has also led to the transcription 
of 70% to 90% of the mammalian genes (Fang and Fullwood 2016; Kashi et al. 2016; Lu et al. 
2013; Spizzo et al. 2012). 
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Around 2% of the transcribed genome is composed of proteins, specifically coding RNA. 
However, the majority of the transcribed genes, around 70% to 90%, are noncoding RNA, 
which is either short or long in nature. Short noncoding RNA usually has less than 200 
nucleotides and includes ribosome RNA (rRNA), transfer RNA (tRNA), micro RNA (miRNA), 
small RNA (SRNA) with between 21 and 24 nucleotides (nt), and piwi interacting-RNA (piRNA) 
(Fang and Fullwood 2016; Lu et al. 2013; Sun et al. 2014; Villegas and Zaphiropoulos 2015). In 
contrast, LncRNA contains more than 200 nucleotides that produce coding with a low 
expression level and low conservation. The definition of LncRNA is insufficient and arbitrary 
with the 200-nt cut-off, depending on the RNA purification method and according to the RNA 
binding to the cilice column during the RNA isolation process. LncRNA has an essential role 
not only in cell differentiation, proliferation and angiogenesis, but also the reduction of the 
apoptosis and the expression of tumour suppresser genes (Fang and Fullwood 2016; Lu et al. 
2013; Sun et al. 2014; Spizzo et al. 2012; Ponting, Oliver, and Reik 2009). 
Therefore, a better understanding of LncRNA’s biological functions and molecular 
mechanisms is necessary to study cancer development and prognosis. One of the 
characteristics of the protein-coding gene (PCG) is open-reading frame (ORF), which requires 
less than 100nt to synthesize proteins. LncRNA has a non-functional ORF with more than 
100nt without a synthesis protein, however, bifunctional RNA has been recognised as having 
the ability to either code or non-code the protein. LncRNA is variable, ranging between 
unstable (29%) with two-hour half-life and extra stable (70%) with a 12-hour half-life (Fang 
and Fullwood 2016). Moreover, LncRNA, located in the cellular cytoplasm and the nucleus (Lu 
et al. 2013) is involved in various diseases, especially glioblastoma and leukaemia, breast, 
colon, liver, prostatic, and bladder cancers. LncRNA can work as a proto-oncogene LncRNA 
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(AnRNA) or present as a tumour suppressor genes (TSG) such as maternity express gene 3 
(MEG3), which was found to be downregulated in relation with NSCLC. 
Research has found that the (MEG3) is regulated normally in glioblastoma cell lines, working 
as a TSG to reduce proliferation and increase apoptosis. MEG3 has been recognised to be lost 
in the early stage of tumour formation because of MEG3 hypermethylation in either the 
promoter or the intergenic sequence. Also, SPRY4-IT1 LncRNA was found to be 
downregulated in NSCLC patients with short-term survival, therefore both SPRY4-IT1 and 
MEG3 can be used as markers for the poor prognosis of NSCLC patients. Moreover, circulating 
LncRNA PR11-397D12-4, AC007403-1, and -ERICHI-AS1 plays a role in cancer prognosis and 
development, therefore it is used as markers to predict tumour genesis in NSCLC patients (Lu 
et al. 2013; Tang et al. 2015; Villegas and Zaphiropoulos 2015). 
LncRNA has a unique role as a histone marker in the promoter region such as trimethylation 
in lysine 4 and lysine 36 of histone 3 (H3K4m3 and H3K36m3, respectively) with the presence 
of a polymerase II (pol II) binding site, which can transcribe both PCGs and LncRNA (Figure 
1.11). Furthermore, LncRNA shows mono-methylation of lysin4 of histone 3 (H3K4m1) as 











Figure 1.11: LncRNA characteristics (Adapted from (Fang and Fullwood 2016). 
 
HOTAIR and MALAT were the first LncRNA distinguished before reviling the epigenetic 
markers. These LncRNAs act to suppress gene transcription by interacting with polycomb 
group proteins, around 20% interacting with polycomb repressive complex2 (PRC2) (Spizzo et 
al. 2012). LncRNA regulates gene expression through altering histone markers and changing 
chromatin structures by directing the polycomb protein to the target region in DNA, e.g. 
enhancer of Zeste homolog 2 (EZH2), which is a histone-lysine N-methyltransferase enzyme 
catalase subunit member in PRC2. The overexpression of EZH2 has been reported in NSCLC 
(Sun et al. 2014). LncRNA regulate transcription and translation mRNA, including through 










Figure 1.12: Transcriptional regulation mediated by long antisense noncoding RNA: (A) 
Antisense LncRNA is created at bidirectionally transcribed loci; (B) LncRNA is expected to 
co-operate “with regions of homology in a sense promoter-associated transcript”. 
Otherwise, LncRNA can work with the desirable strand. For example, interfaces are assumed 
to generate the recruitment of chromatin-remodelling proteins DNA methyltransferase 3a 
(DNMt3a), Argonaute 1 (Ago-1), enhancer of Zeste (ezh2), suv39 h1, histone deacetylase 1 
(HDAC-1), and G9a. (C) Local chromatin construction is altered by chromatin-remodelling 
complexes counting methylation of DNA, particularly at loci directed by the LncRNA. 
Antisense strand; sense strand in black. Adapted from (Saayman et al. 2014). 
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1.6.1.2 Antisense RNA 
LANCL1-AS1 is an antisense RNA, which is one of the LncRNA members. Antisense is a 
transcript frame, an opposite strain to the PCG ‘sense’. Around 63% of the transcriptional 
strain has an antisense pair with low expression level. Antisense can operate in a cis or trans 
way, depending on where they are active. Operating through the cis means that antisense 
RNA will interact with sense gene transcript frame in the same DNA region. Moreover, trans 
means the antisense RNA will interact with transcript gene in distance loci or on other 
chromosomes (Villegas and Zaphiropoulos 2015) (Figure 4.13). LncRNA application function 
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Figure 1.13: Antisense LncRNA classification scheme. Intergenic: when the sense and 
antisense near the head or the tail 3’ end of the sense near 3’ of antisense or 5’ end of the 
sense near the 5’ of the antisense. Divergent: when the head to the head of the sense and 
antisense. Convergent when tail to tail of the sense and antisense. Overlap: when the sense 
and antisense completely overlap. Adapted from (Villegas and Zaphiropoulos 2015). 
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1.6.3 LANCL1 
Lanthionine synthetase-like protein 1 LANCL1 is also known under alternative names, such as 
P40 or GRP69A. LANCL-like proteins are part of a big family containing groups of peptides that 
modify enzymes found in plants and bacteria. LANCL1 is the mammalian member in the 
LANCL-like protein (Huang et al. 2014), with LANCL1, LANCL2, and LANCL3 in humans. 
LANCL13 is still under investigation, while LANCL2 has a role in diabetes. LANCL1, which will 
be studied in this research, has 399 amino acids. Initially, research indicated LANCL1 as a 
factor of stomatocytosis due to the combination with the erythrocyte protein stomatin 
(Zhang et al. 2009).  
Due to the fact that the LANCL1, gene overlaps with LANCL1-AS1 and in order to learn more 
about LANCL1-AS1 (Figure 1.14) we chose to proceed with our investigation and inquire 
whether LANCL1-AS1 plays a specific role in the regulation of the LANCL1 gene. Furthermore, 
based on the study conducted by Zhang et al (2009), LANCL1 is known to establish a direct 
effect to protect the brain cell against oxidative stress, which plays a major role in 














Figure 1.14: (A) LANCL1(Chr.2: 210431249-210477618) and antisense LncRNA LANCL1-AS1 
(Chr. 2: 210324712 – 210470333), LANCL1-AS1 transcription occurs in the reverse direction 
from LANCL1. Carbamoyl phosphate synthase 1 (CPS1), that is localized in mitochondria and 
plays a role in regulatory the pyrimidine/purine balance to control the integrity of nuclear 
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DNAs. Silencing of the CPS1 gene expression result to an incomplete S-phase or apoptotic cell 
death due to increased DNA damage. The duplicated GGAA present in the CPS1/LANCL1 
bidirectional promoter region, is indicative of genes expressing mitochondria localised 
proteins and DNA repair related protein encoding genes (Uchiumi et al. 2017). (B) Despite 
their co-localisation, the two genes have no overlap at all in their exonic areas. However, the 
overlap of the preRNA forms in nucleus may affect splicing. Antisense transcription has been 
shown to control sense gene splicing. (Alló et al. 2009). At this locus, co-expressed sense and 
antisense transcripts can form double-stranded RNA (dsRNA) over the region of sense–
antisense overlap, leading to splice site masking and a following shift in mRNA isoform 
production (Garcia-Blanco, Baraniak, and Lasda 2004). (C) LANCL1 is highly expressed in the 
brain and testes while demonstrating moderate expression in lung. It has been chosen for 
investigation being the coding counterpart gene for LANCL1-AS1. – Figures adapted from 
https://www.ncbi.nlm.nih.gov/gene/10314 . 
 
However, little data have been published about LANCL1 function and characterisation in 
cancer development. LANCL1 was found to have a role in the development of breast cancer 
(Mayer et al. 2001; Althubiti et al. 2014) and prostate cancer (Wang et al. 2018). 
LANCL1 is highly expressed in the brain, testes, kidneys, and other organs (Mayer et al. 2001; 
Zhang et al. 2009) which display the crystal structure of LANCL1 in both free and complex 
forms with glutathione (GSH) showing a double-seven helix barrel fold; LANCL1 also contains 
many GxxG sequence motifs (Figure 1.15) its structure also allowing binding with the SH3 
domain of the EP58 signalling protein. Correspondingly, research shows that LANCL1 plays a 
role in signalling and differentiation, as LANCL1 mutation in PC12 cells (neuronal cell) may 
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result in defects in EP58, which lead to the inhibition of the neural growth factor (NGF), 




Figure 1.15: LANCL1 structure. The inner 
helix barrel is represented in yellow, while 
the outer helix barrel is shown in red. The 
seven GxxG-containing bulges are 
presented in blue, the cyan colour indicating 
the N-terminal, while the green colour 
showing C-terminal regions. The Zn2+ ion is 
represented with a magenta sphere. 
Adapted from (Rao's 2009). 
 
LANCL1 is essential for neural development, due to its role in protecting neural cells from 
oxidative stress damage (Huang et al. 2014), as deletion of LANCL1 in neural cells can lead to 
neural damage, caused by accumulating reactive oxygen species (ROS) in the brain and 
related protein, lipid, and DNA damage as well as mitochondrial dysfunction (Zhong et al. 
2012). As mentioned before, LANCL1 protects neural cells from oxidative stress (Huang et al. 
2014), in other words LANCL1 has a responsibility in reducing oxidative stress by binding with 
cystathionine β-synthase (CBS) and regulating CBS activity., the suppression of LANCL1 
expression increasing the CBS activity (Zhong et al. 2012). More particularly, CBS plays an 
important role in regulating oxidative stress by reducing GSH; that is, under oxidative stress, 
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CBS dissociates from LANCL1 and CBS activity begins to maintain the ratio between GSH and 
GSSG, this is reduced and oxidised glutathione (Zhong et al. 2012). 
Therefore, this research suggests that LANCL1 is an antioxidative gene. In addition, high 
LANCL1 expression was observed in prostate cancer (Wang et al. 2018).. The latter study also 
highlights the role played by LANCL1 in cell proliferation and that suppression of LANCL1 by 
siRNA in prostatic cells leads to cell death, being associated with apoptosis through inhibition 
of the JNK pathway (Wang et al. 2018). The high expression of LANCL1 is related with cancer 
cells, with a role in cell survival, especially in breast cancer (Althubiti et al. 2014). 
 
1.6.4 Reactive oxygen species (ROS)  
Reactive oxygen species (ROS) play a critical role within the cell through signalling 
transduction and modulate phagocytosis. Multicellular function can induce ROS, involving 
carefully regulated free radicals (e.g. superoxide, hydrogen peroxide). An essential production 
of free radicals can form a free electronic transport system (ETS) that manages oxidative 
stress inside the inner mitochondria membrane. During the ETS, two electrons are 
transported via oxidative phosphorylation involving adenosine triphosphate (ATP) (Figure 
1.16). 2% of the electrolyte escape electronic transport system produces ROS, which can 
interfere with various cellular micro-components, molecules such as proteins, lipids, DNA, 
and interact with essential functions inside the cell. Moreover, alterations caused by ROS can 








Figure 1.16: ETS electronic transport system. Free radical superoxide anions (O2-) are 
produced when electrons are given from complex I ‘NADH dehydrogenase’ and II 
‘succinate dehydrogenase’ of ETS to O2 instead of the suitable ETS subunit. Generally, it 
transports electrons to the CQ10 co-enzyme to end up with 4 electrons with subsequent 
transferal to oxygen. 2_4% of the total O2 consumption may go toward the production 
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1.6.4.1 Oxidative stress mediate cell cycle and apoptosis 
Oxidative stress targets many cellular molecular components such as cellular lipids that 
generate electrophilic aldehyde, the electrophilic proportion which allows aldehyde to 
interact with the nucleophilic group, e.g. amino acids cysteine, and serine. These are essential 
compared with the enzyme active site and are also important to maintaining the protein 
structure. The interaction of the aldehyde with protein leads to the inhibition of the enzyme 
and changes in the cellular receptor structure, which can interfere with cytotoxicity (Conklin 
2004). 
In the stimulation of oxidative stress, natural antioxidative molecules are not enough to 
prevent the damage caused by ROS. Chemotherapeutic agents generate reactive oxygen 
species (ROS) in patients undergoing chemotherapy, in whom toxically oxidative stress is an 
important contributor in the response to anticancer therapies (Conklin 2004). 
Prolonged exposure to chemotherapy-induced ROS has been reported to induce drug 
resistance. Chemotherapy may even cause cancer cells to have increased genetic instability 
due to mutations caused by ROS. (Sallmyr et al. 2008).  
Platinum coordination complexes and alkylating agents induce higher levels of ROS (Wang et 
al. 2013), while vinca alkaloids, nucleotide analogues and antimetabolites, including 
nucleoside, generate lower levels of ROS (Conklin 2004). 
There are two main reasons for increased cellular ROS production during chemotherapy. The 
first is the mitochondria ROS initiation and inhibition of the cellular antioxidant system. 
Chemotherapy has been identified to induce a loss of mitochondrial membrane potential and 
stop complexes I and II, resulting in disruption of mitochondrial electron transport chain (ETC) 
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and electronic leakage, as platinum also targets mitochondria and induces cellular ROS 
generation (Marullo et al. 2013). The second reason for elevated cellular ROS production 
during chemotherapy is the inhibition of the antioxidant system, which includes low 
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1.7 Extracellular vesicles role in chemosensitivity 
Exosomes work as cargo transporters by carrying multiple components from cells to other 
cells to facilitate communication (Simons and Raposo 2009). Recently, researchers have found 




Studies have reported that exosomes remain attached to the cell surface and may work as a 
signalling platform. Therefore, exosomes are more than a method to collect contents from 
the cells, working as cargo transportation to send information between cells (Bebelman et al. 
2018). 
Communication between cells is essential for development. More specifically, cells can 
communicate intracellularly with either neighbours or distance cells, local communication 
being facilitated by gap junctions that allow the signalling molecules pass through the 
cytoplasm. Communication over long distances by sending signals through hormones ca be 
achieved via the circulation. Extracellular vesicles (EVs) were found to play an essential role 
in either local or distant intercellular communication between the cells, an interaction which 
can alter the behaviour of the target cells. Exosomes play an essential role in cell 
communication by delivering information between cells following the release into the 
extracellular space (Bebelman et al. 2018). 
In 1983, exosomes discovered during maturation of sheep reticulocytes, small vesicles 
released in the extracellular space experience a generation of an “intracellular sac filled with 
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small membrane-enclosed structures of nearly uniform size” (Pan and Johnstone 1983). In 
1989, Rose Johnstone proposed the name ‘exosomes,’ when it was first mentioned as a term 
(Pan and Johnstone 1983). EVs work as cargo transporters carrying survival components like 
protein, RNA, and DNA to other cells (Bebelman et al. 2018). 
 
1.7.1.1 Structure, Formation, and Regulation 
Exosomes have a small cell size of 30 to 150nm and originate from endosomes that are 
released from all cell types and present cell fluids similar to saliva (Gallo et al. 2012), urine, 
(Lv et al. 2013) and blood (Hu et al. 2010). Exosomes, one of the EV subgroups generated 
directly from the plasma membrane, are spherically shaped and nanometers in size, 
containing bilayers consisting of multiple proteins and lipids derived from the parental cell 
(Bebelman et al. 2018). Moreover, when stained with negative staining under transmission 
microscopy, they are cup-shaped cells which (Simons and Raposo 2009) can be identified by 
specific proteins, such as tetraspanin proteins CD63, CD9, and CD81 (Simons and Raposo 
2009). To understand exosomes’ biogenesis, the following will describe intraluminal vesicle 
(ILV) budding and multivesicular body (MVB) formation (Figure 1.17) (Bebelman et al. 2018). 
The development of endocytic vesicles occurs from the plasma membrane by internalizing, 
through invagination, a part of the endosome small vesicles created inside endosomes, 
followed by the inward budding of the endosomes. Creating vesicles inside the lumen 
“intraluminal vesicles” leads to the accumulation of ILVs which could promote MVB 
formation. Ceramide is one of the lipid types that can regulate the formation of curvature of 
limiting membranes to form MVBs and ILVs (Heijnen et al. 1999). Ceramide forms the 
membrane’s curved shape created by sphingomyelin which can be hydrolysed by neutral 
sphingomyelinase (ns Masch), leading to budding ILV conversion into MVBs. Furthermore, 
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endosomal sorting complex required for transport (ESCRT) is responsible for sorting and 
ubiquitinating proteins in ILVs (Trajkovic et al. 2008). An infusion of MVB with plasma 
membrane causes the release of the vesicles’ content, i.e. exosomes. The release mechanism 
of these intracellular vesicles outside the cells is opposite from the mechanism of 
eternalization of extracellular molecules to inside a cell (Henne, Buchkovich, and Emr 2011). 
MVBs transport to plasma membrane along the microtubules through molecular motor 
kinesins, which regulated by ArI8 and RAB7-dependent protein complexes and docking MVBs 
to plasma membrane controlled by RAB27 and RAB35. Also, this process is assisted by 












Figure 1.17: Exosome Formation: The exosome originates from the endosome, formed from 
the plasma membrane. Early endosomes become mature later and the inward budding 
appears to create numerous ILV. The accumulation of ILVs could lead to MVBs. There are 
two ways that MVB can present, either by degradation by lysosomes or fusing with the 
plasma membrane to release exosomes. Moreover, microvesicles can also form the budding 
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After transport and docking, MVBs bind with soluble N-ethylmaleimide-sensitive factor 
attachment protein receptors (SNAREs) to infuse with the plasma membrane. SNARE has 
been reported to have a role in releasing exosomes in cancer cells such as SNAP23, syntaxin-
4, and vesicle-associated membrane protein (Verweij et al. 2018), therefore suggesting the 
ability of a multifaceted mechanism to control SNARE by phosphorylation or other different 
residues that regulate exosomes release (Snyder, Kelly, and Woodbury 2006). At the end of 
MVBs’ infusion with plasma membrane, the release of the exosomes in the extracellular 
environment leads to the interaction with and influence of the extracellular matrix; it can also 
enter the circulation through lymphocytes or blood. Ras-related protein (Rab27a and Rab27b) 
are responsible for regulating exosome secretion, with researchers finding that 
downregulating Rab27 affects Synaptotagmin-Like Protein 4 (SYTL4), which blocks exosomes’ 
secretion (Ostrowski et al. 2010). 
The endosomal sorting complex required for transport (ESCRT) family includes ESCRT 0, ESCRT 
I, ESCRT II, ESCRT III, which are essential for sorting special proteins into ILV (Katzmann, 
Odorizzi, and Emr 2002). Regarding factors blocking ESCRT that lead to the inhibition of 
exosome secretion, studies have found that the inhibition of Hrs (hepatocyte growth factor-
regulated tyrosine kinase substrate), which is one component of ESCRT-0 membranes, may 
result in a reduction of exosomes released in HeLa cells (Hoshino et al. 2013). Moreover, 
diminished tumor susceptibility gene 101 (TSG101) leads to a reduction in exosomes release 
among tumour cells, immobilizing in human retinal pigmented epithelial 1 (RPE1) cells (Figure 
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Figure 1.18: ESCRT family. ESCRT-0 plays a fundamental role in the creation of multivesicular 
bodies by binding and cargo clustering ubiquitinated proteins and/or receptors on 
endocytosed receptors. This cargo protein will join with ILV and become part of exosomes. 
ESCRT I helps in the generation of multivesicular bodies by clustering ubiquitinated proteins 
and operating as a bridge between the ESCRT-0 and ESCRT-II complexes, including tumour 
susceptibility gene 101 (TSG101), which incorporate with ubiquitinated cargo protein and 
lead to the activation of ESCRT II. ESCRT II has multifaceted functions primarily observed 
during the biogenesis of MVBs and the delivery of ubiquitin-tagged proteins to the 
endosome. Once active, the budding can start, generating MVB proteins. Ubiquitin-tagged 
proteins are passed from ESCRT-0 to ESCRT-I and then to ESCRT-II. ESCRT III, which pinches 
the cargo containing closed vesicles, “forms long filaments that coil around the site of 
membrane constriction just prior to membrane cleavage” and is disassembled by vascular 
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1.7.1.2 Contents 
Exosomes can carry different components, such as proteins, lipids, RNA and DNA, which make 
it a potential tool for genetic therapy to control gene expression (Figure 1.19) (Bebelman et 
al. 2018). 
Exosome membranes involve many proteins and lipids, having the ability to carry a large 
molecule such as a protein (Clayton et al. 2007).  
Many studies have reported that EVs collected from alternate media or plasma were found 
to include genomic DNA (Balaj et al. 2011), mitochondrial DNA, (Sansone et al. 2017).  
The RNA, which is transported by exosomes to target cells, has the ability to transform 
horizontally from the donor cell to the recipient cell, which was first demonstrated by 
Ratajczak in 2006. Messenger RNA (mRNA) and microRNA (miRNA) have been found in 
exosomes (Villarroya-Beltri et al. 2013; Gibbings et al. 2009). Short-noncoding RNA is 
abundant in eukaryotic cells. Exosomes contain more noncoding RNA, which can modify gene 









Figure 1.19: Exosomes structure: exosomes have the ability to involve a wide range of 
molecules including viruses, nucleic acids (RNAs and DNA), and microRNAs depending on a 
variety of factors, including cell type or origin. Many factors inducing exosomes content 
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1.7.2.3 Trafficking Exosomes 
Different means of exosome interaction with recipients include delivering interactions 
between transmembrane protein exosomes with signalling receptors of target cells or 
infusing the exosomes with the plasma membrane. Once exosomes are engulfed by recipient 
cells, they merge with endosomal components in order to undergo another stage of 
transcytosis and be released to the neighbouring cells (Zhang et al. 2015). 
 
1.7.3 Exosomes Function 
Communication is facilitated between the cell and transport components to show 
physiological response, as the old function of exosomes was assumed to be that of a carrier 
for all the unwanted protein during cell maturation. Exosomes can play a role in the biological 
process, such as removing all unrequired protein and RNA, as well as antigen presentation in 
the immune response, coagulation, inflammation, and angiogenesis and transferring miRNA 
horizontally (Bebelman et al. 2018). Exosomes are often associated with many diseases. For 
instance, in cancer, exosomes play an essential progression role in preparing the protumour 
microenvironment by transferring proteins and miRNA to remote areas to induce 
angiogenesis, thrombosis, and proliferation. Exosomes carry the misfolded protein derived 
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1.7.4 Exosomes and Cancer 
Mature MVBs can operate in two ways, either fusing through the plasma membrane to 
release exosomes, or degrade their cargo by fusing with lysosome (Riches et al. 2014). The 
rate between these two pathways is recognised to be imbalanced or shifted in cancer cells, 
which was reported to cause exosome release in cancer cells more so than normal cells 
(Riches et al. 2014; Muntasell, Berger, and Roche 2007). 
The properties of exosomes in the cancer microenvironment are recognised by their cargo 
and the dynamic of the release and uptake. It has been shown that cancer cells release EVs 
more than normal cells and that overexpression of ESCRT syntenin and heparan has been 
reported in tumour cells (Koliopanos et al. 2001).  
 
1.7.5 Exosome-Induced Chemoresistance  
Drug resistance can spread between cells by molecular changes carried by exosomes which, 
engulfed by recipient cells, receive drug resistance information from the resistant cells 
(Giallombardo et al. 2016). There are three methods for exosomes to mediate drug 
resistance: drug export to the exosome pathway, neutralization of an antibody-based drug, 
and exosomes mediation of the miRNA transfer (Figure 1.20) (Giallombardo et al. 2016). 
Firstly, the drug export via the exosome pathway includes the biological reaction for 
regulation by an influx and efflux of the biological matrix through the nuclear and plasma 
membrane (Azmi, Bao, and Sarkar 2013), for example, in ovarian cancer cells (Giallombardo 
et al. 2016). In this case, researchers have found that the resistance against cisplatin in ovarian 
cancer was related with abnormality in protein trafficking and secretion. Lysosomes have 
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decreased by 40% in resistance cell lines as compared to sensitive cell lines. Also, exosomes 
released from resistance cells contained 2.6-fold more cisplatin than those released from 
sensitive cells. Besides, it has been concluded that a significant increase in gene expression 
may produce function in membrane fusion and vesicle trafficking (Safaei et al. 2005). 
Resistant cells have reduced in size remarkably due to abnormality in lysosome proteins and 
partially transport cisplatin to exosomes. (Safaei et al. 2005). 
 
1.7.6 Exosome in therapy 
Exosomes are used for both diagnosis and therapy, for example the diagnosis of cancers such 
as prostate and breast cancers. 
Although small interference RNA (siRNA) is used in genetic therapy to disrupt the gene of 
interest, siRNA has a low stability and fast degradation in the systemic circulation. Using 
exosomes to deliver siRNA can act as a protector for siRNA to deliver it to the target (Alvarez-
Erviti et al. 2011). Researchers have attempted to find a way to deliver the vector in gene 
therapy, believing that exosomes can deliver siRNA to T-cells and monocytes in a safe way 









Figure 1.20: Outline of three exosome-mediated drug-resistance mechanisms. Adapted from 
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1.7.6.1 Delivering Drugs 
Exosomes are involved in many biological and pathological processes. More specifically, the 
fact that exosomes work as a transporter allows scientists to identify new approaches to 
delivering drugs and other nanoparticles (Azmi, Bao, and Sarkar 2013). Recently, researchers 
have been hoping to use exosomes as a drug delivery system based on exosomes properties 
(Ingato et al. 2016; Boelens et al. 2014). 
However, a later study isolated exosomes or EVs from prostatic cancer cells, followed by 
loading the exosomes with paclitaxel and found that paclitaxel delivered to recipient cells led 
to an increase in cytotoxic effects (Armstrong, Holme, and Stevens 2017). 
Last but not least, exosomes were determined to be a new approach to deliver drug therapy. 
It offers a survival advantage, such as avoiding build-up or turnover in the liver as well as 
preventing the first-pass metabolic effect that reduces the concentration of drug at the target 
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1.8 Aims and Objectives 
The main aim of this study is to expand the current knowledge in sensitizing non-small cell 
lung cancer (NSCLC) cells to four chemotherapeutic agents (cisplatin, carboplatin, 
gemcitabine and Vinorelbine).  
The specific objectives are: 
1- To investigate the efficiency of two epigenetic (Decitabine, valproic acid) and two 
non-epigenetic (aminomethylphosphonic acid and fendiline) compounds in 
modifying the sensitivity of NSCLC cells to the four above mentioned 
chemotherapeutic agents. 
2- To explore the role of LANC1 and LANCL1-AS1 genes in chemosensitivity to the four 
drugs. 
3- To investigate the changes that extracellular vesicles (EVs) undergo following drug 
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Chapter 2: Materials and Methods 
 
2.1 Non-small cell lung cancer cell lines and growth 
condition 
Eight non-small cell lung cancer (NSCLC) cell lines have been used in this study, namely (A549, 
CALU-3, CALU-6, COR-L23, H358, LUDLU, SK-LU-1, and SK-MES-1 (seeTable 2.1). Prior to any 
experimentation, cell authentication has been performed using the GenePrint® 10 system (cat 
no. B9510, Promega, UK; see Table 2.2). In addition, the mycoplasma-free condition was 
verified using an e-Myco™ plus Mycoplasma PCR Detection Kit (cat no. 17341). We amplified 
10 ng of DNA from each NSCLC cell line using an Applied Biosystems® 3130 Genetic Analyzer 
(Thermo Fisher Scientific, UK). Also, amplification products were mixed with an Internal Lane 
Standard 600 and allelic ladder using the GeneMapper® ID-X software (Applied Biosystems). 
The allelic profiles found (Table 2.2.) where verified against the data in ATCC database. Eight 
NSCLC cell lines (A549, CALU-3, CALU-6, COR-L23, H358, LUDLU, SK-LU-1, and SK-MES-11) 
were grown and maintained in Dulbecco’s modified Eagle medium (DMEM/F-12 medium 
supplement [1:1]) with L-glutamine LOT1737510 and 5% foetal bovine serum Fetal bovine 
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Table 2.1: NSCLC cell lines used in this study and their associated histological types 
NSCLC cell line Histological type 
A549 Adenocarcinoma 
CALU-3 Adenocarcinoma 
CALU-6 Anaplastic carcinoma 
COR-L23 Large cell carcinoma 
H358 Bronchioloalveolar adenocarcinoma 
LUDLU-1 Squamous cell carcinoma 
SK-LU-1 Adenocarcinoma 
SK-MES-1 Squamous cell carcinoma 
 
Table 2.2: STR profiles of NSCLC cell lines  
 A549 CALU-3 CALU-6 COR-L23 H358 LUDLU1 SK-LU-1 SK-MES-1 
Amelogenin X, Y X X X,Y X, Y X X X, Y 
CSF1PO 10, 12 19 12 11 11, 12 11 10 12 
D13S317 11 12 11 10, 11 8, 12 12 10 11 
D16S539 11, 12 12, 14 13 11, 13 12, 13 13, 14 8 13 
D5S818 11 11 11 10, 12 10, 12 12 11 11 
D7S820 8, 11 10, 11 10 9 10, 11 10, 12 9 8 
TH01 8, 9.3 6, 9, 3 9 9 6 6 7 6, 9.3 
TPOX 8,11 8 8 8, 11 8, 9 8, 11 8, 10 8 
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2.2 Cell exposure to chemotherapeutic agents 
2.2.1 Cell growth curve 
A cell growth curve was generated to determine the characteristics of each cell line. 
Therefore, in order to maximize growth, 103 cells were seeded in flat-bottomed, 24-well 
plates in six replicates and cultured in 1 ml of DMEM + 5% FBS. In order to count living cells, 
MTT assay was then performed for six replicates every 24 h over 4 days. The average of the 
cell counts was calculated for six replicates on a daily basis. A pilot test was implemented 
before the actual cell growth to establish sitting protocol. 
 
2.2.2 Examination of cellular phenotypic characteristics 
We used an Eclipse TS100 inverted microscope (Nikon) to examine the cell line phenotype 
and to monitor cell growth rungs, confluence, and the formation of colonies. 
 
2.2.3 NSCLC cell lines treated with chemotherapeutic agents 
Depending on the proliferation rate of NSCLC cell lines, 103 cells of A549, CALU-6, COR-L23, 
H358, SK-LU-1, and SK-MES-1  and 104 cells of CALU-3 and LUDLU-1 were seeded in each well 
of flat-bottomed, 48-well plates in six replicates, cultured in 500 µl growth medium + 5% FBS, 
and incubated overnight. The next day, confluence reached 40% and the medium was 
replaced with fresh medium containing a range of concentrations of 0–4 µM gemcitabine (cat 
no. G6423, Sigma-Aldrich), 0–0.5 µM vinorelbine (VRL; cat no. V2264, Sigma-Aldrich), 0–0.1 
mM cisplatin (cat no. P4394, Sigma-Aldrich), 0–0.1 mM carboplatin (cat no. C2538, Sigma-
Aldrich) cell lines were incubated for 48 h in a 37°C, 5% CO2 incubator. 
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2.2.4 NSCLC cell lines treated with H2O2  
The eight NSCLC cell lines were each seeded in 25-cm2 flasks with medium + 5% FBS, left 
until confluence reached 70%, then treated with two different doses of 25 µM/ 50 µM H2O2 
for two different periods, namely 3h and 6h to extract RNA. In order to confirm the results, 
SK-MES-1 was seeded in a flat-bottomed, 12-well plate until reaching 70%, and six replicates 
were control untreated while the other six replicates treated with 25µM H2O2 for 6h. 
Furthermore, parental cell line SK-MES-1, scrambled and overexpressed LANCL1-AS1 clones 
were grown in coumermycin or novobiocin. Also, knocked down LANCL1 clones A6/26, A9/10 
were treated with seven different doses of H2O2 range between (100µM-0) and incubated in 
37°C, 5% CO2 for 48 h after MTT assay was performed. 
 
2.2.5 Drugs sensitization experiments  
For the epigenetic sensitization such as DNA methylation/histone acetylation inhibition, the 
two most resistant cell lines to the (cisplatin, carboplatin, gemcitabine and vinorelbine) drugs 
were treated, once combined, with the same range of concentrations once combined 
epigenetic agent 100 nM of decitabine (5-Aza-2’deoxcytidine [DAC]; cat no. A3656, Sigma-
Aldrich) or 1 mM valproic acid (VPA; cat no. P4543, Sigma-Aldrich) with chemotherapeutic for 
48h or pre-exposed epigenetic agents for 48 h. Then, refresh the medium with the range of 
chemotherapeutics concentrations alone or plus the epigenetic drugs mix, while incubation 





95       
 
Additionally, we attempted to sensitize the same two resistant cell lines for each 
chemotherapeutics combined with 25 mM of aminoimethyl phosphonic acid (AMPA; cat no. 
324817, Sigma-Aldrich) or 10 nM fendiline (cat no. 6407, Tocris Bioscience, Minneapolis, 
Minnesota, UK), followed by incubation for 48 h.  
 
2.3 Proliferation (MTT) assay  
The cell viability of NSCLC cell lines, overexpressed LANCL1 AS1 and knocked down LANCL1 
clone, and drug toxicity were measured by using an MTT proliferation assay. MTT assay can 
assess metabolic activity inside a cell by determining the purple-coloured formazan product 
of reducing tetrazolium dye MTT 3-(4, 5-dimethylthiazol dimethylthiazol-2-YL)-2, 5-diphenyl 
tetrazolium bromide, with absorption of the purple colour product occurring at ~570 nm. 
However, as dead cells lose the ability to reduce MTT into insoluble formazan, this makes MTT 
becomes a useful marker for cell viability (Berridge, Herst, and Tan 2005). 
Cells seeded in flat-bottomed, 48-well plates to measure cell viability or treated with 
chemotherapeutic agents for a suitable duration to measure drug toxicity were washed with 
PBS and incubated with MTT (cat no. 45655, Sigma-Aldrich) and made up in fresh DMEM 
medium to a final concentration 0.75 mg/ml of MTT reagent; also, the incubation was for a 
period of 2.5–3.0 h at 37°C and 5% CO2. During this time, formazan crystal lysis with 200 µl 
of 0.04 HCL in isopropanol alcohol was completed. In the minutes thereafter, the developed 
purple colour became observable, its intensity being related to cell viability. To measure 
colour absorbance, a GENios plate reader (Tecan Austria GmBH) was used to record the 
optical density (O.D.) at 590 nm with a 630 nm reference absorbance (Figure 2.1). 
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Figure 2.1: MTT assay for SK-LU-1 NSCLC cell line treated with VRL. The first six columns 
from the left were treated with VRL different doses for 48h, and the remaining six columns 
were treated with VRL different doses + VPA (1mM) for 48h; the first row is the control. 
Concentration of cell viability was seen more in the columns treated with VRL depending on 
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2.4 Apoptosis Caspase-Glo3/7 assay 8/9 
The Caspase-Glo® 3/7 assay (Promega) is a homogeneous, luminescent assay that can 
measure the activity of caspase 3/7. The assay contains a luminogenic caspase-Glo® 3/7 
substrate is cleaved to liberation aminoluciferin, a substrate of luciferase used in the 
production of light, substrate involves the tetrapeptide sequence DEVD. Caspase-Glo® 3/7 
reagent is optimised for determining the caspase activity, luciferase activity, and cell lysis. The 
addition of Caspase-Glo® 3/7 reagent in the mixture lead to cell lysis, followed by caspase 
cleavage of the substrate and production of a glow-type luminescent signal. The Caspase-Glo® 
3/7 assay is aimed at practising with multi-well plate formats, making it perfect for automated 
high-throughput screening of caspase activity or apoptosis. The experiment was performed 
on resistant NSCLC cell lines seeded in white well, 96-well plates (LUMITRAC™ 200 Lot 
E14030M5; Greiner Bio-One) for the stated chemotherapeutics alone and chemotherapeutics 
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Figure 2.2: Apoptosis Caspase-Glo3/7 assay. Resistant NSCLC cell lines for the 
chemotherapeutics were seeded in a white 96-wells plate after treatment with desirable 
drug alone or combined with sensitizers for a suitable time period in 37°C, 5% CO2 condition. 
To prepare the reagent, the Caspase-Glo 3/7 substrate was mixed with Caspase-Glo buffer. 
Next, the plate was removed from the incubator, and reagent was added to the treated or 
control medium (1:1 ratio). The plate was incubated in RT for 1.5–2.h in darkness; this 
protocol results in cell lysis, followed by caspase cleavage of the substrate and generation 
of a glow-type luminescent signal measured by a luminometer gene plate reader (Tecan 
Austria GmbH). Image taken from (Promega 2019a). 
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2.5 The neutral Comet assay  
Also known as the single-cell gel electrophoresis assay (SCGE), the neutral comet assay is used 
to evaluate DNA strand break or damage in eukaryotic cells. Cells were treated with desirable 
chemotherapeutics combined with epigenetic agents for a suitable period in 37°C, 5% CO2. 
Cells were encapsulated in a low-melting point agarose suspension and embedded in high 
salt, resulting in the formation of nucleoids involving a supercoiled loop of DNA linked to the 
nuclear matrix. Electrophoresis was performed to the lysed cells at high pH that led to the 
‘structures resembling comets’, which were then stained with fluorescent stain SYBR® Safe 
DNA Gel Stain (cat no. P/N S33102, Thermo Fisher Scientific); as seen in Figure 2.3, the comet 
tail is the result of the amount of DNA damage. 
 
Figure 2.3: The neutral comet assay procedure. Adapted from (BiotechAdvisers 2019) 
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2.6 mRNA expression analysis 
2.6.1 RNA extraction  
We used a Direct-zol™ RNA MiniPrep Kit (Zymo Research, Irvine, California, UK) to extract 
RNA, with a centrifuge set at 16,000 ×g for 1 minute. Total cell line RNA extraction was 
preceded by cell lysis once confluence had reached 80%–85% in the culture flask. First, the 
liquid medium was discarded, and cells were washed with Dulbecco Phosphate-Buffered 
Saline (PBS); 600 µl of TRIzol® Reagent (Thermo Fisher Scientific) was then used for cell lysis. 
Cells were scraped with a plastic cell scraper and collected into 1.5-ml Eppendorf tubes and 
vortexed. An equal amount of ethanol 100% was added to homogenised lysate and mixed 
well by vortex for 1 minute. The whole mixture was transferred by micropipette to a Zymo-
Spin II column (Zymo Research) with a collection tube and then centrifuged. The collection 
tube containing the flow-through was discarded and replaced with a new one. Next, the 
DNase I treatment was conducted, followed by washing the column matrix 400 µl RNA Wash 
Buffer, and centrifugation. Also, the flow-through that followed the incubated DNase I 
treatment and contained 5µl DNase 1 with 75µl DNA digestion buffer was discarded. The 
DNase I treatment mix was prepared in an RNA-free tube, while the incubation was extended 
by 15 minutes at room temperature. 400 µl of the pre-wash buffer was added to the column 
after the incubation buffer, then centrifuged at this time for 2 minutes. To ensure that all the 
buffer had been removed, dry spin was performed for, a 4 minute. After transferring the 
column to the RNA-free tube, 40 µl of DNase/RNase-free water was warmed and then added 
directly to the column and incubated for 2 minutes; the at room temperature mixture was 
centrifuged for 2 minutes to elute the RNA. All RNA was stored in –80°C for future study, 
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except for a small amount of DNA that was taken to perform quality and quantity checking 
using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific). A UV-Vis 
spectrophotometer was used to identify RNA purity and quantity at 280/260 nm wavelength.  
 
2.6.2 Reverse transcription 
We created a single-strand cDNA using a high-capacity cDNA reverse transcription kit (Applied 
Biosystems). The manufacturer’s protocol, briefly explained below, was followed. the 
preparation of the master mix of reverse transcript (RT) included 2 µl of 10X RT buffer, 2 µl of 
Random Primer (RP), 0.8 µl of NTP mix (100 mM), 1 µl of MultiScribe™ Reverse Transcriptase 
(Invitrogen, Thermo Fisher Scientific), and 4.2 µl of RNAse free H2O. Thermal cycling was then 
used to perform transcript reaction under the following conditions: 10 minutes at 25°C, 120 
minutes at 37°C, and 5 sec at 85°C; the product cDNA was then diluted with ddH2O five times, 
and 3 µl of cDNA was used for the subsequent quantitative PCR reactions. 
 
2.6.3 Quantitative real-time PCR expression assay  
LANCL1 and LANCL1-AS1 were selected based on existing data taken from the lung group, 
who performed the investigation of the long non-coding RNA (LncRNA) dysregulated in 
NSCLC. The LncRNA profiles were carried out with the use of 44 pairs (normal, tumour) and 
completed both technical (29 pairs) and independent biological (38 pairs) validation of aims, 
with the intention of identifying LncRNA profiles significantly discriminating NSCLC tissue 
from paired normal lung tissue. Based on lung group findings, LANCL1 and LANCL1-AS1 were 
targeted to identify the state of expression on lung cancer by using qPCR-based expression to 
minimize optimisation time; also, a predesigned FAM-MGB-labelled TaqMan expression assay 
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was used to determine the expression level of both LANCL1 and LANCL1-AS1 in NSCLC cell 
lines and lung cancer tissue (Table 2.3). 
 
Table 2.3: Assay IDs and reporter dye of predesigned (Life Technologies) FAM-MGB-labelled 
TaqMan expression assays for the LANCL1 and LANCL1-AS1 genes 
Gene Assay ID Reporter dye Quencher 
LANCL1 H498-42-1438 FAM1 MGB-NFQ2 
LANCL1-AS1 H23-19-4440 FAM MGB-NFQ 
1FAM: Fluorescein amidite, 2MGB-NFQ: minor groove binding- non fluorescent quencher 
 
Endogenous controls ACTβ and TBP were selected as reference genes based on data from a 
microarray experiment (ALMAC Platform 2009) that clearly showed similar levels of ACTβ and 
TBP transcripts among lung normal and tumour samples (Table 2.4, Figure 2.4). 
 




(5’    3’) 
Reverse Primer 
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Figure 2.4: TaqMan Probe qPCR Method. Regarding the closeness of the reporter to the 
quencher stopping its fluorescence emission, the hydrolysation of the probe by 5' to 3' 
exonuclease activity of the Taq polymerase liberates the reporter and thus allows the 
emission of fluorescence. Subsequently, an increase in the product targeted by the 
reporter probe at each PCR cycle leads to a proportional increase in fluorescence. 
Fluorescence is exposed and measured in a qPCR. Adapted from (SinoBiological 2019). 
 
qPCR reaction (20µl total) were run in duplicate and contained 10µl of 2X QuantiTect Probe 
PCR Master Mix (Qiagen), 900nM of each F and R primer and 250nM probe (for both target 
and endogenous control) and 3µl of cDNA. Reactions were run on a 7500 Fast Real-Time PCR 
system (applied Bosystems. Cycling conditions are given in Tables 2.5 and 2.6); the Applied 
Biosystems 7500 software v.2.3 was used to analyse the data. Relative quantification value 
(RQ) expressed the mRNA level, calculated as RQ=2 (–DDCT). A calibrator sample (that 
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Table 2.5: Thermal profiles of LANCL1 quantitative fluorescence PCR 
Step Temperature Time No. of Cycles 
Taq Activation 95°C 15 minutes 
45 
Denaturation 94°C 15 Sec. 
Annealing 55°C 15 Sec. 
Extension 60°C 50 Sec. 
 
Table 2.6: Thermal profiles of LANCL1-AS1 quantitative fluorescence PCR 
Step Temperature Time No. of Cycles 
Taq Activation 95°C 15 minutes 
50 
Denaturation 94°C 15 Sec. 
Annealing 55°C 20 Sec. 
Extension 60°C 45 Sec. 
 
2.7. Detection of LANCL1 splice variation in NSCLC 
The LANCL1 gene schematic is shown in (Figure 2.5). The splice variant PCR assay was 
designed by using the oligo 7.0 primer (Molecular Biology Insights, Inc., UK). An endpoint PCR 
reaction was utilized with a final volume of 20 µl that contained 10 µl of 2X HotStarTaq Master 
mix (Qiagen), 0.8 µl of end primer mixture (stock solution, 100 mM), 5 µl of reverse primer 
RP (stock solution, 100 mM), and added 3 µl of reverse transcript RT product (cDNA diluted 
five times); this added up to 6.2 µl ddH2O with primer vortex and spin to react in endpoint 
thermal cycle (Table 2.8) annealing temperature (Table 2.7). That product is then used to 
determine the quality and quantity of the umbilical sample by performing 2% agarose gel 
electrophoresis and UV visualisation on a UVP VisionWorks™ LS instrument.  
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Figure 2.5: LANCL1 splice variation 
 
Table 2.7: LANCL1 transcript variants assay designed assays for endpoint PCR 
Assay 
Forward Primer 
(5’    3’) 
Reverse Primer 






AAG GGC TTC AGG ACG CGC 
(Exon) 






CCT GGC AGG AAC TGG GC 
(Exon) 
GCA GCA TCA AAG TAG CCT TCG 
(Exon) 
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Table 2.8: Thermal profile of LANCL1 splice variants endpoint PCR reaction 
Step Temperature Time No. of Cycles 
Taq Activation 95°C 15 minutes 
40 
Denaturation 95°C 30 Sec. 
Annealing X*°C 30 Sec. 
Extension 72°C 30 Sec. 
Final Extension 72°C 10 minutes 
 X* Table 2.7 (Annealing Temperature X°C) 
 
2.8 DNA methylation analysis 
2.8.1 DNA extraction 
DNeasy® Blood & Tissue Kit (spin column protocol; Qiagen) was used to isolate DNA from the 
NSCLC cell lines. The manufacturer’s protocol was followed and is briefly described below. All 
centrifuge settings were 16,000 × g, and NSCLC cell lines were seeded in 75 cm2 until 
confluence reached 80%–85%. The medium was then aspirated, and cells washed with PBS. 
Next, 500 µl ATL lysis buffer with 10 µl Proteinase K (Qiagen) was added. Cells were scraped 
by plastic scraper, followed by the addition to the mixture 500 µl of AL lysis buffer and mixed, 
the cell lysates were transferred to a 2 ml centrifuge tube; the tube was incubated in at 56°C 
for 15-30 minutes. After finishing the incubation period, 500 µl of Ethanol (100%) was added 
and the resultant mixed well via vortex. The entire mixture was then transferred to the 
DNeasy Mini Spin column (containing a silica-based membrane), which was placed in a 2 ml 
collection tube. Centrifuge followed for 1 minute, 700 µl of AW1 buffer was then added to 
the column, followed by another centrifuge for 1 minute. Next, 680 µl of AW2 buffer was 
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added and centrifuged for 1 minute, followed by the repetition of the AW2 buffer wash. 
Furthermore, a dry spin centrifuge was conducted for 4 minutes to ensure that the entire 
DNeasy membrane was dry. The DNAeasy column was then transferred to a new 1.5 ml 
Eppendorf tube and 50 µl warm AE buffer added, with incubation at room temperature for 5 
minutes. The sample was eluted by centrifuge for 1 minute, and a NanoDrop 2000 
Spectrophotometer was used to assess the quality and quantity of the DNA sample at 
wavelength 260/280 nm. 
 
2.8.2 Sodium bisulphite treatment of DNA 
To determine LANCL1 methylation status in 60 samples containing 40 NSCLC tumour samples 
and 20 normal samples (control), the EZ DNA Methylation-Gold™ Kit (cat no. D5005 & D5006, 
Zymo Research) was utilized to perform bisulphite genomic sequencing. In the bisulphite 
conversion reaction, the methylated cytosine (mC) does not change, while the unmethylated 
cytosine (C) is converted to Uracil (U). The manufacturer’s protocol was followed. First, CT 
conversion reagent was prepared by adding (in order) 900 µl of water, 300 µl of M-Dilution, 
and 50 µl M-Dissolving buffer mixture with vortex for 2 minutes, then left for 8 minutes in the 
rotor that will prepare the reaction and ensure preparation of the M-wash buffer by adding 
24 ml of Ethanol (100%) to 6 ml M-wash buffer concentration (D5006) or 96 ml of Ethanol 
100% to 24ml of M-wash buffer concentration (D5006) before use. To start the conversion 
reaction in the PCR tube strip, mix 130 µl of CT conversion reagent were mixed with 20 µl of 
each DNA sample (1.6 µg of the sample), mix by pipetting upside down or by flicking the tubes, 
followed by the centrifuge of the tubes, replacement of the tubes in the thermal cycler, and 
the next step of 98°C for 10 minutes, 64°C for 2.5 h. 
 
 
108       
 
2.8.3 Reaction clean-up 
Following the conversion reaction, samples were transferred to a 1.5 ml Eppendorf tube. The 
pipetting of 600 µl of M-binding buffer in a 1.5 ml Eppendorf tube was conducted successfully. 
The entire mixture was then transferred into a Zymo-spin™ IC column placed into a collection 
tube, centrifuged at >10,000 × g for 1 minute, followed by the discarding of the flow. 
Subsequently, 200 µl of M-Desulphonation buffer was added to the tube and left at room 
temperature (20°C–30°C) for 15–20 minutes; after the incubation period was then followed 
by high-speed centrifuge for 30 sec, and flow-through discarding. Then, 300 µl of M-wash was 
added to the tube and centrifuged at high speed for 30 sec; this step was repeated, followed 
by 4 minutes of dry spin to ensure removal of all traces of alcohol. Next, the Zymo-Spin™ IC 
column was transferred to a new 1.5 ml tube, and 35 µl of warm M-Elution buffer was added, 
followed by 5-minute incubation at the new temperature; a 1-minute high-speed spin eluted 
the sample DNA. 
 
2.8.4 Preparation of pyrosequencing samples 
The method of this technology comprises two parts: the first part is done manually, preparing 
the sample to be sequenced; while second is done automatically, taking place in a 96 MA 
pyrosequencing (Qiagen) instrument.  
The first step of LANCL1 pyrosequencing is to prepare the DNA samples to be sequenced 
through amplification of the target DNA sequence by PCR with LANCL1 assay (GenBank 
accession no. M80343); both primers were designed using PyroMark Assay Design 20 
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Table 2.9: Designed primers for LANCL1 pyrosequencing assays. BIO: biotinylated end 
Promotor Forward Primer (5’   3’) Reverse Primer (3’   5’) Sequencing Primer (5’   3’) 
LANCL1 BIOTTAATAAATTGTAAGAGAGAAGGG CCCCCCAATTCCTACCAA AACCAATCAAAACCTT 
 
PCR amplification for the target sequence was performed using Qiagen HotStarTaq plus 
Master Mix Kit, 5µM biotinylated primer, 10µM non-biotinylated primer, and 4µl 
(approximately 80ng) of bisulphite-treatment DNA; the thermal profile is shown in (Table 
2.10). The quality of the amplification reaction product was assessed by 20% agarose gel and 
visualised on a UVP VisionWorks LS instrument. The result of the amplification reaction was 
that methylated cytosine (mC) transferred to cytosine (C), while uracil (U) transferred to 
thymine (T). We thereby were able to show cytosine C as a C/T SNP (Figure 2.6). 
 
Table 2.10: Thermal profile of LANCL1 endpoint PCR reaction for the production of 
pyrosequencing template 
Step Temperature Time No. of Cycles 
Taq Activation 95°C 15 minutes 
42 
Denaturation 94°C 30 Sec. 
Annealing 53°C 30 Sec. 
Extension 72°C 20 Sec. 
Final Extension 72°C 10 minutes 
 
 




Figure 2.6: Principle of pyrosequencings-based methylation analysis. The methylated C 
(green) and unmethylated C (red) are differentiated by bisulphite conversion and PCR 
During pyrosequencing, DNA methylation at each individual site is determined by the 





111       
 
2.8.5 Pyrosequencing analysis  
The LANCL1 DNA methylation status was examined in 60 samples (40 NSCLC tumour and 20 
normal lung samples) using the Pyromark SQA kit (Qiagen) following the manufacturer’s 
protocol. The reaction took place in a 96 MA Pyrosequencer (Qiagen). Briefly, 75µl of the 
pyrosequencing binding mix included 50µl of PyroMark binding buffer, 23µl of ddH2O, and 
2ml of streptavidin-coated sepharose beads mixed with PCR product; the mixture was then 
transferred to a pyrosequencing plate, with the assistance of a vacuum preparation tool, and 
the beads, in which the desired PCR product was bound, were then held over the filter, 
through a capture step in purification. The tip of the vacuum was then immersed in the second 
out of three baths (first, 70% ethanol, then NaOH for the determination and separation of the 
DNA strand). Finally, a wash buffer was used to neutralize the immobilised strand. This 
process only results in the PCR product containing streptavidin beads, with the biotinylated 
strand remaining attached to the tool. Subsequently, the beads were released in a new 96-
well pyrosequencing plate, which included 45µl of annealing mix per well. This mix was 
prepared in advance with 43.5µl PyroMark annealing buffer and 1.5µl of LANCL1 
pyrosequencing primer. At this point, the plate was incubated at 80°C for 2 minutes, then 
cooled for 2 minutes at room temperature, as incubation period is the time required to 
prepare the pyrosequencing cartridge by dispensing the nucleotide, substrates, and enzyme 
reagents out of the proper well. The pyrosequencing plate and cartridge are then placed into 
the pyrosequencing instrument, while the DNA template, with annealing sequencing primer, 
were being incubated with enzyme DNA polymerase, ATP sulfurylase, luciferase, and apyrase, 
and additionally, enzyme substrates adenosine phosphosulfate (APS) and luciferin.  
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In a systematic manner, triphosphates (dNTP) were injected into the reaction one by one, 
respectively. In the DNA strand, if the first dNTP creates a U base pair with a template strand, 
the DNA polymerase will catalyse the incorporation, as each incorporation is finished by the 
release of inorganic pyrophosphate (PPi) with an equal amount to incorporate the nucleotide. 
PPi converts to ATP in present APS by ATP sulfurylase (PPi works as a substrate for ATP 
sulfurylase). The amount of the ATP released equals oxyluciferin ATP that helps drive luciferin, 
and this generates a visible light signal wherein the amount of the signal is equal to the 
amount of the ATP. The charge coupled device (CCD) captures the light produced as a result 
of the luciferase-catalysed reaction and displays it as a peak in the diagram. The number of 
nucleotides incorporated was proportionate to the height of each peak (light signal) (Figure 
2.7). The unincorporated nucleotides were removed by apyrase along with ATP, and 
nucleotide degradation in-between base addition by apyrase is important in the coordinated 
DNA synthesis. Subsequently, the complementary DNA strand is built up and the nucleotide 
sequence is identified from the signal peaks in the program (Figure 2.7).  
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2.9.1 LANCL1 knockdown by shRNA 
Five different constructs were utilised to target LANCL1 mRNA expression: four in the CDS 
region and one in 3’-UTR (Table 2.11) which belongs to type PLKO-hPGK-Puro vector, along 
with the scrambled control MISSION PLKO-hPGK-Puro non-mammalian shRNA Control 
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2.9.1.1 Propagation of MISSION short-hairpin (shRNA) constructs 
All the MISSION shRNA constructs (Figure 2.8) used in this research were propagated in a 
Luria-Bertani (LB) broth medium. 100 µl of the constructs was added to 150 ml LB medium 
supplement in 100 µg/ml of ampicillin and were left on the shaker overnight at 37°C and 150 
rpm. The next day, plasmid extraction was performed. 
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Figure 2.8: Graphic maps of MISSION PLKO-hPGK-Puro non-mammalian shRNA Control 
Plasmid DNA (Sigma-Aldrich). 
 
2.9.1.2 shRNA construct DNA isolation  
We used a ZymoPURE™ plasmid Maxiprep Kit (cat no. D4202&D4203) to extract the plasmids 
of the shRNA constructs, following the manufacturer’s protocol. Briefly, after the propagation 
step, 150 ml of fresh bacterial culture was divided in 3X 50 ml falcon tubes and centrifuged at 
3,400 × g for 10 minutes, followed by the supernatant being discarded in a beaker containing 
Chemgene. 14 ml of ZymoPURE PI buffer (red colour) was added to the pellet (~4.6 ml in each 
tube), re-suspended carefully via vortex, and then combined within one falcon tube. 14 ml of 
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ZymoPURE P2 buffer (green) was added and mixed by inverting the tube four to six times; for 
ensuring complete lysis, the tube was left standing for 1 minute. Next, 14 ml of ZymoPURE P3 
(yellow) was added and completely mixed until the entire tube mixture became yellow in 
colour, which meant that neutralization was complete; the tube was left standing for 5–8 
minutes to give the precipitate time to float to the top; then, ensuring that the bottom of the 
ZymoPURE syringe filter was plugged, followed by transferring the mixture to a ZymoPURE 
Syringe Filter with Luer Lock, the plug was removed from the bottom of the syringe filter and 
placed into a 50-ml conical tube. The solution was then pushed through the syringe filter by 
placing the plugs in the syringe, the result recovering around 35–33 ml of clean lysate. 14 ml 
of ZymoPURE binding buffer was added and mixed by inverting the tube 10 times. The Zymo 
spin™ V-P column assembly was then placed into the vacuum and the connections were 
ensured to be tight. The entire mixture was transferred to the column and the vacuum turned 
on until all of the mixture had passed through. After turning off the vacuum, the 50 ml 
reservoir from the loop of the column was discarded, followed by 5 ml of ZymoPURE wash 2 
added to the V-P column. Turning on the vacuum allowed all the liquid to pass through, 
therefore 5 ml of ZymoPURE wash 2 was added and the vacuum was turned on until all the 
liquid passed through, a step further repeated. To ensure removing all remaining wash buffer, 
the V-P column was placed in a collection tube and centrifuged at >10,000 × g for 4 minutes 
(dry spin). After transferring the V-P column in a new 1.5 ml Eppendorf tube, 400 µl of warm 
ZymoPURE elution buffer was added to the column and incubated for 2 minutes at room 
temperature, then centrifuged at >10,000 × g for 1 minute to elute the plasmid. A NanoDrop 
2000 spectrophotometer was used to assess the quality and quantity of the DNA at 
wavelength 260/280 nm. 
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2.9.1.3 Transfection of the cell line 
As SK-MES-1 shows the highest LANCL1 expression compared with the other NSCLC cell lines, 
it was chosen to be transfected with the LANCL1 constructs. TRCN0000011687, 
TRCN0000011690 were used with FuGENE® HD Transfection reagent (Promega), following the 
manufacturer’s protocol. Briefly, 5 × 105 cells/1 ml of SK-MES-1 cell line was seeded in a 10 
cm tissue culture dish and cultured in 8 ml of DMEM culture medium containing 5% FBS serum 
and antibiotic, incubated in 37°C and 5% CO2, and maintained until confluence reached 50%. 
As transfection was now possible, 5 µg of plasmid DNA was added to 15 µl FUGENE® HD 
reagent to reach a final volume of up to 400 µl diluted with fresh medium containing FBS and 
mixed by vortex for 5 sec, followed by a brief spin. Incubation was at room temperature for 
7–15 minutes, during which the medium in the dish was aspirated and the dish washed with 
10 ml PBS after the addition of 8 ml of medium + 2.5% FBS and antibiotic selected marker 
puromycin 3 µg/ml (the short hairpin construct has the puromycin resistance gene); after the 
incubation period, the mixture was then added dropwise carefully into the dish in the cell 
culture medium while rotating the dish then incubate in 37°C, 5% CO2 for 24–48 h; after 
incubation, the transfected mixture was removed by aspiration and the dish was washed with 
PBS, then 8 ml of the medium was added with 2.5% FBS + puromycin. Incubation of the dish 
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2.9.1.4 Generation of SK-MES-1 down-regulated stable cell line clones 
The SK-MES-1 cell line was transfected with shRNA constructs in order to down-regulate the 
expression of the LANCL1 gene. The short hairpin construct carries the puromycin resistance 
gene. To optimise the suitable concentration of puromycin to kill cells from SK-MES-1, the 
presence of puromycin was applied in different concentrations. The optimal low puromycin 
concentration that can stimulate complete SK-MES-1 death was identified as 3 µg/ml; after 
the incubation period of 24–48 h of transfection, LANCL1 shRNA and scrambled plasmid to 
SK-MES-1 cells were growing in a growth medium containing puromycin. The growth medium 
with antibody refreshed as needed. Therefore, after approximately 10 days of selection, 
colonies were isolated by using cloning cylinders, trypsin, and flask transfer to develop under 
normal growth condition 37°C, 5% CO2 and in the presence of puromycin as the selected 
marker. LANCL1 down-regulation was checked both at mRNA and protein level. The selected 
colonies with >50% knockdown efficiency were grown for the use in the further functional 
analysis. 
 
 2.9.2 Construction of a LANCL1-AS1 inducible expression plasmid 
system 
This commercially available (Promega) expression system is composed by two plasmids 
(Figure 2.9) and allows for the inducible expression of the target transgene using 
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Figure 2.9: Coumermycin switch on/off system. The pReg neo Vector is designed to express 
a chimeric transactivator protein that interacts with the promoter region in pF12 RM Flexi® 
Vector in response to coumermycin and novobiocin. The pReg neo vector expressed the 
chimeric transactivator, which consisted of three parts: a λ repressor DNA binding domain 
(λRep), a bacterial gyrase B subunit domain (GyrB), and a NF-kB p65 transcriptional 
activation domain (AD). To activate the transcription, it needs coumermycin-dependent 
binding the bacterial GyrB domain and following dimerization of the chimeric transactivator 
protein. One molecule of coumermycin can dimerize two subunits of the GyrB domain, 
permitting the λ repressor domain to bind λ operator sequences to turn it on. That brings 
the NF-kB p65 transcriptional activation domain of the chimeric transactivator protein in 
adjacent proximity of the minimal promoter and induce transcription of the sequence of 
interest. In the present, of novobiocin in cells cause dissociation of the dimerized trans 
activator to switch OFF the trans-gene and render the constitutive expression of the trans 
activator. Adapted from (Promega 2019b). 
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2.9.2.1 Pf12ARM vector preparation 
Pf12ARM plasmid (cat no. C9470, Promega; Figure 2.10) carried human LANCL1-AS1 mRNA in 
mammalian cells and the G418 resistance gene as a selective marker to ensure the success of 
the transfection. 
One shot TOP10 chemically competent E.coli (cat no. C4040-03, Life Technologies). The 
manufacturer’s protocol (Life Technologies) was followed. Briefly, 1µl (50µg/µl) of the DNA 
was added to a vial of one shot cells (E.coli) and incubated on ice for 30 minutes, followed by 
exposure to a heat shock for 45 sec at 42°C to ensure the bacterial cell was open to engulf the 
plasmid, then placing the vial on ice for 2 minutes. Subsequently, 900µl of pre-warmed Super 
Optimal Broth S.O.C medium was added to the mixture and incubated in a shaking incubator 
at 37°C for 1h at 225rpm. After incubation, 200µl of mixture was spread on a selective plate 
(Luria-Bertani-medium [LB] containing ~50–100µg/ml ampicillin) and incubated overnight at 
37°C. After the incubation, some of the bacteria was picked and transferred to a flask already 
containing (150ml of LB + 150µl ampicillin), followed by incubation in a shaker incubator at 
37°C overnight, 80rpm. Plasmid was then isolated using ZymoPURE™ Plasmid Maxiprep that 
is explained in 2.9.1.2. 
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Figure 2.10: Graphic maps of Pf12ARM_LANCL1-AS1 plasmid digested using AsiSI, PmeI, and 
Bsrfa1 enzymes (Sigma-Aldrich). 
 
2.9.2.2 Pf12ARM vector digestion 
12µl of 10µg pf12-968 vector DNA was digested with 4µl of 10 unit/µl AsiSI (cat no. R0603L, 
New England Biolabs [NEB]), 4µl of 10 units/µl PmeI (cat no. R0560L, NEB), and 4µl of 10 
units/µl Bsrfa1 (cat no. R06825, NEB) in 12µl NEB buffer and incubated at 37°C in the PCR 
overnight. After the incubation period, the product was run in a 0.8% low-melting-point 
agarose gel. The DNA fragments were then cut from the agarose gel by scalpel and transferred 
in a colourless tube.  
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2.9.2.3 Gel clean up 
QIAquick® Gel Extraction Kit (cat no. 28704&28706, Qiagen) was used to clean up the gel. 
First, the gel, which was first weighed, then a three-time column of QG gel buffer was added 
to one-time volume gel; the following ftep includes the incubation for 10 minutes in S.O.C, 
then vortex for 2–3 minutes to ensure the gel dissolved completely and that the  pH < 7.5 by 
shaking, and the colour was yellow. An equal amount of isopropanol to the gel volume was 
then added and mixed, the mixture was transferred to a QIAquick spin column and vacuum 
was used to discard the flow, after adding 500 µl buffer QG, vacuum was then applied. At that 
time, 750 µl buffer PE was added and left for 2–3 minutes, followed by vacuuming. Dry spin 
was then applied by transferring the column in a collection tube and centrifuging it for 4 
minutes at 17,000 × g. The column was placed in a new collection tube, and 30 µl of pre-warm 
buffer EB was added to elute the DNA. NanoDrop 2000 Spectrophotometer was used to 
assess the quantity and the quality of the DNA at 260/280 nm, and 2% agarose gel was applied 
to ensure the success of digestion through the band size of the digestion and clean up. 
 
2.9.2.4 Alkaline phosphatase calf intestinal CIP treatment  
The alkaline phosphatase calf intestinal (cat no. M02905, NEB) treatment was performed to 
prevent re-ligation of linearized plasmid DNA. CIP is usually used to eliminate 5’-phosphate 
groups from DNA, and the elimination of 5’-phosphates is very valuable in preventing self-
ligation of cleaved DNA vectors. This property significantly decreases background (plasmids 
without insert) in cloning procedures. Briefly, from the previous step gel clean up, the DNA 
eluted was 30µl, added to 2µl of 10 units/µl of alkaline phosphatase calf intestinal (C/P) plus 
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and 11µl cut smart buffer (10X) mix, followed by incubation for 1h at 37°C in PCR, then 65°C 
for 20 minutes and placed on ice; PCR purification was then performed. 
 
2.9.2.5 PCR purification  
Moreover, the alkaline phosphate treatment QIAquick PCR Purification Kit (cat no. 28104, 
QIAGene) was used to clean up the product DNA following the manufacturer’s protocol. After 
adding five times the volume of buffer PB to a one-time volume of DNA, mixing was done and 
pH < 7.5 was ensured by checking that the colour was yellow. The mixture was transferred in 
a QIAquick column, then the vacuum was applied to discard the flow. The wash step was 
performed by adding 750µl buffer PE, left for 2 minutes at room temperature, and vacuum 
applied as well. Dry spin was performed to ensure all wash buffer residue was removed by 
placing the column in the collection tube, followed by a 4-minute centrifuge at 17,900 × g. 
The column was placed in a new tube, 30µl of pre-warmed buffer EB was added and left for 
2 minutes at room temperature, followed by a 1-minute centrifuge at 17,900 × g to check the 
purification DNA quality, and 2% agarose gel was applied. 
 
2.9.2.6 Ligation 
The ligation reaction set up according the 1:3 molar ratio of vector: insert. (64.5ng) 1.5µl of 
vector (Pf12ARM) DNA (183ng) and 1.5µl of LANCL1-AS1 insert DNA mix by inverting the tube 
and incubating at 65°C for 5 minutes, then 2 minutes on ice. After that, 2µl buffer T4 and 1µl 
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2.9.2.7 Transfection of E. coli with Pf12ARM-LANCL1-AS1 plasmid 
Transformation was performed to propagate the genetically engineered plasmid Pf12ARM-
LANCL1-AS1 One Shot TOP10 chemically competent E.coli cells. The procedure was 
manufactured on a 2.9.2.1 section at the final step after incubating with S.O.C for 1h. A serial 
dilution was performed, then plated on TOP10 chemically competent E.coli cells (50µg/µl) 
ampicillin, followed by incubation overnight at 37°C. The next day, the clones picked from the 
plate and each clone will mixed in 4mL LB+Ampicillin and incubate for 7h then 2 ml from each 
tube incubated at 4°C and the other 2ml was centrifuged at high speed for 2 minutes; 
supernatant was discarded in a beaker containing Chemgene, followed by the pellet then 
mixed in 120µl TET. Next, 5-minute boiling at 95°C was conducted, then centrifuging at 12,000 
× g for 5 minutes; from the supernatant, 60µl of this DNA was taken in a new tube to perform 
2% agarose gel. Determination of the quality and quantity of the sample was done by 
performing 2% agarose gel, electrophoresis, and UV visualisation on a UVP VisionWorks LS 
instrument. All the tubes or samples showed success transfection of the plasmid. Then, three 
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Figure 2.11: 2% agarose gel for the successful transfect of the Pf12ARM-LANCL1-AS1 
plasmid 
 
2.9.2.8 Plasmid Miniprep isolation  
To extract the plasmid from the three successfully chosen samples, growth in LB + ampicillin 
overnight was needed; the following day, ZymoPure™ Plasmid Miniprep Kit (cat no. D4208, 
D4209, D4210, D4211, D4212, Zymo Research) was used to isolate the plasmid. First, 6ml of 
bacterial was transferred in a falcon tube and centrifuged full speed for 10 minutes, followed 
by flow discard, then 250µl of P1 (red) added to re-suspend the pellet with vortex. 
Subsequently, 250µl P2 (green) was added, then the tube was mixed by inverting left for 3 
minutes to ensure complete lysis; next, 250µl P3 (yellow) was added, followed by mixing via 
inversion until the mixture was yellow to ensure complete neutralization, incubation of the 
mixture on ice for 5 minutes, and centrifugation at 16,000 × g for 5 minutes. 600µl from the 
supernatant was then transferred to a new Eppendorf tube, followed by the addition of 275µl 
ZymoPURE binding buffer and mixing by inverting the tube. The Zymo-spin 11-P column was 
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applied until all the mixture passed through, then 800µl of ZymoPure wash 1 was added to 
the column, followed by opening the vacuum to pass the wash buffer and then turning it off, 
adding 800µl wash 2, then turning the vacuum on until the wash buffer passes through. This 
step was repeated with 2,000µl wash buffer 2, followed by dry spin centrifugation at 10,000 
× g for 4 minutes. The column was then placed into a new collection tube, 25µl of warmed 
ZymoPure elution buffer was added, and the tube was left standing for 2 minutes, followed 
by centrifugation for 2 minutes at 10,000 × g. A NanoStep 2000 Spectrophotometer was used 
to assess the quality and quantity of the DNA. Then, for each sample 550ng in two tubes was 
needed to perform the sequencing assay—one for the forward primer, and one for the 
reverse primer. 
 
2.9.2.9 Sequencing of Pf12ARM-LANCL1-AS1 plasmid 
Sequencing reactions were prepared in two tubes containing Pf12ARM-LANCL1-AS1 DNA 
plasmid and the forward and reverse sequencing primers in respect (Table 2.12). Primers 
were designed using Primer Express Software V3.0—3µl of the sequencing buffer, 6µl BigDye 
sequencing, 3µl sequencing primer, and 6µl DNA template (recombine plasmid, then the tube 
is placed on a thermal cycler; Table 2.13).  
 





Pf12A-RM-SeqR 5’-TCC TTT CGG GCT TTG TTA-3’ 
Pf12A-RM-SeqF 5’-GTT TAG TGA ACC GTC AGA TCC-3’ 
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Table 2.13: Thermal profile amplification PCR reactions 
Step Temperature Time No. of Cycles 
Taq Activation 96°C 1 minutes 
27 
Denaturation 95°C 20 Sec. 
Annealing 50°C 15 Sec. 
Extension 60°C 3 minutes 
Final Extension 60°C 10 minutes 
 
2.9.2.10 Sequencing Analysis 
Samples were dried by vacuum and then re-suspended in 1 µl Hi-Di formamide (cat no. 
4311320, Life Technologies). Afterwards, the suspension was heated at 95°C for 2 minutes 
then placed on 2 minutes, and samples were analysed by 3130 Genetic analysers (cat no. 
3130-01R, Applied Biosystems). The sequence Pf12ARM-LANCL1-AS1 plasmid was confirmed. 
 
2.9.2.11 Transfection of SK-MES-1 cell lines with Pf12ARM-LanCL-AS1 plasmid  
SK-MES-1 cell line was transformed with Pf12ARM-LANCL1-AS1 plasmid following the 
procedure mentioned in 2.9.1.3 and confirming LANCL1-AS1 mRNA overexpression was 
performed by qPCR. Following the procedure in section 2.6.3, the successful clone LS3 was 
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2.9.2.12 Using coumermycin and novobiocin to regulate expression of 
transgene  
To measure transgene expression, coumermycin and novobiocin were used to regulate the 
expression. While coumermycin increased the expression of the transgene, novobiocin 
worked in an opposite manner. During the experiment, to maintain the expression, clone LS3 
will be seeding in 10nM coumermycin called (LS3C) and 10 µM Novobiocin called (LS3N). 
 
2.10 Western blot 
2.10.1 Bicinchoricacid BCA assay for qualification of the protein 
2.10.1.1 Protein extraction 
The eight NCLCS cell lines plus the knockdown LANCL1 and overexpressed LANCL1-AS1 clones 
were seeded in 75cm2 flask until confluence reached 75%–80%. The medium was aspirated, 
and the flask washed twice with PBS, then was placed immediately on ice. Cells were then 
lysed with 800µl (RIBA) buffer (cat no. 89900, Thermo Fisher Scientific) plus 8µl proteinase 
inhibitor; all adhesion cells were scraped off with a plastic scraper, a step processed on ice). 
A Bioruptor sonication system (cat no. B01010001 [UCD200TM], Diagenode) was used as an 
extra lysis step to sonicate the cells following the manufacturer’s instructions. Briefly, we 
ensured that the bioruptor sonicator was kept at 4°C, a tempersture reached by adding ice-
chilled water; the cell lysis tube holder was then placed and sonicated in cycle condition 15 
sec ON and 15 sec OFF for 3 minutes, and the tube was centrifuged at 12,000 × g for 15 
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minutes at 4°C to remove the remaining insoluble material. Supernatant was then transferred 
to a new Eppendorf tube; the rest was stored at -20°C for use in future analyses. 
 
2.10.1.2 Preparation bovine serum albumin BSA standard curve 
In order to create the standard curve, serial dilution or different concentration of BSA (0.125, 
0.25, 0.5, 1, 2, 4, and 8) mg/ml was prepared from 20 mg/ml main stock calculated from BSA 
(cat no. A7906, Sigma-Aldrich) by using the serial dilution RIBA buffer. Following the 
manufacturer’s procedure, BCA working reagents were prepared. Briefly, 5 units of reagent A 
were mixed with 1 unit of reagent B (cat no. 23224, Thermo Fisher Scientific). 4µl of BSA was 
diluted, and the samples were added to 80µl of BCA working reagents and mixed by vortex. 
The mixture was incubated at 37°C for 30 minutes, left to stand at room temperature for 5 
minutes with a brief vortex; the BSA curve was plotted, and the unknown samples were 
measured using the NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific) following 
the user manual V1.0. 
 
2.10.3 Electrophoresis immunoblotting and detection 
2.10.3.1 Electrophoresis preparation 
Preparing the samples for Sodium dodecyl sulfate SDS polyacrylamide gel electrophoresis, 20 
µg of total protein from eight NSCLC cell lines, knocked down LANCL1, and overexpressed 
LANCL1-AS1 clones were mixed with 2.5 µg of (4X)-6.25µl NuPAGE® LDS sample buffer (cat 
no. NP0008, Life Technologies), 2.5 µl of (XOX) NuPAGE® reducing agent (cat no. NP0004, Life 
Technologies), and adding H2O up to the total reduction of the volume 25 µl gel capacity 
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volume mix, followed by being, briefly determined by incubating the mixture in 70°C for 10 
min. 
 
2.10.3.2 NUPAGE® cells electrophoresis for protein  
NUPAGE® Novex Bis-Tris-Acetate (SDS-PAGE) mini gels (cat no. NP0321, PK2-Novex) was used 
for total protein electrophoresis. After removing the white tape near the bottom, the gel was 
placed in the X cell sure lock TM mini-cell gel running tank (cat no. EI001, Invitrogen). 200 ml 
of 1XNUPAGE Tri-Acetate-SDS running buffer mixed with 500µl NUPAGE antioxidant (cat no. 
NP0005, Invitrogen) was used to fill the lower chamber, while ~700 ml of 1XNUPAGE Tris-
Acetate SDS running column was used to fill the upper chamber. Then, the combe was 
removed from the gel wells, and the well was washed twice with 1XNuPEGE Tris-Acetate SDS 
running buffer (cat no. LA0041, Invitrogen). After that, all the preparation samples were 
loaded onto the gel (also, see blue® plus 2 pre-stained standard loaded [cat no. LC5925, 
Invitrogen]). Finally, run the gel at 200 V (110–125) mA/gel for 90 minutes.  
 
2.10.4 iBlot western blot detection  
An iBlot® dry blotting system (cat no. IB1001, Invitrogen) was used for blotting 
electrophoresis proteins. After electrophoresis, the gel was removed from the cassette plate 
and washed with ddH2O three times in 5 minutes. The gel was then placed onto a PVDF 
blotting surface of an anode iBlot gel transfer stack (cat no. IB8010-01, Novex) and covered 
with pre-soaked iBlot filter paper which was pre-placed in deionised water at the top of the 
filter paper, and cathode iBlot was placed on with side facing up and aligned along the right 
edge. A blotting roller was placed to help remove the air bubbles. Finally, a disposable sponge 
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with metal in the corner was placed on the upright curve on the lid. After ensuring that the 
lid was closed securely, the iBlot dry blotting system was switched on at setup in program P3 
for standard (voltage: 20 and time: 9 minutes). After transfer was finished, the gel and 
membrane were washed three times with PBS-T. The gel was then stained with compass blue 
(e.g. simple blue safe stain; Invitrogen), distain with (methanol 40% + Acetic acid 10%), and 
photographed with the aid of UV Prism works instrument; the PVDF blotting membrane was 
used to complete the iBind by using the iBined western system (Life Technologies). The 
membrane was kept with 5ml iBind complex (1XBind addictive). iBind was used to apply the 
Binding primary antibody and secondary contain (1:1000 with same diluent) and washing stop 
by iBind complex. Rabbit monoclonal primary antibodies to LANCL1 (cat no. PA5-57107 & PAS-
31080, Thermo Fisher Scientific) and actinb (cat no. 84575) cell signalling technology were 
used as primary antibody, while, the secondary antibody was antirabbit IgG HRP-linked 
antibody (cat 70745-cell signalling technology); all antibodies were used following the 
manufacturer’s protocol, and no further calibrator was required because they worked well. 
The first chamber was filled with primer antibodies LanCL1 plus Actb, the second chamber 
with iBind complex for washing, the third chamber with secondary antibody, and the fourth 
chamber with iBind for complete washing. The reset of the immune complex was detected by 
using the chemiluminescence imaging system GENE system (synGENE). After iBind, the 
membrane was washed with ddH2O, then placed on the nailon; we prepared HRP 
chemiluminescent substrate reagent (cat no. WP20005, Invitrogen) 1:1 reagent 1 and 2, then 
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2.11 Wound healing assay 
The wound healing assay (scratch assay) was chosen to measure cell migration and wound-
healing capacity, of SK-MES-1 parental, scramble, overexpress LANCL1-AS1, and knocked 
down LANCL1 clones. Approximately 5 × 104 cells were seeded in flat-bottomed, six-well 
plates cultured with medium + 5% FBS and antibiotic. Upon confluence, covered the well, the 
monolayer was scratched by using a tip, plates were washed with PBS, and the medium was 
refreshed with +5% FBS. Time lap images was digitally captured by microscope (EVOS XL core 
imaging system, cat no. AMEX1000, Thermo Fisher Scientific) at different time points on 0h, 
3h, 12h, 24h, 36h, and 48h with digital camera, precision optics, LCD display, and USB storage. 
The open wound area was calculated/measured by ImageJ software (Fiji) (Rasband 1997-
2018).  
 
2.12 Invasion assay 
Cell movement was monitored through extracellular matrices, fundamental function, and 
cellular processes (e.g. angiogenesis, metastasis). The assay was carried out in flat-bottomed, 
24-well plates, where the trans well (ThinCert™ Cell Culture Inserts 24 Well cat no.662638 
Greiner Bio-One) was placed in one of the wells, then 100µl of Geltrex™ (cat no. A15696-01, 
Life Technologies) was added to the trans well and incubated in 37°C; 5% FBS + AB was added 
under each trans well, adding around 10,000 cells in 200µl medium + 5% FBS with antibiotic 
added on top of the gel mixture and incubated in 37°C 5% FBS for 24h. After incubation, the 
medium was discarded in a beaker containing Chemgene; we then washed the well with PBS, 
transferred the trans well into a new well, added 100µl of cold methanol to the trans well, 
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and incubated it in the freezer for 10 minutes. After discarding the methanol on the beaker, 
washed twice with PBS, then 100µl of (1:4, 20% methanol + 0.16% crystal violate) was added 
to the trans well and incubated for 30 minutes. After incubation, the stain was discarded and 
the well washed twice with PBS. A cotton badge was used to remove the remaining cells on 
top of the trans well. A microscope (EVOS XL core imaging system, cat no. AMEX1000, Thermo 
Fisher Scientific) was used to capture the images under different magnifications (4×, 10×, 20×, 
40×). 
 
2.13 Statistical analysis 
The entire statistical analysis was performed using IBM® SPSS® (statistics precision 2). 
Continuous variables were checked for normal distribution using the 1 K-S test. As this 
demonstrated lack of normal distribution the non-parametric Mann–Whitney test was 
selected to compare continuous variables in two independent categorical groups. The 
Wilcoxon signed-rank test was used to compare between different expressions of LANCL1 and 
LANCL1-AS1 between tumour and adjacent non-tumour samples in a paired fashion. 
The IC50 values were determined by using Prism 8.0 (graphpad) that can fit the dose 
responses with log concentration values (on the X-axis), while the response plot in Y-axis P < 
0.05 was considered/selected statistically significant. In Prism, the IC50 values were 
calculated by (inhibitor) vs normalized response variable slope equation. The (also non-
parametric) Spearman's rank-order correlation was used to examine associations between 
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2.14 Preparation of the cell or special feeding for the cell to 
extract extracellular vesicles EVs 
Isolating exosomes from the NSCLC cell lines requires a special medium. Therefore, once 
confluence had reached 80%, the flask was washed with PBS twice, then the medium DMEM 
without FBS was added. Serum-free medium is used to minimise the albumin and different 
other proteins and metabolites in serum contamination in the FBS; the ratio is 1 ml medium: 
2µl cocktail, 500X TC (Table 2. 14; e.g. T75:10 ml medium + 20µl cocktail will be added). The 
cell is left in the incubator at 37°C, 5% CO2, maximum from 12–16h; the medium is then 
collected to extract exosomes. The medium was collected with cocktail TC 500X that contains 
EVs in a universal tube, centrifuged at 300 × g for 5 minutes, then filtered through 0.22µM in 
a falcon tube. 
 
Table 2.14: TC 500X  
Substance 1X 500X Stock 
Tri-iodothyronine 10 ng/ml 5 ug/ml 
EGF 10 ng/ml 5 ug/ml 
Insulin 2 ug/ml 1 mg/ml 
BSA 2 ug/ml 2 mg/ml 
Holo-transferrin 5 ug/ml 2.5 mg/ml 
Epinephrine 1 ug/ml 500 ug/ml 
Glucose 95 ug/ml 47.5 mg/ml 
Hydrocortisone 0.5 ug/ml 0.25 mg/ml 
 
 
135       
 
2.15 Count extracellular vesicles EVs using NanoSight  
Cells were seeded in Xwell plates or else using serum free medium. At the selected time for 
each experiment, the supernatant medium was collected, span at 300g for 10 min, filtered 
through 0.22 µm syringe filters and applied onto Nanosight instrument following the 
supplier’s standard protocol. Three measurements of independent injections on the machine 
were taken for each specimen. The mean number of EVs and the size distribution was 
reported for each specimen. 
 
2.16 Protein extraction from EVs 
A biolipid affinity spin column (exoEasy Kit. cat no. 77044, Qiagen) was used to efficiently 
isolate EVs for this purpose. After collecting the serum-free medium plus cocktail containing 
EVs, XBP to bind the filtered sample to the column, buffer was added in an equal amount to 
the medium and mixed in a rotator for 3 minutes. The liquid was then transferred onto a filter 
and collection tube; all the mixture was filtered through the vacuum, XWP buffer was added 
to the tube and then filtered through the vacuum, centrifuged in 4,000 × g for 5 minutes (dry 
spin), and XE elution buffer added to elute the samples. EV isolates were dialysed twice 
against PBS (300 ml) using TSlide-A-Lyzer®, (cat no. P00090554, Thermo Fisher Scientific) 
Then, the dialysis performed (Figure 2.12). 
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Figure 2.12: Isolate EVs from overexpressed LANCL1 AS1 clones grown in coumermycin and 
novobiocin by using an exoEasy Kit. Most of the exoEasy product dialysed to reduce the 
toxicity of the elution buffer, and NanoSight was used to count the EVs, small parts of the 
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2.17 Exchanging the whole medium between sensitive 
LS3Cand resistant LS3N cell lines 
Seeding overexpressed LANCL1-AS1 with medium + 5% FBS grown in novobiocin LS3N in flat-
bottomed, 48-wells plate until confluence, reached 40%. Then, the medium was changed in 
half of the plate by serum-free media, conditioned for 48h in overexpressed LANCL1-AS1 cells 
grown in coumermycin (heterologous) or novobiocin (autologous). The other half of the plate 
was treated with IC50 gemcitabine 0.6μM added to serum-free media, conditioned for 48h in 
overexpressed LANCL1-AS1 cells grown in coumermycin (heterologous) or novobiocin 
(autologous). Following incubation for 48h in 37°C, 5%CO2, the cell viability was measured 
using an MTT assay (Figure 2.13). 
The reduction in replication shown in the autologous medium replacement most probably 
reflects the partial exhaustion of medium resources as the growth factors in SF-media are 
being degraded (control receives fresh SF medium with supplements for the corresponding 
48h incubation). In contrast, the heterologous replacement with media from cells with high 
LANCL1-AS1 expression, causes a significant reduction on the target cells (with low expression 
of LANCL1 -AS1). 
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Figure 2.13: Exchanging medium between low and high LANCL1 AS1 expression. Low LANCL1 
AS1 expression cell line grown in novobiocin seeded in flat-bottomed, 48-wells plate until 
confluence reached 40%. Then, half of the plate was treated with 0.6 µM GM. The medium 
was exchanged with filtered medium collected from (N) low LANCL1 AS1 expression grown in 
novobiocin, (C) high LANCL1 AS1 expression grown in coumermycin, and (UN) medium with 
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2.18 Exchange EVs between cell lines 
We seeded overexpressed LANCL1-AS1 with medium + 5%FBS grown in novobiocin LS3N in 
flat-bottomed, 48-wells plates until confluence reached 40%. The medium of half the plate 
was then replaced with serum-free medium with cocktail and exosome isolated from 
overexpressed LANCL1-AS1 grown in coumermycin (heterologous) or novobiocin 
(autologous). The other half of the plate was treated with IC50 gemcitabine 0.6μM added to 
serum-free medium with cocktail and exosome isolated from overexpressed LANCL1-AS1 
grown in coumermycin (heterologous) or novobiocin (autologous). Following incubation for 
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Figure 2.14: Exchanging EVs low and high LANCL1 AS1 expression. Low LANCL1 AS1 expression 
grown in novobiocin seeded in flat-bottomed, 48-wells plate until confluence reached 40%. 
Then, half of the plate was treated with 0.6 µM GM. Exchanged EVs isolated from (N) low 
LANCL1 AS1 expression grown in novobiocin, (C) high LANCL1 AS1 grown in coumermycin, and 
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Chapter 3: Epigenetic sensitization of non-small cell 
lung cancer (NSCLC) to chemotherapeutic compounds 
 
3.1 Introduction  
Sensitising NSCLC by combining chemotherapeutics with other sensitizer drugs that are 
already approved and available. Chemotherapy is still used to treat either early or late stage 
NSCLC (Zhou et al. 2011). Four chemotherapeutic agents (cisplatin, carboplatin, gemcitabine, 
and vinorelbine) were chosen to be re-sensitized in NSCLC cell lines by combining them with 
sodium valproate (VPA) (Schiffmann et al. 2016), decitabine (DAC) (Szyf 2009), 
aminomethylphosphonic acid (AMPA) (Li et al. 2013), and fendiline (van der Hoeven et al. 
2013). 
VPA and DAC have been identified as epigenetic regulation agents. Valproic acid can inhibit 
histone-deacetylation. It selectively induces proteasomal degradation of HDAC2 (Krämer et 
al. 2003), while decitabine inhibits methyltransferase and leads to increased demethylation. 
(Szyf 2009). Decitabine induces selective degradation of DNA methyltransferase 1 by a 
proteasomal pathway (Ghoshal et al. 2005). 
Therefore, the epigenetic drugs (VPA or DAC) can play a role in epigenetic regulation, as both 
can increase tumor suppressor gene expression or other oncogenes that may improve the 
chemo-sensitivity. 
Moreover, aminomethylphosphonic acid (AMPA) AMPA works as Serine 
hydroxymethyltransferase1 (SHMT1) inhibitor and SHMT plays a role in epigenetic alteration. 
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Also, AMPA has been determined as a proliferation inhibitor which also increases the 
apoptosis activity in pancreatic cancer (Naseer et al. 2018). Fendiline works as a calcium 
channel blocker and pointing calcium signalling can reverse epigenetic silencing of tumour 
suppressor genes (Raynal et al. 2016). Fendiline inhibits proliferation and invasion by 
interfering with β -catenin signalling in the WNT pathway, which is often deregulated in 
cancer (Alberg et al. 2013). 
Therefore, AMPA and fendiline are evidenced to play a role in epigenetics modulation and 
inhibiting proliferation. Pointing epigenetic pathways is a promising method for cancer 
therapy. As such, they were chosen to be combined with four chemotherapeutic agents in 
this research in order to investigate their roles in NSCLC (van der Hoeven et al. 2013; Li et al. 
2013). 
The aim of this part of the study was to explore and assess sensitization of NSCLC cell lines 
to the four chosen chemotherapeutic agents. For this purpose, the following objectives were 
set: 
a) Determine the IC50 for the four selected chemotherapeutic agents (cisplatin, 
carboplatin, gemcitabine, and vinorelbine) in eight NSCLC cell lines.  
b) Examine the effect of combined epigenetic drugs (VPA and DAC) with 
chemotherapeutics in both conditions (synchronous and pre-treatment) Sensitizing NSCLC 
c) Investigate the mechanism of cell death in combined chemotherapeutics by using 
caspase 3/7 activity to determine apoptotic, and the neutral comet assay to determines DSB 
d) Explore the effect of co-treatment of anti-proliferation agents (AMPA and fendiline) 
combined with chemotherapeutics in the cell viability.   
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3.2 Results 
3.2.1 Chemo-sensitivity of non-small lung cancer cell to 
gemcitabine, vinorelbine, cisplatin, and carboplatin 
The sensitivity of the four most commonly chemotherapeutic agents used in lung cancer– 
gemcitabine (Gemzar), vinorelbine (Navelbine), cisplatin (Platinol®), and carboplatin 
(Paraplatin®) was determined on eight NSCLC cell lines, namely A549, CALU-3, CALU-6, COR-
L23, H358, LUDLU-1, SK-LU-1, and SK-MES-1. Half-maximal inhibitory concentration (IC50) 
was used to estimate the chemo-sensitivity of the cell lines, following a 48h exposure to the 
different compounds. The MTT assay was used to measure the cell viability and IC50 values 
were calculated using Graph Pad Prism version 8.0 software. As expected, sensitivity ranged 
widely among the eight NSCLC cell lines (Table 3.1, Figure 3.1). All the chemotherapeutic 
agents reduced the cell growth in a concentration-dependent manner. The effective 
concentration of each compound was, again not surprisingly, different. Specific information 
on each of the drugs is shown below. 
Evaluation of the IC50 values and the 95% confidence intervals following 48 hours treatment 
of the NSCLC cell lines with (0-4µM) gemcitabine showed that A549 with IC50 (0.04539µM) 
and SK-MES with IC50 (0.04582µM) were the most sensitive NSCLC cell lines, while CALU-6 
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Furthermore, after 48h treatment with (0-500nM) vinorelbine, lowest absorption reading 
detected in both COR-L23 and CALU-6 with IC50 (0.01094nM-0.03036 nM). While, CALU-3, 
SK-LU-1, and A549 have highest IC50 with (61.79nM-23.99nM-12.26nM) respectively. 
In cisplatin, the MTT absorption reading identified CALU-6 (1.103µM) and COR-L23 (1.609µM) 
with low IC50 values; the most resistance cell lines after 48h treated with (0-100µM) cisplatin 
with the highest IC50 were in CALU-3 (7.01µM), H358 (6.903µM), and A549 (4.922µM). 
Moreover, following 48h treatment of the NSCLC cell lines with (0-100µM) carboplatin, the 
IC50 were highest in SK-MES (25.53µM), A549 (21.25µM), and COR-L23 (12.4µM), and the 
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Figure 3.1: Heterogeneous response of the studied eight non-small cell lung cancer cell lines 
following 48h hours: graph represent the MTT absorbance readings for gemcitabine (GM), 
vinorelbine (VRL), cisplatin (CIS), and carboplatin (CARB). 100% dose state in the X axis 
corspond to the concentation of the drugs (cisplatin (100µM), carboplatin (100µM) 
gemcitabine (4µM), and vinorelbine (0.5µM). In eight NSCLC cell lines A: A549, B: CALU-3, 
C: CALU-6, D: COR-L23, E: H358, F: LUDLU, G: SK-MES-1 and H: SK-LU-1. COR-L23 and SK-
MES-1 are the most resistant cell lines for carboplatin, while H358 and A549 are the most 
resistant cell lines for cisplatin. For vinorelbine, both A549 and SK-LU-1 showed the highest 
resistance. SK-LU-1 and CALU-6 showed resistance for gemcitabine. The mean and error 
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Table 3.1: The IC50 values of the eight NSCLC treated with four chemotherapies: IC50 values and their respective 95% confidence intervals of 
eight non-small cell lung cancer cell lines exposed to gemcitabine (0-4µM), vinorelbine (0-0.5µM), cisplatin (0-0.1mM), and carboplatin (0-
0.1mM) 
Cell line IC50 (µM) 95% CI (µM) IC50 (nM) 95% CI (nM) IC50 (µM) 95% CI (µM) IC50 (µM) 95% CI (µM)
A549 0.045 0.034 - 0.058 12.260 10.65  - 13.91 4.922 4.165 - 5.8 09 21.250 15.02 - 30.06
CALU-3 0.220 0.139 - 0.343 61.790 47.52  - 79.75 7.010 6.096 - 8.052 5.957 3.232 - 10.34
CALU-6 0.392 0.263 - 0.585 0.030 4.2 E-4  - 0.230 1.103 0.932 - 1.292 9.604 8.340 - 11.02
COR-L23 0.057 0.048 - 0.067 0.011 3.179E-6  - 0.183 1.609 1.437 - 1.794 12.400 9.507 - 15.99
H358 0.329 0.169 - 0.626 4.648 3.372  - 5.828 6.903 5.090 - 9.34 1 3.033 0.98 - 5.65
LUDLU 0.096 0.061 - 0.143 0.356 0.0308  - 1.190 4.152 3.574 - 4.813 10.250 7.005 - 14.65
SK-MES-1 0.046 0.034 - 0.059 1.544 0.8326  - 2.387 3.079 2.754 - 3.436 25.530 17.87 - 36.39
SK-LU-1 0.319 0.279 - 0.364 23.990 16.33  - 33.21 2.566 2.248 - 2.919 4.934 1.931 - 9.294
Gemcitabine Vinorelbine Cisplatin Carboplatin
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3.2.2 Epigenetic modulation of drug sensitivity by deoxy-
azacytidine (DAC) and sodium valproate (VPA). 
Epigenetic inactivation of key genes controlling cell growth is a frequent event in human 
cancer (Schiffmann et al. 2016). Gene silencing can be achieved by a combination of 
epigenetic events such as DNA methylation, histone modifications and changes in the non-
coding RNA patterns. Re-expression of genes epigenetically deactivated may result in disease 
state suppression or sensitization to specific treatments. Small molecules that reverse 
epigenetic inactivation, such as valproic acid and decitabine, are currently undergoing clinical 
trials for tumours (Hubaux et al. 2010; Tan et al. 2010). 
Epigenetic deregulation has been identified as one factor leading to chemosensitization 
(Steinhardt and Gartenhaus 2013). In this study, epigenetic sensitisation of four 
chemotherapeutic agents was investigated in NSCLC cell lines, using drugs VPA (an HDACi) 
and DAC (a DNMTi). VPA can induce cell cycle arrest in G1 (Catalano et al. 2005). Since 
epigenetic drugs can arrest the cell cycle at a specific point, therefore reducing proliferation 
rates, they could have an opposite to the desired effect on chemotherapeutic agents targeting 
dividing cells. Therefore, we attempted to examine both the effect of pre-treating the NSCLC 
cell lines with epigenetic agents before treated with chemotherapeutics, also the effect of 
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 Our hypothesis was investigated through extensive research that identified the potential 
efficacy of combining epigenetic agents with chemotherapy in various cancer types (Lin et al. 
2008; Kanda et al. 2005; Del Bufalo et al. 2014; Steinhardt and Gartenhaus 2013).  
In this study, we examined the influence of epigenetic drugs in re-sensitizing gemcitabine, 
vinorelbine, cisplatin, and carboplatin in resistant NSCLC cell lines, as identified from our 
previous experiments (Table 3.1): CALU-6, H358, and SK-LU-1 to gemcitabine, SK-LU-1 and 
A549 to vinorelbine, H358 and SK-LU-1 to cisplatin, and COR-L23 and SK-MES-1 to carboplatin. 
While the DAC and VPA toxicity was tested in this study by the MTT assay to measure cell 
viability, apoptotic death was determined by caspase 3/7 activity. 
 
3.2.2.1 Toxicity of the two drugs alone 
Initially, we determined the toxicity of the two drugs alone. The final concentration of the two 
compounds was decided to match the clinical dose. The normal prescription for VPA is 
1000mg per day, which in an adult with an average 5lt blood volume, corresponds to 1 mM. 
The DAC dose was decided based on 100nM our results show that DAC and VPA slightly affect 
cell proliferation. The toxicity result is shown in (Figure 3.2) the rate of cell viability after 
exposed to VPA and DAC not change comparing with the control which mean the drugs are 
safe. However, CALU-6 showed a significant decrease in cell viability with P=0.004 under both 
VPA and DAC that may different genotype showed different effect (Mann Whitney).  
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Figure 3.2: Bar charts exhibiting DAC and VPA toxicity NSCLC cell lines. It displays the MTT 
absorbance readings for resistant cell lines A: H358, B: SK-LU-1, C: A549, D: COR-L23, E: 
CALU-6 and F: SK-MES-1 were treated with 1mM VPA and 100nM DAC at 48-hour exposure, 
in six replicates. Error bars represent 95% confidence intervals. *Indicate the significant 
differences (Mann Whitney). 
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3.2.2.2 Apoptotic death induced by DAC and VPA by measuring caspase 3/7 
activity 
In addition, we measured the apoptotic death induced by DAC and VPA by measuring caspase 
3/7 activity (Figure 3.3). DAC did not show a significant increase in the caspase 3/7 activity in 
A549, H458 and SK-LU-1 while significant reduction in the activity was observed in SK-MES-1 
(Mann Whit test). VPA showed a significant decrease in caspase 3/7 activity within A549, SK-
LU-1 and SK-MES-1 and a significant increase in the activity within H358.  
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Figure 3.3: Caspase 3/7 activity assy in NSCLC cell lines treated with DAC and VPA. The 
resistant cell lines A: A549, B: H358, C: SK-LU-1 and D: SK-MES-1, were treated with 1mM 
VPA and 100nM DAC at 48-hour exposure, in six replicates. The caspase 3/7 activity assay 
used to measure the apoptosis activity. Bar charts represent six technical replicates; the 
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3.2.2.3 Conditions to sensitizing the NSCLC cell lines by epigenetic drugs 
Based on our previous observations, the pre-treatment or synchronous treatment with DAC 
and VPA may affect the efficiency of each drug differently. As a result of a pilot test (Figure 
3.4). The pilot test showed no chang in cell viability when the NSCLC cells treated with either 
gemcitabine combined with DAC for 48h or when the cells pre-treated with DAC for 48h then 
gemcitabine added for 48h. While, reduction in cell viability have been noticed when pre-
treated with VPA for 48h then gemcitabine was added for the next 48h. It was decided to 
perform and compare both pre-treatment and synchronous treatment with VPA/DAC for all 
the cell lines and drugs tested. A final concentration of 100nM DAC and 1mM VPA was used 
along with the variable doses of GM, VRL, Cis and CARB (Tables 3.2 and 3.7). We also tested 
whether replenishing VPA and DAC at the time of main drug added had any effect during the 
pre-treatment experiments, given that after 48 h, the VPA and DAC activity was expected to 
decrease significantly. However, replenishing VPA and DAC did not demonstrate any 
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Figure 3.4: Pilot test for synchronous and pre-treatment for both VPA/DAC combined with 
GM. The bar charts present the results of the MTT absorbance readings. H358, one of the 
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Figure 3.5: Epigenetic agents (VPA-DAC) combined with VRL. The Figure display MTT 
absorbance readings. Blue line: VRL alone 48h and two conditions for combined epigenetic 
agents with VRL (red line is synchronous and purple and green line pre-treatment). After 
the pre-treatment with VPA 48h, the cell either exposed to the chemotherapeutic purple 
line alone 48h or green line chemotherapeutic combine with VPA 48h. 
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3.2.2.4 Decitabine DAC 
Our results (Table 3.2: Figure 3.6) identified that synchronous treatment of DAC with VRL 
showed a reduction in IC50 values in both SK-LU-1 and A549 cell lines compared to VRL alone. 
In addition, A549 showed more cell reduction when pre-treated with DAC for 48h than with 
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Figure 3.6: Sensitization of the two most VRL resistant cell lines with DAC: the graphs 
represent the response of the MTT absorbance readings of 48h VRL exposure (blue line), 
synchronous 48h DAC with VRL (red line), and 48h pre-treatment with DAC followed with 
48h VRL exposure (green line) in both A549-SK-LU-1 NCSLC cell lines. The mean and error 
values in all graphs represent six technical replicates, and the error bars represent 95% 
confidence intervals.  
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Table 3.2: Modulation of drug response (IC50 values) following DAC co-treatment. 
Drugs Cell Lines  Drug alone Synchronous Pre-treatment 
    Drug + DAC 




IC50 (µM) 0.392 0.525 0.698 
95% CI (µM) 0.118-0.954 0.372-0.758 0.025-1.65 
SK-LU-1 
IC50 (µM) 0.319 0.561 1.976 
95% CI (µM) 0.044-0.804 0.07-0.878 0.998-4.885 
Vinorelbine 
A549 
IC50 (nM) 12.260 0.452 0.314 
95% CI(nM) 7.675-17.364 0.249-0.96 0.141-1.396 
SK-LU-1 
IC50 (nM) 23.990 19.672 32.542 
95% CI (nM) 11.65-14.286 13.583-29.96 24.985-39.753 
Cisplatin 
H358 
IC50 (µM) 6.903 17.069 12.555 
95% CI (µM) 4.661-12.106 13.946-20.331 8.968-21.0 
SK-LU-1 
IC50 (µM) 2.566 8.139 8.864 
95% CI (µM) 1.985-3.217 5.631-9.655 1.745-3.126 
Carboplatin 
COR-L23 
IC50 (µM) 12.400 12.400 22.708 
95% CI (µM) 7.641-19.429 6.98-19.892 21.39-27.543 
SK-MES-1 
IC50 (µM) 25.530 25.530 30.943 
95% CI (µM) 18.346-33.9 17.812-30.043 15.627-50.822 
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3.2.2.5 Sodium valproate VPA 
In contrast, our study (Table 3.3) showed significant results in sensitizing platinum with VPA. 
VPA worked significantly with Cis in all conditions, either synchronous or pre-treated in H358, 
compared to Cis alone. Synchronous VPA and Cis resulted in a significant reduction cell 
viability in SK-LU-1 compared to Cis. Moreover, the IC50 reduced and VPA sensitized Carb in 
both COR-L23 and SK-MES-1. Synchronic treatment reduced COR-L23, while the pre-
treatment condition showed more significant reduction in both COR-L23 and SK-MES-1 cell 
lines compared to Carb alone. 
The results revealed a significant reduction in MTT absorption readings and IC50 values when 
VPA was combined with GM in SK-LU-1 compared to GM alone. However, the pre-treatment 
of both cell lines (CALU-6, SK-LU-1) with VPA for 48h and exposure to GM for another 48h 
showed more significant cell reduction. 
Pre-treatment of VPA added to VRL 48h showed a reduction with IC50 in SK-LU-1, but more 
reduction in A549 compared to VRL alone. Additionally, synchronous VPA with VRL showed a 
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Table 3.3: Modulation of drug response (IC50 values) following VPA co-treatment. 
Drugs Cell Lines  Drug alone Synchronous Pre-treatment 
    Drug+VPA 




IC50 (µM) 0.392 0.334 0.191 
95% CI (µM) 0.267-0.573 0.188-0.581 0.125-0.284 
SK-LU-1 
IC50 (µM) 0.319 0.242 0.079 
95% CI (µM) 0.057-1.514 0.0486-0.488 0.027-0.486 
Vinorelbine 
A549 
IC50 (nM) 12.260 8.409 5.158 
95% CI(nM) 9.8-14.795 5.077-10.762 2.119-7.963 
SK-LU-1 
IC50 (nM) 23.990 2.904 8.205 
95% CI (nM) 19.582-44.69 0.764-5.603 6.592-9.68 
Cisplatin 
H358 
IC50 (µM) 6.903 0.071 0.051 
95% CI (µM) 3.696-8.836 0.043-0.99 0.024-0.819 
SK-LU-1 
IC50 (µM) 2.566 0.891 2.740 
95% CI (µM) 0.85-4.733 0.052-2.576 0.45-4.322 
Carboplatin 
COR-L23 
IC50 (µM) 12.400 1.842 0.969 
95% CI (µM) 7.914-16.321 0.526-3.059 0.171-2.526 
SK-MES-1 
IC50 (µM) 25.530 39.563 23.131 
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Figure 3.7: The response of sensitizing the two most NSCLC resistance cell lines with VPA: the graphs represent the result of the MTT absorbance 
readings: the blue line represents 48h chemo exposure, the red line represents synchronous 48h DAC with chemo, and the green line represents 
48h pre-treatment with VPA followed by 48h chemo exposure in the two most resistant cell lines for each drug. A and B represent carboplatin, 
C and D represent gemcitabine, E and F represent cisplatin and G and H represent vinorelabine. The X axis is log10, the mean and error values 
in all graphs represent the six technical replicates, and the error bars represent 95% confidence intervals. 
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3.2.3 Caspase-Glo® 3/7 activity assay determines the apoptosis 
activity 
In order to explore the apoptosis activity in the most resistant NSCLC cell lines treated with 
DAC and VPA in both conditions synchronous and pre-treatment following exposure with four 
chemotherapies (GM, VRL, Cis, and Carb). Caspase-Glo® 3/7 activity assay has been used 
(Figure 3.8). The assay was targeted to measure the caspase 3/7 activities, which played an 
essential role in apoptosis. Therefore, the amount of luminescent signal is associated with the 
amount of caspase 3/7 activities. 
Most of the chemotherapeutic agents showed a significant increase in caspase 3/7 activity in 
all tested cell lines. Remarkably, carboplatin in SK-MES-1 showed a significant result in 
synchronous P=0.029 with VPA, while in COR-L23 the results were significant in synchronous 
P=0.034 with VPA and significant results in both conditions with DAC P=0.01. Moreover, 
cisplatin showed an increase in 3/7 activity significantly in H358 when pre-treated or 
synchronous with DAC and only with pre-treatment with VPA with P=0.004, however, 
synchronous VPA in SK-LU-1 P=0.004 were elevated in 3/7activity. Gemcitabine or vinorelbine 
in both synchronous and pre-treated with VPA and DAC did not show any caspase 3/7 activity 
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Figure 3.8: Caspase 3/7 activity in two most resistant NSCLC cell lines treated with platin 
(A and B represent carboplatin) (C and D represent cisplatin) agents in the 
presence/absence of VPA and DAC as synchronous treatment (s) or pre-treatment (p) for 
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3.2.4 Evaluation of DNA damage  
Following the observation of the VPA/DAC effect on the drug efficiency, as seen above (Figure 
3.8 and 3.9), we investigated the potential changes that VPA/DAC could confer to DNA 
damage induced by the chemotherapeutics examined in this study. The neutral comet assay 
is an established assessment of a fraction of DNA strand breakage by measuring the 
percentage of DNA in the tail (Figure 3.9). DNA double strand breaks (DSBs) in a single cell 
leave a tail, which creates the comet shape. Eight NSCLC cell lines treated with drug alone, 
synchronous VPA and the drug for 48h, and pre-treated 48h with VPA followed by 48h with 
drug were tested. Only gemcitabine, both alone and with VPA pre-treatment showed 
increased DNA DSBs in A549, COR-L23 and CALU-6 NSCLC cell lines. Our results showed a 
significant increase in the percentage of DNA DSBs in A549 P=0.009 CALU-6 P=002, and COR-
L23 with p=0.029 when pre-treated with VPA 48h followed by GM 48h, compared to GM 
alone (Table 3.4, Figure 3.9) (Mann Whitney). 
 
Table 3.4: Percentage of DNA double strand breaks in A549, CALU-6 and COR-L23 treated with 
gemcitabine and pre-treated with VPA followed with gemcitabine  
Tail % A549 CALU-6 COR-L23 
GM 16% 23% 31% 
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Figure 3.9: The neutral comet assay for NSCLC cell lines treated with gemcitabine alone or 
pre-treated with VPA for 48h: the comet shape present in the NSCLC cells after treatment 
with gemcitabine for 48h in A-A549, C- CALU-6, and E-COR-L23. Pre-treated VPA for 48h 
followed by a 48h exposure of the cell with gemcitabine in B-A549, D- CALU-6, and F-COR-




Figure3.11: The neutral comet assay for NSCLC cell lines treated with gemcitabine alone or 
pre-treated with VPA for 48h: the comet shape present in the NSCLC cells after treatment 
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3.2.5 Other drugs sensitivity NSCLC to the chemotherapeutic agents 
3.2.5.1 Fendiline 
Fendiline was chosen in this research to re-sensitize chemotherapeutics, based on recent 
evidence in pancreatic cancer which showed that fendiline inhibits proliferation and invasion 
(van der Hoeven et al. 2013; Li et al. 2013). The two most resistant cell lines to the four 
chemotherapies (GM, VRL, Cis, and Carb) were co-treated for 48h with 10nM fendiline (Table 
3.5, Figure 3.10). Even though there was a significant reduction in IC50 for SK-LU-1 when 
treated with fendiline in combination with GM compared to GM alone, however, it did not 
sensitize CALU-6. The combination also revealed a remarkable decrease in viable cells in SK-
MES-1 when treated with fendiline in combination with Carb IC50, compared to IC50 Carb 
alone, while, without any success when combined with COR-L23. However, the fendiline and 
Cis combination did not show any reduction in the IC50 in both SK-LU-1 and H358. Also, the 
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Figure 3.10: The cell survival rate of NSCLC resistance cell lines treated with fendiline 
combined with carboplatin or gemcitabine or vinorelbine: MTT absorbance readings are 
displayed in the graph. The mean and error values in all graphs are the six technical 
replicates, and the error bars represent 95% confidence intervals for the NSCLC treated 
with 48h drug alone (green line) and combined with fendiline for 48h (pink line). A: SK-
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Table 3.5: IC50 values of sensitizing NSCLC with fendiline: the IC50 and their respective 95% 
confidence intervals of the two most resistant cell lines of each drug treated with combined 
fendiline with one of the four chemotherapies (GM, VRL, Cis, and Carb) for 48h. 
Drugs Cell Lines  Drug Drug+ Fendiline 
Gemcitabine 
CALU-6 
IC50 (µM) 0.392 0.842 
95% CI (µM) 0.259-0.589 0.466-1.512 
SK-LU-1 
IC50 (µM) 0.319 0.079 
95% CI (µM) 0.164-0.497 0.027-0.274 
Vinorelbine 
SK-LU-1 
IC50 (nM) 12.260 21.017 
95% CI (nM) 11.456-13.148 18.272-24.24 
A549 
IC50 (nM) 23.990 22.236 
95% CI (nM) 19.915-35.047 14.736-26.178 
Cisplatin 
SKLU-1 
IC50 (µM) 6.903 11.683 
95% CI (µM) 4.612-8.286 6.291-13.757 
H358 
IC50 (µM) 2.566 2.587 
95% CI (µM) 1.93-3.341 2.234-2.99 
Carboplatin 
SK-MES-1 
IC50 (µM) 12.400 2.587 
95% CI (µM) 8.87-16.609 0.01-2.139 
COR-L32 
IC50 (µM) 25.530 50.996 
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3.2.5.2 Aminomethylphosphonic acid AMPA 
Aminomethylphosphonic acid AMPA has been determined to be a proliferation inhibitor and 
increase the apoptosis activity in pancreatic cancer (Parajuli et al. 2016). MTT assay was used 
to measure cell viability in the two most resistant NSCLC cell lines, which were treated with 
IC50 of the compounds (GM, VRL, Cis, and Carb) and 25mM AMPA (Figure 3.11). 
AMPA alone had no effect on cell viability in the examined cell lines with the exception of 
H358; in fact, the results showed significant reduction in viability when AMPA was combined 
with cisplatin in SK-LU-1 and H358 compared to the cisplatin alone (Figure 3.11). Moreover, 
the combination of AMPA with Cis showed a significant reduction of viable cells, similar to the 
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Figure 3.11: The response of NSCLC resistant cell lines treated with AMPA and 
chemotherapies: the bar charts represent the MTT absorbance readings of the resistant 
NSCLC (SK-LU-1, H358) treated with drug alone for 48h and AMPA combined with one of 
the chemotherapies (A: gemcitabine, B: vinorelbine, and C&D cisplatin). The mean and 
error values in all graphs are the six technical replicates, and the error bars represent 95% 
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3.3 Discussion 
Resistance to chemotherapy is well established to date through multiple preclinical studies 
and clinical trials. Despite the fact significant research efforts have been allocated to 
investigate reversing mechanisms of this resistance, the problem still persists (Wangari-
Talbot and Hopper-Borge 2013). The chemotherapeutics were chosen in this research are 
cisplatin, carboplatin, gemcitabine and vinorelbine.  
The aim of this part of the project was to re-sensitize NSCLC cell lines against chosen 
chemotherapies (gemcitabine, vinorelbine, cisplatin, and carboplatin). As expected (Wangari-
Talbot and Hopper-Borge 2013), the degree of sensitivity to the different drugs of the 
examined cell lines varied significantly. The IC50s calculated were different to those found in 
literature, which are diverse themselves anyway. Besides the difference in laboratory 
conditions, source, preparation and storage of the chemicals, this is also due to the fact that 
each lab works with different passages of the cell lines. Nevertheless, it is crucial to highlight 
that these cell lines have considerably evolved in each lab, depending on the conditions and 
time grown, therefore, genetic, epigenetic and phenotypic differences are manifested. We 
selected the two most resistant cell lines for each drug to carry out the downstream 
sensitization experiments. 
In this study, we attempted to sensitize the resistant NSCLC cell lines to GM, VRL, Cis, and 
Carb by using the epigenetic drugs VPA and DAC. VPA is one of the HDACi, in both 
synchronous and pre-treatment re-sensitized NSCLC cell lines. The latter was a decision taken 
based on the reproducible observations that following pre-treatment, keeping the epigenetic 
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drug during chemotherapy treatment did not have a differential effect (example in Figure 
3.5). 
Significant sensitization of A549 to VRL was observed for both synchronous and pre-
treatment with DAC. In contrast, sensitization of SK-LU-1 to VRL was only achieved during the 
synchronous treatment. This is due to the different genotypes that may give different 
responses to combined therapy.  
In fact, DAC did not deliver any cytotoxicity advantage to any of the remaining drugs tested 
(GM, Cis, and Carb). DAC shows some clinical activity against metastatic NSCLC in the phase 
I/II study (Momparler et al. 1997), as well as the loss the pro-apoptotic gene, caspase 8 and 
expression because the hypermethylation within the neuroblastoma cell lines has been 
recovered via exposure to decitabine which increases the sensitivity of the 
chemotherapeutics (Eggert et al. 2001). Moreover, decitabine also recovers the cyclin-
dependent kinase inhibitor p21WAF1 (CDKN1A) expression in primary rhabdomyosarcoma 
tumours which was found to be hypermethylated (Chen et al. 2000). 
Published literature (Glasspool et al. 2014; Viet et al. 2014; Momparler et al. 1997) provides 
a number of examples where DAC shows certain benefits in combination to chemotherapy.  
One of the researches  points towards the requirement of the design of clinical trials on 
patients with advanced NSCLC, to focus on understanding the pharmacology of decitabine 
and its delayed epigenetic action on cancer cells. (Momparler 2013). 
Despite the fact that DAC combined with cisplatin showed beneficial results in squamous cell 
carcinoma of the cervix, the toxicity was significant (Viet et al. 2014; Pohlmann et al. 2002). 
Combining Cis with DAC increased drug sensitivity in the head and neck squamous cell 
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carcinoma (Viet et al. 2014). However, there are also studies more in line with our results, 
DAC increased the resistance rather than reversed it when combined with Carb in ovarian 
cancer (Glasspool et al. 2014). Decitabine has been studied in phase I–II in patients with stage 
IV NSCLC who survived 81 months (Momparler and Ayoub 2001). 
A combined treatment of decitabine with EZH2 inhibitors displayed a synergistic 
antineoplastic activity on human lung carcinoma cells. The combined drugs have induced 
signs of senescence and apoptosis, and the combinations increased the expression of several 
tumour suppressor genes to a greater extent than either agent alone. (Nascimento et al. 
2016). 
Exposure to epigenetic therapy azacytidine might promote the response of lung tumours to 
irinotecan. While there is no evidence of enhanced response with epigenetic treated with 
other chemotherapeutic agents, the effects of epigenetic pre-treatment of NSCLC on 
response to subsequent chemotherapy appear to be highly context-dependent. (Vendetti et 
al. 2015). 
The novel finding that DAC sensitize s VRL requires further investigation. Moreover, DAC may 
work by reactivating the transcriptional activity of silenced genes, which may be involved in 
the chemo resistance pathway, following the aberrant hypermethylation of the promoter at 
a specific site such as tumor suppressor genes (TSGs) that may benefit re-sensitization to 
chemotherapy (Schiffmann et al. 2016). To know more about the sensitivity, neither 
combined decitabine and vinorelbine in both conditions (synchronous and pre-treatment) 
displayed any significant increase in the caspase 3/7 apoptotic activity, not did the neutral 
comet assay used here to show any DSB. We suggest future investigations of the mechanism 
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behind sensitivity, using cell cycle flow cytometric analysis with propidium iodide DNA 
staining to examine the role of combined DAC and VRL in the cell cycle process.  
48h VPA pre-treatment sensitize d CALU-6 and SK-LU-1 to gemcitabine, A549, COR-L23, and 
SK-MES-1 to carboplatin, as well as A549 and SK-LU-1 to vinorelbine and H358 to cisplatin. In 
contrast, synchronous VPA treatment had an effect on vinorelbine in SK-LU-1 and A549, 
cisplatin response in SK-LU-1 and carboplatin in COR-L23. To our knowledge, this novel finding 
demonstrates that VPA can potentially be used for the sensitization of chemotherapies, 
specifically GM, VRL, Cis, and Carb, in NSCLC. this finding is in accordance with (Hubaux et al. 
2010), who determined that VPA has a beneficial effect when used as a first line regimen 
including Cisplatin plus etoposide in small cell lung cancer (Hubaux et al. 2010). Previous 
research has provided multiple examples of HDACi anticancer properties when combined 
with more than 70 combination chemotherapies(Tan et al. 2010; Lane and Chabner 2009). 
The combination of HDACi with platinum to increase the sensitivity in cancer has also shown 
interesting results, such as the VPA increased sensitivity to cisplatin in ovarian cancer (Lin et 
al. 2008) or the GM sensitivity in pancreatic cancer (Ji et al. 2018). Furthermore, HDACi shows 
a favourable result when combined with cisplatin in gastric cancer (Mutze et al. 2010) as well 
as with NSCLC (Yamaguchi et al. 2013). 
HDACi have multiple biologic effects developing from alterations in patterns of acetylation of 
histones and various non-histone proteins, which contain proteins complicated in the 
regulation of gene expression, pathways of extrinsic and intrinsic apoptosis, as well as cell 
cycle progression (Blackwell et al. 2008). HDACi can induce the death of transformed cells in 
both proliferative and non-proliferative phases of the cell cycle (Burgess et al. 2004). 
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Therefore, it can be concluded that the mechanisms of action of HDACi are complex and not 
completely clear. 
HDACi work as microtubule-associated deacetylases and effect acetylation of lysine40 of α-
tubulin that cause inhibition of cancer cell growth (Blagosklonny et al. 2002). A previous study 
conducted by (Yagi et al. 2010) found that VPA has a synergistic effect with PTX microtubule 
targeting drugs in gastric cancer. Therefore, as shown in this study, synchronous VPA with 
Vinorelbine (an anti-mitotic) increase sensitivity. 
Furthermore, further in vivo pre-clinical studies can be performed by using animals such as 
zebrafish and mice to analyse the toxicity of the combination and the implication of the drugs. 
Following this significant result, we may hypothesize the administration of sodium valproate 
to the NSCLC patient two days before the chemotherapy, especially patient treated with 
(platinum or gemcitabine) that may increase the chemosensitivity. As a result, for NSCLC 
patients who were scheduled to be operated with vinorelbine, the best option is combining 
VRL with VPA at the same time. Certainly, this hypothesis requires clinical validation in the 
form of a clinical trial.  
Throughout the experiments in this chapter, it has become apparent that concurrent 
treatment with both VPA and DAC does not have significant advantage. With minor 
exceptions, VPA has been a much more potent sensitizing compound, therefore making a 
better candidate for clinical applications. A significant additional factor to this is the 
differential toxicity of these two compounds, with DAC being severely more toxic to humans 
than VPA. For example, haematological toxicity (myelosuppression) was observed when DAC 
was combined with carboplatin in cervical cancer (Stephan and Momparler 2015). In contrast, 
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VPA has been identified as a safe drug to use in treating epilepsy (seizures) and as a mood 
stabiliser in decays (Detich, Bovenzi, and Szyf 2003). Thus, repurposing this drug for cancer 
treatment seems much easier. The most recent example is the on-going SAVER trial, led by 
Prof. R.J. Shaw at the University of Liverpool, which is evaluating the use of VPA to suppress 
and/or reverse premalignant oral lesions. 
Caspases are critical protease mediators of apoptosis triggered by different stimuli. To study 
the mechanism of epigenetic drugs sensitizing the NSCLC cell lines, we choose the caspase 
3/7 activity to examine the influence of VPA and DAC treatment against the apoptosis. This 
activity was unnoticeable when the NSCLC cell lines were treated with DAC alone in all the 
tested cell lines, except for SK-MES-1, which manifested a significant increase in the apoptosis 
activity. Exposure of the NSCLC cell lines to sodium valproate alone determined a substantial 
decrease in apoptosis activity except in H358 where it shows a considerable increase in 
caspase 3/7 activity. As expected, chemotherapeutics (cisplatin, carboplatin, gemcitabine and 
vinorelbine) resulted in a significant increase in the apoptosis activity. A similar trend was 
recorded when the selected NSCLC cell lines were treated with carboplatin in COR-L23 and 
cisplatin in H358 combined with decitabine in both synchronous and pre-treated types, while 
not showing any change when DAC combined with gemcitabine and vinorelbine. 
Cisplatin activated caspase-3 activation followed the processing of caspase-9, to produce an 
inactive p37 form (Checinska et al. 2007). While the mechanism responsible for cisplatin-
trigger caspase-3 activation in NSCLC cells is not yet clear, one of the researches has provided 
evidence that caspase-8 plays a role in starting caspase in this situation in a Fas/FasL-
independent manner. They noticed that a minor proportion of caspase-9 was processed into 
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p35 fragment, but it still remained catalytically inactive (Ferreira et al. 2000). Cisplatin is 
known to enhance apoptosis activity in a p53 dependent manner (Jiang et al. 2004).  
Gemcitabine activated the mitochondrial apoptosis pathway downstream of mitochondria 
without the activation of originator caspases (Pasqualetti et al. 2011).  
The noscapine and gemcitabine combination treatment activated initiator caspases, such as 
caspase-8 (intrinsic pathway) and caspase-9 (extrinsic pathway) followed by the activation of 
effector caspase-3 (Chougule et al. 2011). Noscapine alone can initiate of apoptosis targeting 
the mitochondrial pathway through repression of Bcl2 expression and upregulation of 
proapoptotic  genes (Jackson et al. 2008). It has been also shown that a noscapine/ 
gemcitabine combination treatment leads to stimulation of Bax, BID and p21 genes, inducing 
apoptosis in lung tumours cells (Chougule et al. 2011). 
The combination of metronomic, vinorelbine and endostar significantly increased antitumor 
activity as compared to the drugs alone, and stimulated apoptosis by down-regulating Bcl-2 
expression and up-regulating expression of Bax and caspase 3/7.(Qin et al. 2018). Vinorelbine 
enhanced apoptosis (Faller and Pandit 2011). 
Impaired apoptosis is mutually critical in cancer development and a major difficulty in 
effective treatment in response to various intracellular damage signals, involving those 
induced by cancer therapy. 
Interestingly, while synchronous treatment with VPA and platin compounds increases 
apoptosis in all tested cell lines, pre-treatment with VPA resulted in no change for SK-LU-1 
and H358 and even showed a drop of this activity in SK-MES-1 and CORL-23 or (Figure 3.8). 
Apart from further providing further evidence of the fact that different cell lines (i.e. different 
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genotypes) will respond differently to intervention, this may imply that pre-treatment with 
VPA potentially triggers cell cycle arrest (Kaiser et al. 2006) which stops the cell from 
recognising the damage and proceeding apoptosis, which in turn may restrict its apoptosis 
potential. Apparently, apoptosis naturally removes most cells whose cell cycle control is 
disturbed by oncogenic mutations (Adams and Cory 2007). In contrast, synchronous 
treatment increases chemotherapy-induced apoptosis by re-activating pro-apoptotic gene 
expression as has been previously shown (Zhang et al. 2012). 
In this study, the epigenetic pre-treatment followed by the four chemotherapeutic agents 
(gemcitabine, vinorelbine, cisplatin and carboplatin) is suggested due to its capacity to put 
cells in an alternative condition by deacetylation and increase the expression of important 
genes that play a role in the pathways of extrinsic and intrinsic apoptosis and cell cycle 
progression (Blackwell et al. 2008). Research shows that the HDAC inhibitor can increase the 
chemosensitivity of lung cancer to cisplatin (Diyabalanage, Granda, and Hooker 2013) and has 
an anti-proliferation effect through cell cycle regulation and apoptosis. 
The effect of VPA on increased chemotherapy-induced apoptosis of NSCLC cells triggered a 
question whether this was mediated by increased DNA damage. It was fully appreciated at 
this point that some of this chemotherapeutics alone induce DNA damage. It was also 
appreciated that the neutral comet assay used here assesses DSBs and would not provide 
information on accumulation of single strand breaks (SSBs) or DNA adducts.  
Gemcitabine lead to profound DNA damage in three out of eight NSCLC cell lines tested, 
showing evidence of DNA strand breaks. Gemcitabine (GM) is a well-known anti-neoplastic 
drug that can stop cell division. It is a replication inhibitor used to treat cancers with mutations 
in homologous recombination HR genes such as BRCA2. GM causes replication fork stalling 
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and double-strand breaks (DSB) that result from the processing of stalled forks. The 
homologous recombination (HR) factor RAD51 mediates fork restart and DSB repair during 
recovery from replication blocks. Moreover, HR defects may lead to sensitize cells to 
replication inhibitors such as GM (Jones et al. 2014). Previous evidence on GM-induced DSBs 
also comes from a Phase I trial on uveal melanoma (Corrie et al. 2005). 
Of importance is the observation that VPA pre-treatment significantly enhanced the presence 
of DSBs. The most probable explanation is that VPA alters the expression of genes that 
influence GM-induced DSBs, however, future work is required to identify those genes that 
may mediate this effect and prove the above hypothesis. 
Fendiline is an anti-arrhythmic, antianginal agent and a coronary vasodilator which works by 
inhibiting the calcium channel function in muscle cells on the excitation-contraction coupling. 
Calcium is a ubiquitous cellular signal, which is vital in cancer. The changed expression of 
specific calcium channels and calcium binding proteins are distinguishing features of lung 
cancer, which control the cell signalling pathway leading to cell proliferation or apoptosis. 
Chemoresistance is common in lung cancer. Changed endoplasmic reticulum calcium 
homeostasis of lung cancer cells is associated with drug resistance (Yang et al. 2010). Calcium 
signalling can reverse epigenetic silencing of tumor suppressor genes (Raynal et al. 2016). 
Our results showed an original finding that fendiline causes a significant reduction in cell 
viability when combined with GM in SK-LU-1, but not in CALU-6. Furthermore, significant 
reduction in cell viability occurred in SK-MES-1 when fendiline was combined with 
carboplatin, though this did not work with COR-L23. However, fendiline combined with 
cisplatin did not work with SK-LU-1 and H358. 
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Gemcitabine, vinorelbine, and carboplatin sensitization in NSCLC cells found in this study has 
not previously been reported. Fendiline showed a significant effect in reducing proliferation 
of pancreatic cancer when combined with gemcitabine (Woods et al. 2015). Moreover, the 
mechanism of fendiline in prostatic cancer showed that fendiline induces intra cellular Ca+2 
release and external Ca+2 entry. A long period of Ca+2 increase inside the cell may lead to cell 
injury and death (Jan et al. 2001). Furthermore, Van der Hoeven et al. (2013) provided a novel 
report in which fendiline blocked the proliferation of lung and other cancers through present 
oncogenic mutant K-Ras (van der Hoeven et al. 2013). 
It has been suggested (van der Hoeven et al. 2013; Woods et al. 2015; Jan et al. 2001) that 
using fendiline as an anti-cancer agent combining with chemotherapeutics in several 
researches. Fendiline has advantage in protecting the cardiomyocytes from cell death to avoid 
cardiotoxicity; while treated with agents, no untoward side effects have been observed even 
at high dosage levels. As showed in the results, combined fendiline with GM, VRL, Carb 
increases NSCLC sensitivity. Fendiline can reduce the clinical application of the 
chemotherapeutics by reducing the dose of agents required to achieve high efficiency. 
It has been approved that fendiline treatment induces G1 arrest in pancreatic cancer cells. 
Treating pancreatic cells (PDAC) with fendiline for 24h shows an accumulation of the cells in 
the G1 phase and cells reduction in S and G2 phase, meaning that fendiline arrest the cell 
cycle in G1 phase which stops the proliferation. As a result, combined fendiline with 
Gemcitabine which works in S/G2 and vinorelbine work in G2/M may increase the drug 
productivity (Woods et al. 2015). 
To move the combination therapy of fendiline with chemotherapeutics from the bench to the 
bedside, many preclinical studies are needed to be designed to yield preliminary efficacy, 
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toxicity, pharmacokinetics, and safety information. Different doses of the drug are tested 
using in vitro (test tube or cell culture) as in pancreatic cells mentioned before and in vivo 
(animal, e.g. zebrafish and mice) experiments which required as a next step, and it is also 
possible to perform in silico profiling using computer models of the drug-target interactions. 
AMPA arrested cancer cells in G1/G0, blocked their entry to S phase, and promoted apoptosis, 
upregulating p53, p21, and procaspase 9 (Li et al. 2013). AMPA can phosphorylate CAMP, 
which is responsible for increased cell cycle regulators, while tumour suppressor genes 
proteins lead to decreased ADC cells in the G2 and S phases (Stepulak et al. 2007). Moreover, 
AMPA is safe and does not reduce cell proliferation in any NSCLC resistant cell lines, except 
for H358. Our results showed a significant reduction in viable cells in SK-LU-1 and H358 when 
AMPA was combined with cisplatin. The combined effect of AMPA with drugs revealed an 
additive effect, which does not indicate any synergetic affect (figure 3.11).  
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3.4 Conclusion 
After having identified the IC50 of the selected chemotherapeutics (cisplatin, carboplatin, 
gemcitabine and vinorelbine) in eight NSCLC cell lines. The epigenetic drugs VPA and DAC 
have no cytotoxicity on selected NSCLC, as well as showing a reduction in the 3/7 activity in 
NSCLC cell lines, while DAC did not have any effect in apoptotic activity. Then, we combined 
them with selected chemotherapeutics in two different conditions, pre-treatment and 
synchronous, based on the results of the pilot test. 
To sum up, this study has determined a potential synergetic interaction between VPA and the 
four chemotherapies, namely gemcitabine, vinorelbine, cisplatin, and carboplatin, as well as 
decitabine sensitize d vinorelbine. Fendiline has a potential benefit with gemcitabine and 
vinorelbine.  
Moreover, this study has determined that the mechanism behind sensitization of the NSCLC 
cell lines with epigenetic agents VPA and DAC is increasing apoptosis though enhanced 
caspase 3/7 activity. Additionally, it has indicated that gemcitabine causes DNA double strand 
break induction, although more research is required to identify the mechanism through which 
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Chapter 4: Impact of LANCL1 and LANCL1-AS1 in Drug 
Resistance 
 
4.1 Introduction  
Antisense LANCL1-AS1 lncRNA was chosen from the array results (Acha-Sagredo et al. 2020). 
To my knowledge, there is not currently any published research about LANCL1-AS1 presuming 
a role in cancer, especially lung cancer. Following the observation of extensive LANCL1-AS1 
loss of expression in NSCLC specimens, we aimed to investigate the potential functional 
significance of this loss in the disease, including tumour phenotype and drug resistance. In 
this effort, we chose to examine the expression and function of the coding counterpart gene, 
LANCL1. Therefore, the LANCL1 gene was chosen to study whether LANCL1-AS1 plays any role 
in regulating LANCL1 and to elucidate its role in NSCLC cells. Given the previous evidence on 
the latter influencing oxidative stress in cells (Zhong et al. 2012), this became one of the 
central points of focus. This chapter determines the experimental work conducted in human 
lung tissue samples (table 8.1) and NSCNC cell lines to specify in detail LANCL1 and LANCL1-
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Given the virtually complete lack of information for LANCL1 and LANCL1-AS1 in lung cancer, 
we set a number of interesting research questions: 
a) Do the mRNA expression levels of LANCL1 and LANCL1-AS1 correlate in lung tissues and 
cell lines? 
b) Are the reported splicing variants present in lung tissues and cell lines? 
c) Is expression of LANCL1 and LANCL1-AS1 epigenetically regulated? 
d) Is LANCL1 protein consistent with the mRNA expression profile? 
e) Is expression of LANCL1 and LANCL1-AS1 regulated by oxidative stress in lung cancer 
cells? 
f) Does expression of LANCL1 and LANCL1-AS1 affect the sensitivity of NSCLC cells to 
cisplatin, carboplatin, VRL and Gemcitabine? 
In order to provide answers to those questions, we exogenously knocked down LANCL1 by 
using shRNA in lung cancer cells and examined the phenotypic responses, including drug 
sensitivity. Finally, we overexpressed the LANCL1-AS1 gene, which is completely knocked out 
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4.2 Results 
4.2.1 Expression of LANCL1 and LANCL1-AS1 in human lung cancer 
tissues 
RNA from primary NSCLC cancer tissues had already been prepared by the lung group for the 
lncRNA study (Acha-Sagredo et al. 2020), therefore I investigated the mRNA expression of 
LANCL1 in 67 lung tumours and paired adjacent normal tissues (Table 8.1), for which LANCL1-
AS1 expression data was already available (Acha-Sagredo et al. 2020). LANCL1-AS1 is highly 
expressed in normal tissue with and diminished in tumour paired tissue (Wilcoxon test, 
P=0.021) (Acha-Sagredo et al. 2020). The mRNA expression level of LANCL1 was only 
moderately higher in tumour samples as compared with in paired adjacent normal tissues, a 
difference which was not significant (Figure 4.1) (Wilcoxon test, P=0.191). 
When tested for bivariate correlation, LANCL1 and LANCL1-AS1 values did not correlate, 
either in normal (Spearman correlation, rho=0.003, P=0.981) or tumour tissues (Spearman 
correlation, rho=0.061, P=0.621). Moreover, the expression of both LANCL1 and LANCL1-AS1 
did not difference among pathological groups such as histology, pT status and pN status 
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Figure 4.1: Boxplot representation of expression of both LANCL1 and LANCL1-AS1 in lung 
tissue samples. (A) LANCL1 expression is not significantly different in tumour tissues 
compared to adjacent normal; in contrast, (B) LANCL1-AS1 is highly expressed in normal 
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Figure 4.2: Bar charts demonstrating the expression of LANCL1 and LANCL1-AS1 
amongdifferent pathological groups in this study. AdenoCa: adenocarcinoma, SqCC: 
squamous cell carcinoma, pT: pathological T status (tumour size), pN: pathological nodal 
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4.2.2 Expression of LANCL1 and LANCL1-AS1 in NSCLC cell lines 
Further investigation of mRNA expression for both LANCL1 and LANCL1-AS1 in eight NSCLC 
cell lines from different histological origins (A549, CALU-3, CALU-6, COR-L23, H348, LUDLU, 
SK-MES-1, and SK-LU-1) was undertaken by RT-qPCR. LANCL1 was variably expressed in NSCLC 
cell lines (Figure 4.3). In contrast, LANCL1-AS1 was either completely undetectable or 
detected after the 50th cycle in qPCR.  
 
Figure 4.3: Bar charts exhibiting the mRNA expression of LANCL1 in NSCLC cell lines. 
SKMES-1 represent the highest expression while, SK-LU-1 represent the lowest. The 
mean and error values in all graphs are the triple technical replicates, while the error 
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Western blotting was used to determine and confirm protein expression for LANCL1 in the 
eight NSCLC cell lines (Figure 4.4). However, the result was not satisfactory as the antibody 




Figure 4.4: LANCL1 protein expression levels quantified by western blot analysis. A549 was 
used as a calibrator (value=1). Band quantitation was undertaken by synGENE. ACTB was 
used as a loading control Protein Ladder, 10 to 180 kDa.  
 
 
4.2.3 Splicing variant expression of LANCL1 in NSCLC 
LANCL1 has 6 transcript splice variants; variants 1, 2, 3 and 5 are coding transcripts.  Variants 
1, 2 & 3 have large size (V1=4270bp, V2=4461 and V3=1385bp) and have been chosen to 
complete the investigation (Figure 4.5). Variant 5 is a very short (570bp) transcript coding for 
an incomplete peptide of unknown function, so it was not considered for this study. 
 
A549 CALU-3 CALU-6 COR-L23 LUDLU-1 H358 SK-MES-1 SL-LU-1 
ACTB 
LANCL1 45 kDa 
41 kDa 40 kDa 
Ladder 
 














Figure 4.5: Nucleotide sequence demonstrating the differences in exon 1 of the reported LANCL1 transcript variants in Genebank database. 
Purple, red and green letters designate exon 1 for variant 1, 2 and 3 respectively. Blue letters denote the common exon 2. Small case letters 
denote promoter/intron sequences that are not part of the mature transcripts. The highlighted sequences show the location of primers used. 
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Two assays were designed to amplify the three LANCL1 transcript variants. The agarose gel 
electrophoresis analysis of all the samples derived from primary tissues (not showing) and cell 
lines (Figure 4.6) revealed the presence of V1 and V3, but not V2. No major differences in the 
variant signals on the gel were detected between normal and tumour tissue to trigger further 
investigation with a quantitative method such as qPCR.  
 
 
Figure 4.6: Agarose gel (2% agarose in TBE) electrophoresis of PCR products from LANCL1 
transcript variants in NSCLC cell lines. Variant V1 (173 bp) and variant V3 (145 bp) can be seen 
in all samples tested, while variant V2 was not detected in any of the samples. The size 








NSCLC cell lines  
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4.2.4 Methylation state of LANCL1 in tumour and normal lung 
samples 
The bioinformatic analysis (EMBOSS CpG plot) revealed the presence of a CpG island in the 
LANCL1 gene promoter; no CpG island was detected in the promoter of LANCL1-AS1 gene. 
We therefore designed a pyrosequencing methylation assay only for LANCL1 promoter 
(Figures 4.7, 4.8). We analysed 60 DNA samples, 40 NSCLC tumour samples and 20 normal 
lung samples, respectively, none of the samples demonstrating any degree of DNA 
methylation (Figure 4.9). Therefore, DNA methylation is considered absent or, in any case, 














Figure 4.7: Sequence of the promoter and exon 1 of human LANCL1 gene. Upper case letters 
denote the exon 1 sequence. Violet letters show the 5’UTR while blue letters show the 
coding sequence. Cytosines in CG dinucleotides are in red letters. Primer annealing areas 
for the pyrosequencing assay is shown in yellow highlight and the CpGs interrogated by the 
assay are indicated in blue highlight. Please note that this is not a bisulphite-converted 
sequence, therefore, the primer sequence does not match. 
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Figure 4.8: Screen clipping image from Pyromark Assay Design demonstrating the DNA 
methylation assay design used. The sequence shown is bisulphite converted DNA; red Ts 
indicate non CpG cytosines, which are converted to Ts following bisulphite-PCR; the circle 
at the 5’ of the forward primer indicates biotinylation of primer; the interrogated CpGs 





Figure 4.9: Representative pyrogram demonstrating lack of DNA methylation in all four 
CpGs examined. The X axis is the nucleotide dispensation order; the sequence shown on 
top left is the interrogated sequence; R (=G/A) in this sequence denotes the cytosines 
tested (reverse strand sequencing) which on the actual pyrogram are shown by the blue 
strips. The % methylation for each CpG is shown in the box above each one; the colour of 
this box indicates the confidence of the quantitation (blue is high confidence, yellow is 
acceptable but moderate confidence). 
 
 
203       
 
4.2.5 Oxidative stress response in NCLC cell lines 
To investigate whether oxidative stress affected LANCL1 expression in six NSCLC cell lines, RT-
qPCR was run in the NSCLC cell lines following treatment, with two different doses of H2O2, 
25 µM and 50 µM respectively, for two different durations, three and six hours, respectively. 
The experiment revealed a gradual increase in LANCL1 mRNA expression in CALU-3 (the most 
significant recorded at 50 µM/6h with P=0.004), COR-L23 (the most significant recorded at 
50µM/6h post-treatment with P=0.003) and H358 (the most significant recorded at 50µM/6h 
post-treatment with P=0.005). A549 showed a mild increase in the LANCL1 mRNA expression 
(the most significant recorded at 25µM/6h with P=0.003), increase in LANCL1 mRNA 
expression in SK-LU-1 after treated with both dose 50 µM and 25 µM at 6h with P= 0.002, 
while LANCL1 expression was most significant high in SK-MES-1 after being treated with 25 
µM for six hours with P=0.008. The experiment for SK-MES-1 was repeated with six replicates 
to confirm the result that shows that LANCL1 increased around four times in SK-MES-1 under 
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Figure 4.10: Bar charts displaying mRNA expression of LANCL1 in different NSCLC cell lines treated with two doses of H2O2 25 µM/50 µM and incubated 
for two different periods of three and six hours, respectively. Green represent the most significant results. The mean and error values in all graphs 
represent six technical replicates, and the error bars represent 95% confidence intervals. (Mann Whitney).  
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4.2.6 Overexpressed LANCL1-AS1 in the SK-MES-1 cell line 
As mentioned above, LANCL1-AS1 expression was found to be suppressed in tumour lung 
tissue samples, while completely absent in the eight NSCLC cell lines. The role of LANCL1-AS1 
has not been investigated yet, hence there are not any published papers describing any 
information relevant to its potential function. Therefore, I exogenously overexpressed the 
gene in NSCLC cell lines in order to determine the phenotypic effects, including its role in 
chemotherapy resistance, following expression restoration. SK-MES-1 was selected as the 
host cell line for this series of experiments, as it had zero expression for LANCL1-AS1 (as every 
other cell line tested) and was the same cell line used to knock down LANCL1. This was 
intended to limit, to the best possible, potential differences originating from the genetic 
background of different cell lines. In addition, the use of an inducible expression vector, 
PF12ARM, was selected in order to minimise the effects of the transfection process, mostly 
insertional mutagenesis by plasmid sequences into the genomic DNA. Therefore, the 
phenotypic results derived from the inducible clone can directly be attributed to LANCL1-AS1 
expression changes, due to the fact that the genotype does not change, as would be the case 
comparing a cell line transfected with a recombinant plasmid versus a control transfected 
with vector only. Following transfection and clone selection, RT-qPCR was used to confirm the 
overexpression of LANCL1-AS1, and only one clone (LS3) successfully achieved inducible 








Figure 4.11: Bar chart demonstrating the coumermycin switch on/off system in 
overexpressed LANCL1-AS1. Overexpressed LANCL1-AS1 (LS3) was the clone, which 
expressed LANCL1-AS1 with LS3 treated with coumermycin (LS3C) elevated the expression 
to triple, while novobiocin decreased LANCL1-AS1 expression. The numbers over the bars 
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Interestingly, the overexpression of LANCL1-AS1 in SK-MES-1 resulted in the overexpression 
of LANCL1 mRNA (Figure 4.12), which is different from the lack of correlation in primary tissue 
samples, as shown at the beginning of this chapter. It must be noted that coumermycin and 
novobiocin exposure of the parental SK-MES cells, which do not carry the PF12ARM-based 
plasmid, did not affect LANCL1 expression (data not shown). 
 
Figure 4.12: Relationship of LANCL1-AS1 and LANCL1 RNA expression in the inducible clone 
(LS3) system in SK-MES-1 cells. Novobiocin, suppresses LANCL1-AS1 expression and this then 
suppressed LANCL1 expression. In contrast, coumermycin exposure induces LANCL1-AS1 
expression and this is caused overexpression of LANCL1. 
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4.2.7 Phenotypic effect on overexpressed LANCL1-AS1 clone 
To investigate the phenotypic effects associated with changing the expression LANCL1-AS1, 
the MTT assay was used to determine the growth rate (proliferation), while wound healing 
assay was applied to determine cell migration, and invasion assay was employed to analyse 
cell movement through an extracellular membrane. 
4.2.7.1 Proliferation 
Proliferation rates were increased by the differential expression of LANCL1-AS1 (Figure 4.13). 
The observed difference between transfected cells grown in coumermycin and grown in 
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Figure 4.13: MTT assay to determine the growth rate in the LS3 clone in the presence of 
coumermycin (green line high LANCL1-AS1 expression) and novobiocin (red line minimised 
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4.2.7.2 Wound healing assay 
Wound healing assay (scratch assay) determined cell migration rate with the use of Fiji 
software. Interestingly, the cells overexpressing LANCL1-AS1 (LS3C) demonstrated a 
significant rapid migration rate compared to those with low LANCL1-AS1 expression (LS3N) 
(Figure 4.14), (Mann Whitney at 72 hours P=0.025) which agreed with the proliferation 
results.  
 
4.2.7.3 Invasion assay 
The Boyden chamber experiments demonstrated faster cell movement through the 
membrane for the LANCL1-AS1 overexpressing cells, the result being more pronounced at 48 










A LS3C LS3N 
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Figure 4.14: Wound healing assay for 48 hours for cells with differential expression of 
LANCL1-AS1. The LS3 clone in the presence of coumermycin (red line high LANCL1-AS1 
expression) and novobiocin (green line minimised LANCL1-AS1 expression). The 
overexpressed LANCL1-AS1 clone demonstrates a faster rate of closing the gap in the assay, 
or potentially is a higher proliferative rate of the LS3C. A pictures were taken at different 
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Figure 4.15: Invasion assay for cells with differential expression of LANCL1-AS1. LS3C 
(coumermycin, i.e. highest expression for the gene) demonstrates a higher number of 
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4.2.7.4 Oxidative stress response in relation to LANCL1-AS1 overexpression. 
 LANCL1 seems to play a major role in protecting neural cells from oxidative damage. As 
shown in various previous studies, there is a relation between oxidative stress and 
chemotherapy sensitivity (Conklin 2004; Zhen et al. 1992). Therefore, the response to 
oxidative stress (exposure to H2O2) was examined for the cells with differential expression of 
LANCL1-AS1. As a result, we concluded that the survival of cells of overexpressed LANCL1-AS1 
was reduced through treatment with seven different concentrations 0–100µM of H2O2 for 48 
hours. The overexpressed LANCL1-AS1 clone was growing with novobiocin (LS3N) and 
coumermycin (LS3C) to regulate the transgene expression; the LS3C clone become more 











 LS3C LS3N 
IC50 (µM) 6.583 14.67 
95% CI (µM) 2.805 to 10.46 9.177 to 21.16 
Figure 4.16: MTT assay demonstrating the sensitivity of the overexpressed LANCL1-AS1 
clone to H2O2. The LS3 clone in the presence of coumermycin (pink line high LANCL1-AS1 
expression) and novobiocin (green line minimised LANCL1-AS1 expression). The means and 
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4.2.7.5 Chemotherapeutics response in overexpressed LANCL1-AS1 clones 
The treatment of the clones with 0–4µM gemcitabine shows a significant reduction in cell 
viability in overexpressed LANCL1-AS1 (LS3C) grown in coumermycin as compared with 
overexpressed LANCL1-AS1 (LS3N), which grown in novobiocin and parental cells (Figure 
4.17). As displayed, overexpressed LANCL1-AS1 increases cell sensitivity to gemcitabine. 
 
 LS3C LS3N 
IC50 (µM) 0.002 0.59 
95% CI (µM) 0.0003 to 0.01 0.14 to 0.90 
 
Figure 4.17: MTT assay exhibiting the sensitivity of the overexpressed LANCL1-AS1 to 
gemcitabine. Overexpression of LANCL1-AS1 sensitize s the SK-MES-1 cells to gemcitabine. 
The LS3 clone in the presence of coumermycin (pink line high LANCL1-AS1 expression) and 
novobiocin (green line minimised LANCL1-AS1 expression). The mean and error values in all 
graphs represent six technical replicates, and the error bars represent 95% confidence 
interval. 
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Also, a significant result was found when the clone’s were treated with vinorelbine (0–500 
nM). The overexpression of LANCL1-AS1 grown in coumermycin (LS3C) shows an increase in 




 LS3C LS3N 
IC50 (nM) 0.013 2.6 
95% CI (nM) 0.003 to 0.34 0.98 to 5.09 
 
Figure 4.18: MTT assay showing the response of the overexpressed LANCL1-AS1 to vinorelbine. 
Overexpression of LANCL1-AS1 sensitize s the SK-MES-1 cells to vinorelbine. The LS3 clone in 
the presence of coumermycin (pink line high LANCL1-AS1 expression) and novobiocin (green 
line minimised LANCL1-AS1 expression). The mean and error values in all graphs represent six 
technical replicates, and the error bars represent 95% confidence intervals. 
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Overexpressed LANCL1-AS1 clones sensitize the SK-MES-1 NSCLC cell line to both gemcitabine 
and vinorelbine. In contrast, treating the clones with platinum agents shows a significant 
increase in resistance. As in overexpressed LANCL1-AS1 grown in coumermycin (LS3C), when 
treated with cisplatin (0–100µM) showed an IC50 increase compared with the same clone 
grown in novobiocin (LS3N). The same response was determined when the clones were 
treated with carboplatin (0–100µM) (Figure 4.19).
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  LS3C LS3N 
Cisplatin 
IC50 (µM) 32 5.96 
95% CI (µM) 19.01 to 48.92 1.53 to 9.54 
Carboplatin 
IC50 (µM 102.12 68.83 
95% CI (µM) 86.21 to 129.80 47.47 to 104.15 
 
Figure 4.19: MTT assay representing the overexpressed LANCL1-AS1 react against platinum. Overexpression of LANCL1-AS1 makes SK-MES-1 cells 
more resistant to both cisplatin and carboplatin. The LS3 clone in the presence of coumermycin (pink line high LANCL1-AS1 expression) and 
novobiocin (green line minimised LANCL1-AS1 expression). The mean and error values in all graphs represent six technical replicates, and the error 
bars represent 95% confidence intervals. 
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4.2.8 LANCL1 downregulated in SK-MES-1 NSCLC cell line 
LANCL1 mRNA expression was detectable in all normal and tumour tissue samples as well as 
the examined cell lines, among which SK-MES-1 demonstrated the highest LANCL1 mRNA 
expression. Therefore, this cell line was selected for genetic manipulation to silence the 
LANCL1 gene by using the small hairpin (shRNA) approach. The aim of this set of experiments 
was to explore the phenotypic effects that LANCL1 expression silencing may trigger; more 
specifically, we measured proliferation, motility and invasion, as well as response to oxidative 
stress and chemotherapeutic agents. 
Five shRNA constructs (materials and methods section2.7.1 Table 10) to knockdown LANCL1 
were used in individual transfections. RT-qPCR was utilized to analyse the mRNA expression 
level of LANCL1 in determined clones to confirm the suppression of LANCL1 expression in SK-
MES-1. Four clones were isolated based on the efficiency of silencing: A6-8 and A6-26 clones, 
derived from TRCN0000011687 plasmid targeting the 3UTR region; A9-10 and A9-28 clone, 
derived from TRCN 0000011690 plasmid targeting the CDS region (Figure 4.20). It must be 
noted that the qPCR analysis of LANCL1-AS1 expression did not show any difference (i.e. 
undetectable expression) regardless of the LANCL1 expression level in the examined cell lines.  
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Figure 4.20: RT-qPCR assessment of LANCL1 mRNA expression in selected SK-MES-1 derived 
transfectants. Values are derived from triplicate experiments and are expressed as fold-
difference to the parental cell line (shown as SKC). SCr: Scrambled transfectant clone. The 
numbers over the bars demonstrate the average fold-expression, while error bars represent 
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4.2.9 Western blot to validate LANCL1 silencing at protein level. 
Using Western blotting to detect LANCL1, and unfortunately, after using two different 
antibodies (catalogue no. PA5-57107 & PAS-31080, Thermo Fisher Scientific) and repeating 
the experiment several times, we could not obtain a successful result demonstrating 
knockdown of LANCL1 (Figure 4.21). 
 
 
Figure 4.21: Western blot results of LANCL1 protein expression. The low quality of the result 
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4.2.10 phenotypic effect on LANCL1 clones 
4.2.10.1 Proliferation 
LANCL1 knockeddown clones displayed reduction in the cell proliferation in all two picked 
clones A6/26 and A9/10 (Mann Whitney at 72 hours P=0.003, P=0.005 respectively) compared 
to the parental and the scramble. Also, the proliferation rate decreased in scramble 
comparing with parental cells that may because the off-target effect (Mann Whitney at 72 
hours P=0.017) (Figure 4.22).  
 
 
Figure 4.22: MTT assay to determine the growth rate in knocked down LANCL1. In knocked 
down clones: A6/26 and A9/10 reported a reduction in cell proliferation as compared with 
the parental SK-MES-1 and the scramble. The mean and error values in all graphs represent 
six technical replicates, and the error bars represent 95% confidence intervals. 
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4.2.10.2 Wound healing assay 
Both knockeddown LANCL1 clones; A6/26 and A9/10 (Mann Whitney at 27 hours P=0.025, 
P=0.008 respectively) showed a slow movement in the migration rate for closing the wound 
versus parental cell SK-MES-1 (Figure 4.23). Parental cells have a higher proliferation rate. 
Therefore, this result might be expected. 
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Figure 4.23: Wound healing assay for 48 hours for cells with differential expression of LANCL1. 
The LANCL1 knocked down clones (red line A9/10 and green A6/26) and blue line parental 
cell line SK-MES-1. The knockdown LANCL1 clone demonstrates a slow rate of closing the gap 










4.2.10.3 Invasion assay 
In the invasion assay, no significant differences were observed between LANCL1 knocked down clones and parental cells (Figure 4.24). 
 
Figure 4.24: Invasion assay for both LANCL1 (A6/26 and A9/10) clones. The rate of cell movement through the extracellular membrane for 48 hours. 
SK-MES-1 A6/26 A9/10 Scramble 
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4.2.10.4 Oxidative stress response in knocked down LANCL1 clones  
MTT assay was employed to analyse the H2O2 toxicity with seven different concentrations (0–
100 µM) on the knockeddown LANCL1 clones. That showed a reduction in cell viability in both 
A6/26 and A9/10 clones mean that the clones become more sensitive to H2O2. Furthermore, 
clone A6/26 showed more increase in the sensitivity to H2O2 than clone A9/10 (Figure 4.25). 
 
 
 SK-MES-1 SCRAMBLE A6/26 A9/10 
IC50 (µM) 116.74 174.90 10.58 84.75 
95% CI (µM) 84.05 to 134.57 132.61 to 197.1 9.235 to 11.99 59.75 to 129.54 
Figure 4.25: Sensitivity of the knocked down LANCL1 clones to H2O2. In MTT assay both 
clones (green line A6/26, orange line A910) show a sensitivity to H2O2. The mean and error 
values in all log10 graphs represent six technical replicates, and the error bars represent 
95% confidence intervals. 




















230       
 
4.2.10.5 Chemotherapeutic response in knocked down LANCL1 clones 
Treatment of the parental SK-MES-1 and the clones with (0–4 µM) gemcitabine shows a 
reduction in cell viability in knockeddown clones show reduction in cell viability in A6/26 and 




 SK-MES-1 SCRAMBLE A6/26 A9/10 
IC50 (µM) 0.023 0.038 0.001 0.002 
95% CI (µM) 0.012 to 0.045 0.001. to 0.068 0.0006 to 0.009 0.001 to 0.014 
Figure 4.26: Sensitivity of the knocked down LANCL1 clones to gemcitabine. Both clones 
(green line A6/26, orange line A910) sensitize the SK-MES-1 (blue line) against gemcitabine. 
The mean and error values in all graphs represent six technical replicates, and the error 
bars represent 95% confidence intervals. 
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A significant result was found when the clones was treating with vinorelbine (0–500nM). 
knockeddown LANCL1 clones also show a reduction in cell viability when treated with VRL in 




 SK-MES-1 SCRAMBLE A6/26 A9/10 
IC50 (nM) 1.54 3.721 0.065 0.001 
95% CI (nM) 0.5867 to 2.666 1.065 to 5.063 0.017 to 0.951 0.002to 0.188 
Figure 4.27: Response of the knocked down LANCL1 clone to vinorelbine. In MTT assay both 
clones (green line A6/26, orange line A910) sensitize the SK-MES-1 (blue line) against 
vinorelbine. The mean and error values in all graphs represent six technical replicates, and 
the error bars represent 95% confidence intervals. 
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Surprisingly, resistance was found in knocked down LANCL1 clones when treated with 
cisplatin and carboplatin, where the IC50 increased in A6/26 and in A9/10 as compared with 
both parental SK-MES-1 and scrambled cell line. The same response appeared when the 
clone was treated with carboplatin: both A6/26 and A9/10 showed an increase in the IC50 
compared with the parental cells (Figure 4.28).
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  SK-MES-1 SCRAMBLE A6/26 A9/10 
Cisplatin 
IC50 (µM) 13.08 6.08 37.344 48.804 
95% CI (µM) 9.631 to 16.589 1.777 to 9.417 24.9053 to 58.965 24.072 to 79.820 
Carboplatin 
IC50 (µM 79.53 120.23 184.4 211.76 
95% CI (µM) 47.82 to 106.25 105.72 to 160.63 218.14 to 157.23 256.91 to 198.16 
 
Figure 4.28: knocked down LANCL1 clones react against platinum. In MTT assay both clones (green line A6/26, orange line A910) make SK-MES-1 
(blue line) more resistance to both cisplatin and carboplatin. The mean and error values in all graphs represent six technical replicates, and the error 
bars represent 95% confidence intervals. 
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4.2.11 Effect of sodium valproate on LANCL1 expression 
LANCL1 is overexpressed in lung tumours and NSCLC cell lines. Given the highly deregulated 
epigenetic control of lung tumours, an interesting research question arising is whether 
LANCL1 expression is under epigenetic control. Previously in this chapter, we observed lack 
of DNA methylation in the promoter of the gene in primary NSCLCs. Therefore, it was decided 
to examine another major epigenetic factor, which is histone deacetylation. For this purpose, 
eight NSCLC cell lines were treated with valproic acid, which is a well-known HDAC inhibitor, 
for 48 hours. Interestingly, all but H358 cell lines showed elevated LANCL1 expression with 








Figure 4.29: Bar chart showing the LANCL1 expression under exposure to sodium valproate. 
Eight NSCLC cell lines were treated with VPA for 48 hours and then the mRNA expression 
was determined by RT-qPCR. The numbers over the bars demonstrate the average fold-
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4.3 Discussion 
Following the observation of LANCL1-AS1 loss of expression in NSCLC tissue and cell lines, we 
examined the potential functional significance of this alteration in the tumour phenotype and 
drug resistance. Currently, the relationship between LANCL1-AS1 and LANCL1 (coding) gene 
is completely unexplored, hence the decision to examine the expression and function of this 
coding (potential) counterpart gene. LANCL1, a GSH-binding protein, plays a fundamental role 
in neural development, more specifically in signalling and differentiation (Zhang et al. 2009). 
Given the previous reports showing that LANCL1 influences oxidative stress in cells (Zhong et 
al. 2012), this became one of the central points of focus in this chapter. 
LANCL1 was overexpressed in the NSCLC tissue compared to the normal lung counterpart 
tissue. While LANCL1-AS1 expression is reduced in the same tumours, no direct correlation 
was observed between the two genes, which is not necessarily surprising and can be 
attributed to the multiplicity of factors controlling the expression of the two genes in the lung 
tissue. When, however, LANCL1-AS1 was overexpressed in a very well controlled system 
(inducible expression in SK-MES-1), LANCL1 expression was increased. 
The mechanism underlining this observation is not known. lncRNAs control the abundance of 
their coding targets in a number of ways, including transcriptional control (e.g. used as 
scaffolds between transcription factors and guides to transcription complexes to the targets 
promoter) as well as controlling the half-life of the nascent mRNA, for example by sponging 
miRNAs (Table 4.1) (Fang and Fullwood 2016). Since the exonic sequence overlap of LANCL1 
and LANCL1-AS1 is zero (Figure 1.14), one can probably exclude the miRNA sponging scenario, 
leaving thus more room towards a transcriptional control hypothesis. This theory needs to be 
experimentally established in future studies. 
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Table 4.1: Function of LncRNA in transcription regulation (Fang and Fullwood 2016). 
Signal RNA Signal in response to different stimuli 
Decoy RNA 
Reduce the availability of regulating factors by using decoy binding sites, 
catalysis proteins, and subunit of long chromatin modification complex 
Scaffold RNA 
Provide the platform to structure multicomponent complexes, e.g. 
ribonucleoprotein (RNP) 
Guide RNA Drive the complex component RNP to the target gene 
Enhance RNA Signal the production from the enhancer region (chromatin interaction) 
Tethers RNA 
Take the interacting protein from the enhancer region to the target 
place 
 
LANCL1 promoter bears a CpG island, which triggered the question of a potential methylation-
dependent deregulation. Pyrosequencing analysis demonstrated, however, that LANCL1 
promoter was unmethylated in both tumour and normal lung samples, excluding this 
scenario. Two of the three reported splice splicing variants (variant 1 and variant 3) were 
detectable in both lung normal and tumour tissues, while variant 2 was not detected in any 
of the tissue or cell line samples. The absence of variant 2 on the gel means that it is either a 
variant not expressed in the lung tissue, or that it is expressed at such low levels that it could 
not be compared to the very high abundance of variant 1 transcripts in a common tube. 
Nonetheless, at this point, variant 2 was considered insignificant to follow; in fact, the general 
absence of any difference in the PCR signals from normal and tumour samples, despite the 
full appreciation that endpoint PCR is not quantitative, led us to abandon this question and 
concentrate on more interesting findings. 
In the complete absence of information regarding the role of LANCL1 in NSCLC, we decided 
to suppress LANCL1 using shRNA in a NSCLC cell line and study its phenotypic effects, such as 
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proliferation, migration, invasion, sensitivity to drugs and oxidative stress. SK-MES-1 cell line 
was chosen as the highest LANCL1 expressor among the available NSCLC cell lines in our lab. 
In order to minimise the off-target effects by the shRNA action, we selected clones from two 
different oligos, namely A6 targeting the 3’UTR and A9 targeting the coding area. It is of note 
that all the phenotypic results observed were common for the two clones, providing high 
confidence for their specificity to the knocked down gene. As a result, the LANCL1 knock down 
led to lower proliferation and migration, however without having any effect on invasion. This 
agrees with the observation of the overexpression of LANCL1 mRNA in primary NSCLC in this 
study and suggests that LANCL1 may provide a selective growth advantage in lung tumour 
cells. LANCL1-AS1 overexpression, which caused increase of LANCL1 expression, led to 
increased migration and invasion but did not affect proliferation. LANCL1 has previously been 
reported to increase cell proliferation (Zhang et al. 2009), the discrepancy of the results 
between LANCL1 and LANCL1-AS1 induced proliferation probably reflecting an independent 
role for the LANCL1-AS1 gene. 
Exposure of all six NSCLC cell lines to different H2O2 concentrations triggered an increase of 
LANCL1 mRNA expression, indicating the direct effect of oxidative stress in the transcriptional 
regulation of LANCL1 expression; this may protect lung cancer cells from the damage, as has 
been previously shown for other cell types (Zhong et al. 2012). While it is currently not clear 
how oxidative stress stimulates LANCL1 transcription, there is a report on prostate cancer 
cells indicating that this is accomplished through the inhibition of the c-Jun NH2-terminal 
kinases (JNK) pathway (Wang et al. 2018). The proximal promoter sequence (1000 nucleotides 
from transcription start site [TSS]) was subjected to transcription factor binding prediction in 
one of the available online tools: http://tfbind.hgc.jp/. The potential transcription factors 
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(TFs) with binding motifs on LANCL1 promoter. Among the predicated TFs (AP1 and p53) 
belong to the JNK pathway. Especially, JNK activity in LANCL1 knockdown prostatic cells 
showed a significant increase in the number of cell death produced by H2O2 treatment (Wang 
et al. 2018). Investigators determined JNK as a core mediator of ROS and oxidative stress 
stimulating apoptosis in several cell types. They report that ROS stimulates the initiation of 
JNK and DNA damage and increases growth arrest/senescence to apoptosis in prostate cancer 
cells. JNK regulates AP-1 and downstream apoptosis pathways, such as p53, PARP-1 
activation. Consequently, JNK pathway is an essential mediator in ROS stimulating prostate 
cancer apoptosis and is a potential therapeutic target (Wang et al. 2018). 
 Interestingly, oxidative stress did not affect LANCL1-AS1 expression at all, a point that will be 
discussed further below when looking into the opposite direction, i.e. the effect of LANCL1-
AS1 expression on the sensitivity of cells to oxidative stress. 
The overexpressed LANCL1-AS1 clones showed increased proliferation, migration and 
invasion properties, which, at first sight, seems contradictory to the finding that LANCL1-AS1 
expression is reduced in primary lung cancer and eliminated in NSCLC cell lines. Such a 
reduction could point to the hypothesis that loss of LANCL1-AS1 expression is a selective 
advantage for lung cancer cells, both in vivo and in vitro. Since the function of LANCL1-AS1 is 
virtually unknown, it is very difficult currently to create hypotheses behind this contradiction. 
One could speculate that the loss of LANCL1-AS1 expression in primary NSCLC is a passenger 
effect, i.e. it is due to alterations affecting its transcriptional regulation, however, its overall 
contribution to tumour phenotype is minor, as it is one among thousands of genetic and 
epigenetic changes occurring in NSCLC. In contrast, in a well-controlled experimental 
environment, such as an inducible expression system, its phenotypic effects may be clearer. 
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It is also important to note that we have only observed this effect in a single cell line (i.e. a 
specific genotype), therefore, a universal such effect cannot be claimed.  
On the other hand, it is of interest that LANCL1-AS1 overexpression resulted in LANCL1 
overexpression in human cancers, including NSCLC specimens examined in this study, as well 
as many NSCLC cell lines. Therefore, the effect of the antisense gene might be a result of the 
modification of the coding counterpart. This is supported by the fact that LANCL1 
downregulation in this study resulted in lower proliferation and migration. No such effect was 
seen for invasion, but this is a difference potentially attributed to the variability occurring in 
experimental system (e.g. effects produced by transfection). 
The overexpression of LANCL1-AS1, provided a rather puzzling result in relation to the 
sensitivity to oxidative stress. Overexpressing LANCL1-AS1 cells became more sensitive to 
H2O2. As noted above, however, LANCL1-AS1 overexpression leads to LANCL1 overexpression 
(Figure 4.12). While currently this cannot be clearly explained, it implies that LANCL1-AS1 may 
have LANCL1-independent functions which may outweigh the LANCL1 overexpression effect 
in relation to oxidative stress. A separate series of experiments involving more cell lines are 
needed to clarify those mechanisms, studying the effects of LANCL1-AS1 in LANCL1 knockout 
cell lines.  
After having indicated that LANCL1 plays a role in protecting lung cancer cells from oxidative 
stress, further research is required to determine how the oxidative stress produced from the 
chemotherapies can increase the resistance against them. We explored the effect of LANCL1-
AS1 and LANCL1 expression modulation on chemotherapy sensitivity. Remarkably, our result 
shows significant sensitization to gemcitabine and vinorelbine of the SK-MES-1 NSCLC cell line 
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in both overexpressed LANCL1-AS1 and both the knocked down LANCL1 clones (A6/26 and 
A9/10).  
In contrast, the same modulation of LANCL1-AS1 and LANCL1 expression triggered a 
significant increase in SK-MES-1 resistance against platinum compounds (both cisplatin and 
carboplatin). It has been determined that oxidative metabolic characteristics increased in 
platinum resistance cells as compared with in the sensitive cells in ovarian cancer (Matassa et 
al. 2016). Oxidative stress works usually to overproduce ROS and damage the function of the 
antioxidative defence (Ma et al. 2014). 
Almost all chemotherapeutic agents create some ROS through the generation of apoptosis in 
cancer cells, which explains the apoptosis generation by one of the chemotherapies through 
the release of cytochrome C from the mitochondria leaf part of ETS, resulting in the 
production of superoxide radicals. The generation of ROS during chemotherapeutic treatment 
can reduce the affinity of anticancer therapy (Debatin 2000). Platinum alkylating 
antineoplastic agents can produce a higher level of ROS compared with vinca alkaloid, which 
produces a low level of ROS (Conklin 2004). 
Moreover, chemotherapy may also induce oxidative stress in cancer cells. In other words, 
increased oxidative stress increases the production of lipid peroxidation, which creates 
multiple electrophilic aldehyde that can target many cellular molecules. The presence of 
oxidative stress leads to the reduced ability of chemotherapy to induce cell death, due to the 
ability oxidative stress can slow cell cycle progresses through checkpoint arrest (Conklin 
2004). Another way oxidative stress can affect the affinity of the chemotherapy to inhibit 
apoptosis is through stopping caspase activity or death receptor inactivation. Therefore, using 
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antioxidative agents with chemotherapy may increase drug productivity through the 
inhibition of creation aldehyde from the oxidative stress (Conklin 2004). 
Furthermore, oxidative stress reduces cell proliferation and limits the transaction from the 
G0/G1 lead to slow progressing from the S-phase lead to inhibit cell cycle passage though the 
restriction point to cause chick point arrest in the cell. Therefore, chemotherapeutic 
antineoplastic cytotoxicity will be diminished due to the chemotherapeutic agents which 
work to increase cell cycle progression through a specific phase and oxidative stress will 
reduce the cytotoxicity. Platinum does not work with the specific phases of other cell cycles; 
however, it regulates the cell rich G2 phase to recognise the damage attributed to platinum 
and induce apoptosis. Therefore, using antioxidants during chemotherapy may increase the 
affinity of the drug (Conklin 2004). 
The consequences of oxidative stress on cell proliferation are almost certainly related to 
block of critical enzymes by the aldehydes, and selective inhibition of DNA polymerases by 
4-hydroxyalkenals has been confirmed (Conklin 2004). The cyclin-dependent kinases (CDKs) 
are other likely targets of the aldehydes (Shackelford, Kaufmann, and Paules 2000). 
Part of chemotherapy induces cell apoptosis through either initial apoptosis from the 
mitochondrial by the release of cytochrome C or the activities of death receptor CD95 by 
ligate with dead receptor ligation CD95L (Debatin 2000). The apoptosis process is mediated 
by caspase, which is a protease that induce cysteine residue interactive sites and requires a 
special environment to initiate the activity. Usually, chemotherapeutics, which targets to 
upregulate death receptor signalling, activates caspase 8 or releases cytochrome C to interact 
with caspase 9 and activate the downstream caspases (3, 6, and 7) that lead to cell death 
apoptosis (Thornberry and Lazebnik 1998). 
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It was proven that ROS is a late event after the cell decides to activate the death program for 
cell death. ROS generation after apoptosis releases cytochrome C. Furthermore, an increase 
in oxidative stress leads to inhibition of caspase activity, which in turn reduces the efficiency 
of other chemotherapeutics to induce apoptosis (Conklin 2004). 
Therefore, oxidative stress may reduce the affinity of agents, inducing apoptosis and 
generating aldehyde to block the caspase activity. The other way oxidative stress reduces the 
agent’s efficiency is by generating lipid peroxidase that targets the death receptor CD95 
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Figure 4.30: A proposed model for the oxidative stress-mediated activation of survival 
pathways in low versus high LANCL1 express in NSCLC treated with platinum, based on 
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LANCL1 can be used as a good marker for NSCLC progression under the platinum therapy, due 
to the fact that low LANCL1 mRNA expression can be used as a marker for poor NSCLC 
progression. LANCL1 expression regulator the defence against oxidative stress. Therefore, 
NSCLC patients who have low LANCL1 expression and are treated with platinum, may show 
increase in oxidative stress levels, which may affect chemosensitivity. As mentioned 
previously, decreased LANCL1 mRNA expression lead to reduced cell defence against 
oxidative stress which is elevated under platinum therapy. Therefore, using antioxidants 
during chemotherapy will increase the affinity of the drug (Conklin 2004; Zhen et al. 1992). 
Most likely, deregulated epigenetic control of lung tumours depend on what is shown before 
overexpressing of LANCL1 in lung tumours and NSCLC cell lines, that led us to investigate more 
whether LANCL1 expression is under epigenetic control. We previously investigate the 
methylation state of LANCL1, and we determined that lack of DNA methylation in the 
promoter of the gene in NSCLCs (Figure 4.9). Consequently, it was obvious to examine another 
major epigenetic factor, which is histone deacetylation.  
Our investigation showed the sodium valproate treatment of all, but one NSCLC cell line 
tested resulted in an increase in LANCL1 expression compared to the untreated cells (Figure 
4.29). Sodium valproate (VPA) is a histone deacetylace inhibitor (HDACi) and can therefore 
activate the expression of a large number of genes, subsequently altering various phenotypic 
characteristics, such as cell proliferation or apoptosis (Figure 1.8) (Bose, Dai, and Grant 2014). 
At this moment, it is not clear whether VPA has a direct effect on the LANCL1 promoter (i.e. 
whether this promoter is subject to histone deacetylation) or it is a secondary effect, i.e. as a 
result of other overexpressed proteins, following HDAC inhibition, binding LANCL1 promoter.   
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4.4 Conclusion 
To sum up, the results found that LANCL1-AS1 diminished in both lung cancer tissues and 
NSCLC cell lines, therefore we discovered that LANCL1 is highly expressed in lung cancer 
tissues and NSCLC cell lines. However, there was no correlation between LANCL1-AS1 and 
LANCL1. Also, lack of DNA methylation in the promoter of the gene in NSCLCs. We determined 
that LANCL1 expression increases in NSCLC cell lines after exposure to H2O2, which means 
LANCL1 may play a role in protecting NSCLC cell lines from oxidative stress. 
Furthermore, overexpressed LANCL1-AS1 increased cell proliferation, migration and invasion, 
while knocked down LANCL1 reduced in cell proliferation and migration. Following, we found 
that both overexpressed LANCL1-AS1 and knocked down LANCL1 clones increase the NSCLC 
sensitivity from the H2O2. Also, both clones had sensitized SK-MES-1 NSCLC cell line for 
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Chapter 5: Exosomes’ Role in Drug Resistance  
 
5.1 Introduction 
We have previously seen in chapter 4, that modulation of LANCL1-AS1 expression affected 
the response of NSCLC cells to gemcitabine and VRL (figures 4.17, 4.18). Given the bystander 
effect that exosomes can induce (Samuel et al. 2017), we therefore decided to assess this in 
relation to LANCL1-AS1 expression and test whether the observed LANCL1-AS1-dependent 
sensitivity modification can be transferred through exosomes. 
It is now well established that EVs function as cargo transporters between cells, carrying 
multiple components and facilitating cell-cell communication. The list of protein and nucleic 
acid cargo of EVs is constantly growing in the literature. Interestingly, LANCL1 was identified 
as one of the cargo proteins in extracellular vesicles (ExoCarta 2016). While this observation 
does not necessitate a role for LANCL1 in EV biogenesis, it was certainly an intriguing research 
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Therefore, we set up a series of experiments to provide answers for the following questions. 
a) Do LANCL1 and LANCL1-AS1 expression levels determine the number of EVs released 
from cells? 
b) Oxidative stress is known to trigger EVs release; do LANCL1 and LANCL1-AS1 
interfere in this process? 
c)  LANCL1 knock-down and LANCL1-AS1 overexpression increase the sensitivity to 
gemcitabine; is this effect associated with an alteration in EV biogenesis? 
d) Can LANCL1-AS1 induced sensitivity to gemcitabine be transferred through 
conditioned media and/or EV transfer to cells with low LANCL1-AS1 expression?  
 
 
249       
 
5.2 Results 
5.2.1 Pilot test to select EVs Harvesting time. 
At first, we assessed the effect of LANCL1 and LANCL1-AS1 expression on EVs release. A 
preliminary experiment was performed to establish the time of culture required to gain an 
EVs count high enough to be measurable by Nanosight (Malvern). As described in the 
methods section, once the medium had been harvested for EVs quantification, the total 
cellullar protein was measured (BCA assay), in order to obtain an accurate estimate of the 
number of cells producing the EVs. In all analyses presented below, we have utilised a 
Normalised EVs Count, conducted using Nanosight, divided by the protein concentration of 
the producing cells. As can be seen in Figure 5.1, there is an increasing number EVs count in 
relation to time of culture, as expected. However, differences were observed in this pilot 
regarding the EVs count per time slot in relation to LANCL1, increase in EV count is only 
observed at 12 and 24 h. In fact, a difference is observed in the knockdown clones (A6/26 and 
A9/10), however a similar reduction was observed in the scrambled, therefore it can by 
hypothesised that this difference is related to transfection stress rather than the LANCL1 
expression. Indeed, an independent experiment (Figure 5.2) at 9 hours harvesting confirmed 
this lack of difference; more specifically, only one of the two clones (A6/26) showed a 
borderline reduction compared to scrambled, thus there is no strong evidence to support the 
involvement of LANCL1 in the EV biogenesis. 
In contrast, LANCL1-AS1 overexpression in the pilot experiment (Figure 5.1) seemed to exert 
a certain positive effect on the EVs count. This was also confirmed by an independent 
experiment at 9h harvesting (Figure 5.3). As LANCL1-AS1 expression in this inducible model is 
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manipulated by coumermycin/novobiocin, the parental SK-MES-1 cells were also exposed to 
these reagents, demonstrating no differences in the normalised EVs count (Figure 5.4). The 
reason for choosing harvesting at 9 hours is that the aim of the experiment is to assess the 
potential effect of exosomes representing cells early reaction to drug exposure rather than 
the exosomes representing just the surviving fraction after prolonged exposure. At the same 
time, we wanted to have a count high enough to measure on the Nanosight, and the 9-hour 
slot combines these two characteristics. 
 
Figure 5.1: The bar charts represent the variable values of exosomes released from parental, 
scramble and clones’ cells in different incubation period. The mean and error values in all 








Figure 5.2: Boxplots displaying the number of the EVs released by parental, scrambled 
and knocked down LANCL1 clones, nine hours post seeding. No significant statistical 
difference is observed, with the exception of a borderline trend between scrambled 
and A6/26. In the absence of reproducing such a difference with the second shRNA 
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Figure 5.3: The EV release is affected by LANCL1-AS1 expression in a dose-dependent 
manner. There is an apparent increase of released EVs (normalised by total protein of 
producing cells) corresponding to the expression of LANCL1 -AS1 in LS3 cells exposed to 
novobiocin (LS3N), controls LS3 cells and LS3 cells exposed to coumermycin (LS3C). 
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5.2.2 EVs release under oxidative stress on cells containing 
knocked-down LANCL1 
Having assessed the EVs count changes in relation to LANCL1 and LANCL1-AS1 expression 
under normal conditions, we performed a series of experiments to study the release of 
exosomes under oxidative stress. We therefore exposed parental cells, scramble and clones 
to H2O2 for nine hours. The results revealed a significant increase in the amount of EVs 
release under oxidative stress in both clones A6/26 and A9/10, as well as the parental and the 
scrambled cell lines (Mann-Whitney test, p=0.014, p=0.019, p=0.021 and p=0.02 respectively) 
(Figure 5.5). As in the case of normal conditions, LANCL1 expression did not affect the EVs 














Figure 5.5: Boxplots demonstrating the number of EVs released after treatment of the 
parental, scrambled and the LANCL1 knock-down clones with 25 µM of H2O2 for nine 
hours. The number of EVs released increases significantly in all the cell lines under 
oxidative stress. The parental, scramble and LANCL1 knock-down clones behave similarly 
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5.2.3 EV Release under Oxidative Stress on overexpressed LANCL1-
AS1 
The same procedure was followed in this experiment for incubation of the overexpressed 
LANCL1-AS1 clones for nine hours with 25 µM of H2O2, to assess the effects of oxidative 
stress. Interestingly, the LS3N clone (low LANCL1-AS1 expression) demonstrated a significant 
increase under the oxidative stress (Mann Whitney test, p=0.004). However, this difference 


















Figure 5.6: Boxplots representing the number of EVs released in overexpressed LANCL1-
AS1 after treatment with 25 µM of H2O2 for nine hours. The number of the EVs released 
increases significantly in the parental and the lower expression of LANCL1-AS1 (LS3N) 
clone under oxidative stress, while it doesn’t change in high expression of LANCL1-AS1 
(LS3C) clone under the oxidative stress. 
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5.2.4 Rate of Releasing Extracellular vesicles under Gemcitabine 
treatment on cells containing knocked-down LANCL1 
The LANCL1 knocked-down clones treated with 0.06 µM of gemcitabine and incubated for 
nine hours. The result showed a slight increase in the rate of releasing EVs from the knocked-
down LANCL1 clones A6/26 and A9/10 after treatment with gemcitabine compared with the 
unexposed cells, while the SK-MES-1 parent cell line shows no difference in the number of 

















Figure 5.7: Boxplots displaying the number of EVs released after parental, scramble and 
knocked-down LANCL1 expression clone’s treatment with 0.06 µM gemcitabine for nine 
hours. The number of EVs released does not change significantly in all the cell lines under 
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5.2.5 Rate of Releasing Extracellular vesicles under Gemcitabine 
treatment on overexpressed LANCL1-AS1 clone 
The LANCL1-AS1 overexpression clones were treated with 0.06 µM of gemcitabine and 
incubate for nine hours. The result revealed that overexpression of LANLC1-AS1 clones (LS3C) 
showed a slight decrease in the number of EVs released after treatment, with gemcitabine 
comparison with unexposed counterpart, while there was no significant change in the 
number of EVs released from (LS3N) lower expression of LANCL1-AS1. Mann Whitney test, 
















Figure 5.8: Boxplots demonstrating the number of EVs released after treatment with 0.06 
µM gemcitabine incubate for nine hours in overexpressed LANCL1-AS1 clone. The number 
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5.2.6 Exchange of conditioned medium between clones with 
different LANCL1-AS1 expression. 
As mentioned in Chapter 4 (section 4.2.7.1), the rate of cell growth increased in high 
expressed LANCL1-AS1 clone LS3C in comparison with the low expressed LANCL1-AS1 LS3N 
(Figure 4.13). Having seen the effect of LANCL1-AS1 in EV release, we decided to examine 
whether exchanging of serum free (SF) conditioned media between high and low LANCL1-AS1 
expressing cells might have an effect on proliferation (Figure 5.9). The results showed that, in 
comparison to control (LS3 supplemented with fresh SF medium and novobiocin), the 
addition of medium conditioned in LS3 cells with novobiocin (autologous, low LANCL1-AS1 
expression) triggered a reduction in proliferation (Figure 5.9). This most likely represents the 
exhaustion of the growth factor cocktail (see materials and methods) used to supplement the 
SF medium, as all these are quite liable and they have been at 37oC for the 48h of 
conditioning. However, the addition in the LS3 cells of the medium conditioned in LS3-
coumermycin cells (heterologous – high LANCL1 expression) triggered a massive reduction in 
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Figure 5.9: The effect of conditioned media exchanging between cells with different 
LANCL1-AS1 expression. LS3 cells were grown in serum free medium containing 
novobiocin (control – green bar). When confluence reached 40%, the medium was 
replaced by serum free media conditioned for 48h in LS3 cells grown in novobiocin 
(autologous – blue bar) or coumermycin (heterologous – purple bar). Cells were grown 
in pre-conditioned media for 48 hours before the MTT assay. The reduction in 
replication shown in the autologous medium replacement most probably reflects the 
partial exhaustion of medium resources as the growth factors in SF-media are being 
degraded (control receives fresh SF medium with supplements for the corresponding 
48h incubation). In contrast, the heterologous replacement with media from cells with 
high LANCL1-AS1 expression, causes a significant reduction on the target cells (with low 
expression of LANCL1 -AS1). The mean and error values in all graphs represent six 
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Moreover, we tested whether exchanging of serum free (SF) conditioned media might affect 
the action of gemcitabine (0.06 µM) between high (coumermycin) and low (novobiocin) 
LANCL1-AS1 expressing cells. The results showed that the proliferation inhibition caused by 
media conditioned in LS3 cells with novobiocin (Mann Whitney test, P=0.043) or 
coumermycin (Mann Whitney test, P=0.053) cause a reduction of the relative toxicity of 



















Figure 5.10: Exchange the unconditional medium added to 0.06 µM of gemcitabine to 
overexpressed LANCL1-AS1 clone. A significant reduction in cell replication was shown in 
the parental after being treated with gemcitabine. Borderline reduction was shown in 
autologous medium replacement from cells with low LANCL1-AS1 expression 
(novobiocin) with GM, and heterologous medium replacement from cells with high 
LANCL1-AS1 expression (coumermycin) with gemcitabine. The mean and error values in 




266       
 
5.2.7 Exchange EVs from Sensitive to Resistance Cell Line  
The conditioned media contain both soluble growth factors and small EVs, as the large EVs 
have been removed during filtration through 0.22 µm filter. We therefore extended our 
experiments to investigate the effects of supplementing only EVs from LS3 cells with high 
(coumermycin) and low (novobiocin) LANCL1-AS1 expression. EVs’ input was normalized by 
protein quantification prior to supplementation as the Nanosight measurement accuracy is 
not high enough to support this experiment. In contrast to the conditioned media experiment 
(Figure 5.13), the supplementation of EVs does not demonstrate any significant difference 














Figure 5.11: The effect of autologous and heterologous EV supplementation comparing 
cell sources with high and low LANCL1-AS1 expression. LS3 cells were grown in serum 
free medium containing novomycin (control – blue bar). Once confluence had reached 
40%, the medium was replaced by serum-free media supplemented with EVs from LS3 
cells grown in novomycin (autologous – green bar) or coumermycin (heterologous – 
purple bar). Cells were grown for further 48 hours prior to the MTT assay. The reduction 
in replication shown in the autologous medium most probably reflects the toxicity from 
the EVs elution buffer, indicating that longer dialysis in PBS should have been 
performed prior to supplementation. The heterologous supplementation does not 
confer a different effect in proliferation. The mean and error values in all graphs 
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5.2.8 Exchange of Exosomes from Sensitive Cell Line to Resistance 
Cell Line Treated with Gemcitabine 
In this experiment, we aimed to determine the effects of gemcitabine 0.06 µM added only to 
EVs from LS3 cells with high (coumermycin) and low (novobiocin) LANCL1-AS1 expression, EVs 
input was normalized by protein quantification. Similar to the conditioned media experiment 
with gemcitabine (Figure 5.10), the supplementation of EVs with of gemcitabine does not 
demonstrate a significant difference between high and low LANCL1-AS1 expression of the 

















Figure 5.12: The exosomes were exchanged with 0.06 µM of gemcitabine in 
overexpressed LANCL1-AS1 clone. A significant reduction in cell replication was shown 
in the parental after being treated with GM. Also, a significant reduction was shown in 
autologous (novobiocin) and heterologous (coumermycin) EVs supplements with 
gemcitabine. The mean and error values in all graphs represent six technical replicates, 
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5.3 Discussion  
Extracellular vesicles (EVs) play an essential role in cell communication as well as the 
pathogenesis of many diseases including cancer (Riches et al. 2014). It has been determined 
that EVs release is frequently higher in cancer cells. Furthermore, elevated EV release may 
influence chemotherapy resistance and even mediate the transfer of resistance information 
between cells (Sweeney, Richards, and Hill 2017). In view of this study’s results, namely that 
LANCL1 and LANCL1-AS1 expression changes can influence the resistance to gemcitabine and 
VRL, we have investigated the hypothesis that EVs may mediate this action. First, we 
examined the role of LANCL1 and LANCL1-AS1 expression in the rate of EVs release. In 
addition, the effect of oxidative stress and chemotherapy with regard to the number of EVs 
discharge was explored. Finally, we designed an experiment to investigate whether 
exchanging EVs between cells with different LANCL1-AS1 expression and consequent 
sensitivity to gemcitabine demonstrate a bystander effect; in other words, LS3 grown in 
coumermycin overexpresses LANCL1-AS1 and is more sensitive while LS3 grown in novobiocin 
has a low LANCL1-AS1 expression and is less sensitive to gemcitabine. 
Our results showed no major difference in the number of EVs released by the knockeddown 
LANCL1 clones compared to the scrambled and parental cell line SK-MES-1. Only a borderline 
effect was seen in one of the two clones. LANCL1 protein has been identified as a frequent 
cargo of human exosomes from different tissues (including lung and kidney) and cell lines 
(ExoCarta 2016). This fact, of course, does not necessitate the dependence of exosome 
biogenesis to LANCL1. Currently, there is no published information regarding the role of 
LANCL1 in EV regulation, therefore we are conscious that our result comes from a single cell 
line, i.e. a single genotype. As a result, LANCL1 may contain certain effectors in its EV-related 
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function that are missing from SK-MES-1. The cell line’s karyotype reveals that normal X, 13, 
and 19 chromosomes were absent and chromosomes 2, 3, 14, 17 and 20 were generally 
monosomic (ATCC 2019). Therefore, this question ought to be expanded in many other cell 
lines before a clearly shaped conclusion can be reached. 
In contrast, to the non-significant EV changes seen in LANCL1 knockdown, the difference in 
expression of LANCL1-AS1 in the inducible LS3 clone triggered a substantial corresponding 
difference in EV release. More specifically, it is worth mentioning that EV count shows a dose 
response effect to LANCL1-AS1 expression (Figure 5.3). While high LANCL1-AS1 expression 
results in high LANCL1 expression in LS3 cells, the absent or moderate effect of the latter on 
the EV count suggests that the EV effect of LANCL1-AS1 is probably a LANCL1-independent 
function. 
The next question posed in this study was whether LANCL1/LANCL1-AS1 expression 
influences the EV release under the conditions of oxidative stress. According to (Szypowska 
et al. 2011), the defence to oxidative stress depends on reprogramming the transcriptional 
profile of the cell. In addition, it has been suggested that exosomes may mediate protective 
signals in response to oxidative stress, based on the argument that exosomes released from 
cells exposed to oxidative stress can transfer protection from oxidative stress to recipient 
cells, which were not exposed to the stress (Eldh et al. 2010). The alteration in exosomes 
phosphoprotein content under oxidative stress has emphasised the role played by exosomes 
in mediating cell–cell signalling during physiopathological events.(Biasutto et al. 2013). It has 
also been demonstrated that oxidative stress can enhance EVs secretion, while soluble 
NKG2D ligands stimulate the impairment of the cytotoxic response (Hedlund et al. 2011). 
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In agreement with all the relevant literature so far, including SK-MES cells (Saeed-Zidane et 
al. 2017), our result shows that under oxidative stress, EVs release increased significantly in 
all of the tested cell lines. LANCL1 has a well-established role in protecting cells, particularly 
neurons, from oxidative stress (Zhong et al. 2012) and this was also confirmed in our cells in 
chapter 4 (Figure 4.25). However, LANCL1 knockdown did not have an effect on the EV count 
released under oxidative stress, thus suggesting that this function is probably not 
accomplished through changing the released EV count. 
Moreover, LANCL1-AS1 overexpression results in a significantly higher EV count under normal 
conditions, while high LANCL1-AS1 expression has only a moderate effect under oxidative 
stress (Figure 5.5). At this moment, it is difficult to assess the significance of this observation, 
especially as LANCL1-AS1 function is largely not known, therefore the need for further 
research. One hypothesis may be that overexpressing LANCL1-AS1 cells approach the EV 
production capacity of these cells under normal conditions, therefore the EV release reaches 
a plateau, a hypothesis which, of course, requires experimental verification. 
It has been previously shown that cells release more EVs when exposed to chemotherapeutics 
(Sweeney, Richards, and Hill 2017). In this study, we tested the effect of gemcitabine on EV 
count, given the fact that both LANCL1 knock-down and LANCL1-AS1 changed the response 
of cells to this drug. However, the findings presented in this chapter show no significant 
change in the EV count of any of the cell lines/clones treated with gemcitabine; in fact, only 
limited information on gemcitabine’s influence on EV release is provided within specialised 
literature, such as a few studies showing that gemcitabine exposure increases EV release in 
pancreatic cancer cells (Sweeney, Richards, and Hill 2017)  and cancer-associated fibroblasts 
(CAF) (Richards et al. 2017), with no relevant results on any other cancer cell type. 
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Despite the lack of quantitative changes in the EV count by gemcitabine, the question whether 
qualitative changes in EV cargo might be influenced by the drug and to what extent this might 
be communicated to other cells arose. Even if this question occurred at a late stage of this 
PhD study, with limited time and resources to explore the cargo profile, it was possible to 
assess the ability of EV-mediated phenotypic alterations in recipient cells induced by EVs with 
different LANCL1-AS1 levels. As LANCL1-AS1 affected proliferation (Figure 4.13), we tested 
the hypothesis that this effect might be transferred through EVs. The first pilot set of 
experiments was to test medium conditioned in LS3 cells grown in novobiocin (low LANCL1-
AS1) and coumermycin (high LANCL-AS1). The recipient cells were LS3 cells grown in 
novobiocin, therefore the transfer of EVs from cells with novobiocin (LS3N) is considered 
autologous, while the transfer from cells grown in coumermycin (LS3C) as heterologous. 
Interestingly, the heterologous transfer caused a significant reduction in proliferation, greatly 
differing from the observed autologous one. The reduction seen in the autologous media 
transfer is most likely due to the weakening of the labile growth factor supplements during 
the 48 hours of conditioning (Figure 5.8). 
However, the subsequent experiment using isolated EV supplementation did not confirm this 
finding (Figure 5.10), for which there are a number of possible explanations for this, both 
technical and biological. First, from a technical point of view, the observed reduction in the 
autologous supplementation (Figure 5.10) can only be explained as toxicity by the EV elution 
buffer, as cells were supplemented with fresh growth factors in this experiment. Indeed, we 
are aware that the elution buffer (XE buffer, Qiagen) is highly toxic to the cells from early pilot 
experiments. Therefore, for this experiment, EVs eluates were dialysed twice against 1 L of 
PBS for 30 min each. However, it became apparent that this is not enough to remove all the 
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XE buffer, therefore leaving residual toxins. As these were the last set of experiments in this 
PhD study, unfortunately there was no time to repeat the experiments with altered 
conditions. 
Another technical reason is that EVs isolated with the ExoEasy kit tend to aggregate in larger 
complexes, which may significantly reduce the absorption of EVs in recipient cells, a result 
based on Nanosight readings, communicated by Dr Amelia Acha Sagredo. However, from a 
biological point of view, looking at the result of the conditioned medium exchange, there is a 
significant negative effect on proliferation exerted by medium conditioned in high LANCL1-
AS1 expressing cells. Apart the technical difficulty discussed above, the lack of reproduction 
of this effect in EVs suggests that the effect may be due to soluble factors and/or >220nm EVs 
released by LS3C cells. It must be reminded that EV isolation includes an initial filtration 
through 0.22 µm filters. 
The final experiments in this chapter addressed the question of LANCL1-AS1 expression, 
which changes the sensitivity of cells to gemcitabine, to influence the EV-mediated 
phenotypic response of cells to this drug. Our experiment, which used either filtered 
conditioned media or isolated EVs, demonstrated only borderline changes. Therefore, the 
potential technical difficulties explained above are deemed to hinder the ability to draw clear 
conclusions. One can speculate though that the reduction in proliferation induced EV 
supplementation from LANCL1-AS1 overexpressing cells might be a reason for the moderated 




275       
 
5.4 Conclusion  
To summarize, our experimental evidence demonstrates that that LANCL1 expression does 
not affect the rate of EVs released. In contrast, LANCL1-AS1 expression appears to stimulate 
EV release. Moreover, our results are concordant with the literature showing increased EVs 
release under oxidative stress. Finally, exposure to gemcitabine had no significant result on 
the rate of EVs released. 
Furthermore, exchanging filtered conditioned media between low expression LANCL1-AS1 
(LS3N) and high expression LANCL1-AS1 (LS3C) showed a significant reduction in cell 
proliferation. However, this effect was not reproduced by isolated EVs exchange. It is 
appreciated that the technical difficulties we recognised may have interfered with this result, 
thus further investigation is required to provide a definite answer on this aspect.   
 
 
276       
 
Chapter 6: Summary of conclusions and future 
prospects 
 
Lung cancer is responsible for the highest malignancy-related mortality rate worldwide and 
the resistance to classical chemotherapeutics and targeted therapies being one of the main 
factors for its very high death rate. While numerous studies so far have attempted to identify 
the determinants of resistance, our knowledge is still poor and confined to only a few clinical 
measures (e.g. K-Ras mutant neoplasms are excluded from TKI therapies). 
The main aim of this study was to explore various means to sensitize NSCLC cells to 
chemotherapeutics commonly used in clinical practice today. While there is promise for new 
therapies (targeted and immunotherapy), one can easily estimate that classical 
chemotherapy will continue to be perceived as the main line of therapy, especially in low-
income countries. In this respect, our starting point was the IC50 profile calculated in eight 
NSCLC cell line (A549, CALU-1, CALU-3, CO-RL23, H358, LUDLU, SK-MES-1, SK-LU-1) for the 
selected chemotherapeutic agents (cisplatin, carboplatin, gemcitabine and vinorelbine). The 
study subsequently focused on the two cells with the highest IC50 for each chemotherapeutic, 
in an effort to assess epigenetic sensitization by Valproic acid (VPA) and decitabine (DAC), as 
well as sensitization by fendiline and AMPA, which have previously been reported to 
demonstrate such a function. 
It is noteworthy to mention that VPA treatment induced a drop in the IC50 in all the four 
chemotherapeutics, suggesting that histone deacetylation inhibition increases the expression 
of essential genes in the apoptosis and proliferation pathway, thus enhancing the 
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chemotherapeutic effect. Furthermore, we observed that VPA showed an increased potential 
when used to treat the cells prior to the chemotherapeutic addition. 3/7 caspase activity 
exhibited a significant increase when NSCLC cell lines were exposed to platinum (cisplatin and 
carboplatin) with epigenetic drug, either pre-treated or synchronous, suggesting that the 
increased apoptotic capacity is a significant mediator of this sensitization. 
The results of this activity of VPA in lung cancer cells is novel; keeping in mind that VPA is 
reported to be a safe and well-established drug, its clinical application can be achieved in an 
easier manner through appropriate clinical trials. Another new finding in this study was the 
DNA damage caused by gemcitabine, as reported by the comet assays. Interestingly, the co-
treatment with VPA further induced DNA damaging, therefore providing evidence for further 
exploitation of this result in preclinical and clinical models. 
Recent improvements in sequencing technology have led to a more consistent exploration of 
the transcriptional map of the entire human genome, showing that 70 to 90% of the 
mammalian genes are transcribed (Fang and Fullwood 2016; Lu et al. 2013; Sun et al. 2014). 
Around 2% of the transcribed genome encode proteins; while most transcribed genes 
produce noncoding RNA (Villegas and Zaphiropoulos 2015).  
Long non-coding RNAs (lncRNAs) compose a class of particular interest due to their 
multiplicity of functions in many aspects of normal physiology. It is, therefore, not surprising 
that their deregulation is involved in many human cancers, including glioblastoma, leukaemia, 
breast, colon, liver, prostatic, and bladder. LncRNAs can serve as proto-oncogenes or tumour 
suppressors (Lu et al. 2013). While research into the function of lncRNAs is increasing 
exponentially, we only understand the functions of a small minority of the lncRNA 
transcriptome, which contain over 9,000 genes (Fang and Fullwood 2016). 
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The lung cancer research group at the University of Liverpool has recently evaluated LncRNA 
deregulation in non-small-cell lung cancer (NSCLC) to support the existing data, determining 
that the 14 LncRNA profile remarkably discriminated NSCLC tissue from normal lung tissue. 
One of them, LANCL1-AS1, which is absent in NSCLC (Figure 1.10), is a lncRNA classified in the 
antisense RNA subgroup, as it is transcribed from the opposite strand of a coding gene, in this 
case, LANCL1. Apart from being significantly decreased in NSCLC tissue, LANCL1-AS1 was 
found to be completely absent in all the NSCLC cell lines studied by the research group (Acha-
Sagredo et al. 2020) This suggested a potential inhibitory role in tumour development, 
although we can never exclude the possibility of this being a passenger alteration. 
Following these observations, the overarching hypothesis of this PhD study was that LANCL1 
and LANCL1-AS1 might contribute to a cancer phenotype. Having no publications available for 
LANCL1-AS1 and only a small number for LANCL1, we had a very large number of research 
questions to answer, starting from whether LANCL1-AS1 could regulate LANCL1 transcription 
and vice versa. Furthermore, knowing that LANCL1 protects the neurons against oxidative 
stress, we wondered whether this characteristic suggests a role for the gene in chemotherapy 
resistance (Zhang et al. 2009). 
LANCL1 and LANCL1-AS1 expression alteration increase the cell NSCLC sensitivity to oxidative 
stress and also increased the sensitivity of gemcitabine and vinorelbine, while reducing the 
sensitivity to platinum, which is known to be dependent on the oxidative stress levels. 
The changes in chemosensitivity induced by LANCL1 and LANCL1-AS1 expression, led us to ask 
one more question: whether there are any changes in the extracellular vesicles (EVs) that may 
be mediating this effect. EVs are known to facilitate cell communication and induce 
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chemotherapy-related bystander effects and it’s been shown that releasing of EVs increase in 
the cancer cell and that can transfer drug resistance from one cell to another. 
We have found, that LANCL1 expression does not present any significant change in the 
number of EVs released. In contrast, LANCL1-AS1 expression affects, in a dose-dependent 
manner, the release of EVs. However, there was no conclusive evidence from exchanging EVs 
between different expressing LANCL1-AS1 cells (i.e. sensitive and resistant to GM) due to 
technical issues. These have now been recognised and will certainly serve as the basis for the 
next research project in the lab. 
Future work regarding increased chemosensitivity with valproic acid can be continued from 
different angles. The drug sensitivity results can be confirmed by proceeding to a preclinical 
test to examine the efficiency of the combined drugs in animals. 
As already known, valproic acid has been used for a decade to treat epilepsy patients. 
Therefore, by looking at the record of overall survival rate of NSCLC patients who have 
epilepsy and were treated with valproic acid and chemotherapeutics and comparing them 
with the overall survival rate of NSCLC who were treated with chemotherapeutics only, we 
can gain useful information. 
Overall, I believe that the present study was successful in adding new evidence to the 
existing preclinical information relevant to lung cancer treatment and provided leads for 
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Chapter 8: Appendix 
Table 8.1 Human lung tissue samples to specify in detail LANCL1 and LANCL1-AS1 in NSCLC. 
PD_MPI Meth 
Data 
Microarray HistNo SampleID Histology 
MD 







91505 0 0   91505 SqCC 1     2 0 M 0 03/06/1937 17/05/2011 74.0 
 
22/05/2011 2 0.2 0.92 0.00 0.09 
20807 1 0 L269 269 AdenoCa 0 1 1 2 2 M 0 02/09/1930 27/11/1997 67.2 
 
04/12/1997 1 0.2 1.13 0.12 0.41 
20709 0 0 L208 208 AdenoCa 0 3 5 1 0 M 0 21/09/1922 12/06/1997 74.7 
 
22/06/1997 1 0.3 1.45 0.20 0.74 
20732 0 0 L215 215 SqCC 1 1 1 2 0 M 0 12/11/1920 26/06/1997 76.6 
 
14/07/1997 1 0.6 0.75 0.00 0.91 
20640 1 0 L183 183 AdenoCa 0     3 0 M 0 29/03/1942 19/02/1997 54.9 
 
06/04/1997 1 1.5 0.89 0.00 0.51 
20785 0 0 L252 252 AdenoCa 0 1 1 4 2 M 0 22/05/1929 21/10/1997 68.4 
 
10/12/1997 1 1.7 0.94 0.00 0.45 
20638 1 0 L181 181 NSCLC   1 1 3 1 M 0 12/04/1923 17/02/1997 73.9 
 
23/04/1997 1 2.2 0.60 0.00 1.12 
20628 0 1 L175 175 AdenoCa 0 1 1 2 0 M 0 21/01/1926 30/01/1997 71.0 
 
07/04/1997 1 2.2 0.64 0.00 0.50 
78749 0 0   78749 SqCC 1     2 1 F 1 11/09/1931 18/09/2008 77.0 11/12/2008   0 2.8 2.04 0.00 0.66 
20753 1 1 L236 236 AdenoCa 0 2 3 3 1 M 0 20/05/1930 18/08/1997 67.2 
 
18/11/1997 1 3.1 1.01 0.00 0.63 
20624 1 1 L171 171 SqCC 1 1 1 2 0 M 0 10/04/1929 23/01/1997 67.8 
 
13/05/1997 1 3.7 0.75 0.00 0.59 
20773 1 1 L240 240 SqCC 1 1 1 3 2 F 1 07/02/1932 15/09/1997 65.6 
 
23/01/1998 1 4.3 1.28 0.00 0.86 
20735 0 1 L218 218 AdenoCa 0 2 3 2 0 F 1 15/03/1942 07/07/1997 55.3 
 
18/11/1997 1 4.5 0.60 0.00 1.14 
20580 0 0 L154 154 SqCC 1 1.5 2 2 2 M 0 11/06/1924 11/11/1996 72.4 
 
09/05/1997 1 6.0 1.52 0.00 0.59 
20733 1 0 L216 216 AdenoCa 0 1 1 2 0 M 0 18/12/1909 26/06/1997 87.5 
 
23/12/1997 1 6.0 1.16 0.14 1.10 
21021 1 0 L288 288 AdenoCa 0 2 3 2 1 F 1 25/05/1950 16/02/1998 47.7 
 
22/09/1998 1 7.3 1.19 0.00 1.34 
20631 1 0 L178 178 AdenoCa 0 1 1 2 1 F 1 16/11/1927 10/02/1997 69.2 
 
17/09/1997 1 7.3 0.82 0.00 0.94 
20434 1 0 L127 127 SqCC 1 2 3 2 2 M 0 06/09/1924 22/07/1996 71.9 
 
07/03/1997 1 7.6 0.90 0.00 0.99 
20682 0 1 L198 198 AdenoCa 0 1 1 4 0 M 0 15/05/1946 28/04/1997 51.0 
 
20/03/1998 1 10.9 1.66 0.12 0.72 
20565 1 1 L146 146 SqCC 1 2 3 2 0 M 0 04/04/1917 16/10/1996 79.5 
 
12/09/1997 1 11.0 1.76 0.08 1.10 
21023 1 1 L289 289 AdenoCa 0 3 5 2 2 M 0 18/07/1939 16/02/1998 58.6 
 
01/02/1999 1 11.7 0.71 0.02 0.46 
20702 1 0 L201 201 SqCC 1 2 3 2 2 M 0 28/09/1921 08/05/1997 75.7 
 
19/05/1998 1 12.5 0.40 0.00 1.50 
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20681 1 1 L197 197 SqCC 1 2 3 2 2 M 0 09/10/1924 28/04/1997 72.6 
 
23/05/1998 1 13.0 1.49 0.00 0.51 
20644 0 0 L186 186 AdenoCa 0 3 5 2 1 M 0 19/07/1937 24/02/1997 59.6 
 
11/04/1998 1 13.7 1.27 0.14 0.64 
20771 1 1 L238 238 SqCC 1 2 3 3 2 M 0 12/09/1934 15/09/1997 63.0 
 
06/11/1998 1 13.9 0.90 0.25 0.82 
20632 1 0 L179 179 SqCC 1 2 3 3 2 M 0 14/05/1940 10/02/1997 56.7 
 
08/05/1998 1 15.1 0.82 0.05 0.52 
20734 1 0 L217 217 AdenoCa 0 2 3 2 2 F 1 13/08/1940 30/06/1997 56.9 
 
03/10/1998 1 15.3 1.71 0.06 1.32 
91559 0 0   91559 SqCC 1 1 1 2 0 M 0 31/08/1931 17/08/2011 80.0 20/12/2012 
 
0 16.4 0.08 0.00 0.44 
20641 1 0 L184 184 SqCC 1 2 3 2 0 M 0 14/02/1935 20/02/1997 62.0 
 
17/08/1998 1 18.1 0.39 0.04 0.71 
20599 0 1 L157 157 AdenoCa 0 2 3 2 1 M 0 26/01/1927 18/11/1996 69.8 
 
26/05/1998 1 18.5 0.49 0.00 1.06 
20566 0 0 L147 147 SqCC 1 3 5 2 1 M 0 13/05/1928 17/10/1996 68.4 
 
01/05/1998 1 18.7 2.73 0.00 1.16 
74 0 0 L260 260 SqCC 1 1.5 2 2 0 M 0 06/02/1939 11/11/1997 58.8 
 
17/06/1999 1 19.4 0.99 0.00 0.45 
20438 0 1 L129 129 SqCC 1 1 1 2 1 M 0 20/10/1922 25/07/1996 73.8 
 
17/03/1998 1 20.0 1.04 0.00 0.72 
20683 0 1 L199 199 AdenoCa 0 1.5 2 2 1 M 0 07/10/1916 28/04/1997 80.6 
 
27/12/1998 1 20.3 0.64 0.00 0.24 
20571 1 0 L152 152 SqCC 1 2.5 4 2 1 M 0 25/10/1940 29/10/1996 56.0 
 
03/01/1999 1 26.5 1.00 0.05 0.80 
79606 0 0   79606 SqCC  1     1 1 M 0 14/01/1943 12/10/2010 67.7 20/12/2012   0 26.7 0.69 0.05 1.18 
20639 1 1 L182 182 SqCC 1 2 3 3 0 M 0 21/03/1947 17/02/1997 49.9 
 
02/06/1999 1 27.8 1.70 0.03 0.91 
20787 1 0 L254 254 AdenoCa 0 2 3 2 0 M 0 16/01/1924 27/10/1997 73.8 
 
19/02/2000 1 28.2 1.45 0.10 
 
20705 1 1 L204 204 SqCC 1 2 3 2 1 M 0 15/07/1937 15/05/1997 59.8 
 
14/09/1999 1 28.4 1.08 0.48 1.12 
20559 1 0 L144 144 SqCC 1 2 3 2 0 F 1 14/10/1935 03/10/1996 61.0 
 
21/03/1999 1 30.0 0.42 0.00 1.04 
20625 0 0 L172 172 SqCC 1 2.5 4 2 1 M 0 09/12/1931 27/01/1997 65.2 
 
01/10/1999 1 32.6 0.84   0.82 
20774 1 0 L241 241 SqCC 1 2 3 2 1 M 0 17/07/1938 16/09/1997 59.2 
 
03/03/2001 1 42.1 0.64 0.13 1.36 
21025 0 0 L290 290 LCCL   1 1 1 0 M 0 14/04/1921 23/03/1998 76.9 
 
14/07/2002 1 52.5 1.78 0.06 
 
20737 0 1 L220 220 AdenoCa 0 3 5 2 0 F 1 18/06/1926 10/07/1997 71.1 
 
27/01/2002 1 55.4 1.23 0.20 1.03 
20570 1 0 L151 151 SqCC 1 1 1 2 1 F 1 28/08/1926 24/10/1996 70.2 
 
10/10/2001 1 60.4 0.46 0.00 0.15 
20643 1 1 L185 185 AdenoCa 0 1 1 2 1 M 0 22/11/1930 24/02/1997 66.3 
 
04/12/2002 1 70.3 0.58 0.00 1.40 
20784 1 0 L251 251 AdenoCa 0 3 5 2 0 M 0 07/04/1923 20/10/1997 74.5 
 
26/11/2003 1 74.3 1.18 0.00 
 
20520 1 0 L136 136 SqCC 1 2 3 2 0 M 0 06/04/1925 12/08/1996 71.4 
 
29/11/2002 1 76.7 0.46 0.45 0.00 
20402 1 0 L112 112 SqCC 1 2 3 2 0 M 0 18/10/1923 03/06/1996 72.6 
 
06/11/2002 1 78.2 2.11 0.00 1.35 
20600 0 1 L159 159 AdenoCa 0 2 3 2 0 M 0 27/05/1948 25/11/1996 48.5 
 
02/06/2003 1 79.3 1.97 0.00 0.65 
20795 1 1 L257 257 SqCC 1 2 3 4 1 M 0 11/04/1926 31/10/1997 71.6 
 
14/05/2004 1 79.6 0.91 0.00 0.27 
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20725 0 1 L221 221 AdenoCa 0 1 1 2 0 F 1 28/08/1929 15/07/1997 67.9 
 
15/02/2004 1 80.2 0.58 0.00 0.66 
20778 0 1 L245 245 AdenoCa 0 2 3 3 2 M 0 01/05/1926 25/09/1997 71.4 
 
17/05/2004 1 80.9 1.07 0.12 0.64 
20707 1 1 L206 206 SqCC 1 3 5 1 1 M 0 01/03/1922 05/06/1997 75.3 
 
14/12/2004 1 91.6 2.00 0.00 0.35 
20595 0 1 L158 158 AdenoCa 0 2 3 2 0 F 1 29/04/1928 19/11/1996 68.6 
 
15/10/2005 1 108.4 0.83 0.05 1.03 
20159 0 0 L369 369 AdenoCa 0 2 3 2 0 F 1 12/06/1932 11/01/1999 66.6 
 
10/07/2008 1 115.6 1.13 0.07 0.93 
20708 1 0 L207 207 SqCC 1 2 3 1 1 F 1 25/04/1943 09/06/1997 54.1 
 
26/05/2007 1 121.3 0.67 0.04 1.08 
39440 1 0   273 SqCC 1     2 0 M 0 11/04/1934 22/12/1997 63.7 
 
26/03/2008 1 124.9 1.53 0.04 
 
20626 1 1 L173 173 SqCC 1 2 3 2 0 F 1 13/03/1924 27/01/1997 72.9 
 
04/07/2007 1 127.0 1.27 0.00 0.46 
21027 1 1 L291 291 SqCC 1 1 1 2 0 M 0 31/12/1937 24/02/1998 60.2 
 
28/02/2009 1 134.1 1.86 0.00 1.99 
20579 1 0 L153 153 SqCC 1 2 3 2 0 M 0 31/01/1930 11/11/1996 66.8 
 
06/07/2008 1 141.8 2.18 0.04 0.61 
20701 1 0 L200 200 SqCC 1 2 3 2 0 F 1 13/09/1925 08/05/1997 71.6 
 
19/05/2009 1 146.5 1.20 0.11 0.60 
20677 1 1 L192 192 AdenoCa 0 2 3 2 0 M 0 25/12/1924 14/04/1997 72.3 
 
15/06/2009 1 148.2 0.55 0.00 0.47 
20985 1 1 L283 283 SqCC 1 2 3 2 1 F 1 04/05/1944 29/01/1998 53.7 16/02/2012 
 
0 171.0 0.57 0.00 0.14 
20703 1 1 L202 202 SqCC 1 2 3 2 0 F 1 20/09/1929 12/05/1997 67.6 16/02/2012   0 179.8 0.55 0.08 1.26 
20627 1 0 L174 174 SqCC 1 2 3 2 0 M 0 18/11/1932 30/01/1997 64.2 20/12/2012 
 
0 193.4 0.58 0.06 0.58 
20620 1 1 L167 167 SqCC 1 2 3 2 0 M 0 05/07/1924 09/01/1997 72.5 20/12/2012 
 
0 194.1 1.06 0.13 1.44 
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